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Pericytes represent a population of potential mesenchymal stem cells (MSC) that reside 
within a perivascular niche until they are required in normal homeostasis and the 
response to injury.  Their mesenchymal capacities for multipotent differentiation, 
immune modulation and release of trophic factors hold great promise for regenerative 
therapies.  Pathological expression of these potentials has been described in disease 
states, while acute or chronic inflammation following injury can lead to the production 
of signalling molecules that ultimately drive these progenitors to a fibrotic fate. The aim 
of this work was to explore how fate decisions of pericytes are regulated by their niche 
(in the setting of osteogenesis), and in the response to acute and chronic injury (in the 
setting of fibrosis).  
 
It was hypothesized that interactions between pericytes and endothelial cells (EC) 
within their perivascular niche are responsible for regulating mesenchymal 
differentiation. The osteogenic, adipogenic and chondrogenic potential of pericytes 
following isolation from multiple human organs was confirmed. The interactions 
between pericytes and EC in 2D and 3D coculture and the production of basement 
membrane proteins in these settings were confirmed. The osteogenic differentiation of 
pericytes was accelerated by EC but no influence of EC on the adipogenic and 
chondrogenic differentiation of pericytes was detected.  Furthermore, data indicated 




The activation of TGFβ (transforming growth factor beta) through αv integrins has 
been suggested as central mediator of fibrosis in multiple organs. We hypothesized that 
selective αv integrin deletions in PDGFRβ (platelet derived growth factor receptor 
beta) expressing pericytes identifies a targetable pathway regulating fibrosis in skeletal 
muscle.  We report that PDGFRβ-Cre inactivates genes in murine skeletal muscle 
pericytes with high efficiency. Deletion of the αv integrin subunit in pericytes protected 
mice from chemical injury induced skeletal muscle fibrosis.  Pharmacological blockade 
of αv integrins by a novel small molecule (CWHM 12) attenuated muscle fibrosis, even 
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Adult stem cells: position among other stem cells in terms 
of biologic and therapeutic potentials 
Stem cell therapies offer potential treatments for a wide range of diseases that involve 
the failure of tissues and organs.  The transplantation of bone marrow has been used 
for over 40 years to treat patients with a wide range of haematological malignancies 
but is currently the only stem cell therapy that is widely practiced.  Although a great 
deal of stem cell therapy remains experimental, greater understanding of how stem 
cells behave in their native environment, and how these characteristics can be 
harnessed, holds great promise for future therapies.  
 
Stem cells are undifferentiated (biological) cells that can differentiate into specialised 
cells and self renew to maintain the stem cell pool.  There are two broad groups of 
therapeutic stem cells: embryonic stem (ES) cells, which are isolated from the inner 
mass of the 5-7 day old blastocyst, and adult stem cells which are found in various 
tissues.  In a developing embryo, ES-like cells differentiate into cell types from each of 
the three embryonic germ layers: the endoderm, mesoderm and ectoderm. In adult 
organisms, stem cells provide a source of cells during normal tissue homeostasis and 
act as a repair system, replenishing tissue in response to injury1 2.     
 
Human embryonic and adult stem cells each have advantages and disadvantages 
regarding potential for cell-based regenerative therapies.  The differentiation potential 
of ES cells is broader than adult stem cells and therefore each ES cell line has a wider 
repertoire of potential therapeutic targets.  However, adult stem cells, with their more 
restricted differentiation potential are established to have lower tumorigenic potential.  
Unlike ES cells, the use of adult stem cells in research and therapy is not controversial, 
General Introduction 3 
as they are derived from adult tissue samples rather than human 5 day old embryos 
generated by in-vitro fertilisation (IVF) clinics designated for scientific research.  
Furthermore, adult stem cells can be used autologously, overcoming many of the risks 
of viral transmission and immune rejection associated with allogeneic transplantation. 
 
Induced pluripotent stem cells (iPSC) are pluripotent somatic cells reprogrammed to 
enter an embryonic cell-like state by being forced to express factors important for 
maintaining “stemness”.  Mouse iPSC were first reported in 2006 and human iPSCs 
were first reported in late 2007.  Mouse iPSC demonstrate important characteristics of 
pluripotent stem cells, including the expression of stem cell markers, the formation of 
tumours containing cells from all 3 germ layers, and the ability to contribute to many 
different tissues when injected into mouse embryos at a very early stage in 
development.  Human iPSC also express stem cell markers and are capable of 
generating cell characteristics of all 3 germ layers.  iPSC offer the broad differentiation 
potential of ES cells without the associated ethical barriers, although these cells require 
further characterisation with ongoing concerns regarding tumorigenicity. 
 
Mesenchymal stem cells (MSC) 
In the 1960’s, the Russian scientist Friedenstein identified a population of adult cells 
within rodent bone marrow that were rapidly adherent to plastic, had the appearance 
of fibroblasts and formed clonal colonies in vitro. These cells were also capable of 
osteogenic differentiation in culture, and could generate bone when implanted in 
ectopic locations in vivo 3-5.  In addition, their demonstrated ability to generate 
heterotopic bone tissue in serial implants suggested their self-renewal6.  Since 
Friedenstein’s early descriptions, numerous laboratories have confirmed and expanded 
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these findings showing that cells with similar abilities to be sub-passaged and 
differentiated in vitro into a variety of mesenchymal cell types such as osteoblasts, 
chondrocytes, adipocytes and myoblasts could be isolated from human bone marrow 7-
10.  Friedenstein had isolated from the bone marrow of rodents what would later be 
coined “mesenchymal stem cells” or MSC by Caplan 11. 
 
MSC have now been isolated from multiple different human tissue types including fat 12 
13 and skeletal muscle14 15among others (Table 1, p5). Considerable work has been done 
to characterise and expand these cells in vitro, and to explore strategies to maintain 
these cells in their stem like state 16-21. This work was driven by the promise of 
therapeutic translation using these progenitors to replace or repair damaged 
musculoskeletal tissues.  Therefore, current knowledge of MSC is almost entirely based 
on characterisation and observations of behaviour in culture – the setting in which they 
are defined - and until recently the in vivo counterpart of culture expanded MSC 
remained a mystery.   
 
With interest so far focused on multipotency and tissue engineering, little is currently 
understood regarding the ontogeny of these cells, their anatomical localisation or their 
natural role in tissue homeostasis, physiology or pathology.  Characterisation of native 
MSC could allow for either pharmacological or genetic manipulations of this cellular 
pool in vivo, or facilitate the purification of populations for tissue engineering 
applications.   
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Table 1   Described sources of MSC (non-exhaustive list) 
 
Definitions and in vitro behaviours of MSC 
Attempts have been made to standardize the nomenclature used in MSC research. 
However, the variation in methods of isolation, culture and assays used to examine 
them has made this issue both difficult and at times misleading. The International 
Society for Cellular Therapy (ISCT) produced in 2006 a position statement in which it 
suggested the minimum criteria required to define MSC 33. They stated that cells must: 
 Be plastic adherent 
 Express the cell surface antigens CD105, CD73 and CD90 
 Not express the cell surface antigens CD45, CD34, CD14, CD11b, CD79α, CD19 
or HLA-DR 
 Differentiate into osteoblasts, adipocytes and chondroblasts in vitro 
These criteria were established to standardize human MSC isolation but may not apply 
uniformly to other species.  For example, murine MSC differ subtly in marker 
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expression and behaviour compared with human MSC 34.  Although not included within 
defining criteria, MSC are recognised to perform a number of roles beyond 
multipotency including immune modulation, haematopoiesis support, and the release 
of trophic factors in response to injury. 
 
(i)  Multilineage potential 
The ability of MSC to differentiate into all the mesodermal cell lineages (bone, muscle 
cartilage, fat, tendon, ligament, marrow stroma, connective tissue) in appropriate 
conditions is well established 11.  This is routinely achieved in vitro by supplementation 
of cultures with lineage specific growth factor combinations.  For example, 
dexamethasone, 3-isobutyl-1-methylxanthine (IBMX) and insulin are used to induce 
adipogenic differentiation while dexamethasone, β-glycerophosphate (BGP) and 
ascorbic acid are used to promote osteogenic differentiation. 
 
(ii)  Support of haematopoiesis 
The crucial role of bone marrow stromal progenitors in supporting haematopoiesis was 
first described by Friedenstein et al., who observed the formation of heterotopic 
ossicles containing bone and haematopoietic tissue, upon ectopic CFU-fibroblast 
derived colony transplantation in semi-syngeneic animals 4. The haematopoietic cells 
were of recipient origin whereas bone-forming cells originated from the donor 
suggesting that transplanted colonies provided a microenvironment favorable for 
haematopoietic stem cell (HSC) homing and subsequent establishment of 
haematopoiesis. Subsequently, Dexter et al. established a system of murine long-term 
cultures to demonstrate that bone marrow stromal cells can maintain haematopoiesis 
for periods longer than 6 months 35.  It was confirmed that a subset of human bone 
marrow stromal cells expressing the STRO-1 antigen possesses haematopoiesis 
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supporting ability, along with the potential to differentiate into multiple mesenchymal 
cell lineages 36 37.  There is accumulating evidence to suggest that bone marrow MSC 
also have promoting effects on HSC engraftment and repopulation. Several studies have 
demonstrated that co-transplantation of human HSC and MSC results in increased 
chimerism and/or haematopoietic recovery, in both animal models and humans 38-44. 
 
(iii)  Immune regulation 
The immunomodulatory properties of bone marrow-derived MSC, including their 
immunosuppressive effects during allogeneic stem cell transplantation have been well 
documented 45-49. The immunoactivity of the cells is mediated by direct cell-cell contact 
and through secreted bioactive molecules involving dendritic cells, B and T cells 
including T regulatory cells and T helper cells and killer cells49 50.  
 
(iv)  Secretion of trophic factors 
Experiments using transplantation of cultured MSC into animals led to the realisation 
that MSC therapeutic effects could not be explained by differentiation into tissue 
specific cells alone 51 52.  As such, transplanted MSC may exert beneficial effects through 
their vast secretome beyond immune regulation 53 54.  Bioactive factors secreted by MSC 
have angiogenic and antiapoptotic properties that serve to limit the extent of tissue 
damage at the injured sites, re-establish blood supply and recruit local progenitors.  
These MSC paracrine effects have been referred to as trophic effects 55.  
 
Nomenclature 
Due to the lack of a unique MSC function and anatomic identity, these cells were termed 
‘mesenchymal stem cells (MSC)’ or more or less synonymously ‘marrow stromal cells’, 
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‘BM stromal cells’ and ‘mesenchymal stromal cells’ 56-58.  Populations of cells that fulfill 
the ISCT MSC criteria yet exhibit broader differentiation capacity have also been 
described 59. Investigators described such cells as ‘multipotent adult progenitor cells’ 
(MAPC) 60, ‘marrow isolated multilineage inducible cells’ (MIAMI) 61 or ‘multipotent 
adult stem cells’ (MASC) 62.  The relationship of these cells to MSC is currently not clear. 
 
Are MSC true stem cells? 
Stem cells are strictly defined by their ability to reconstruct in vivo the tissue of origin 
while contributing to its long term maintenance and repair.  Stem cells differ from 
progenitor cells (or transient amplifying cells) that exhibit extended proliferative 
capacity and multipotent differentiation in vitro but have little ability to contribute to 
long term tissue regeneration in vivo63. There is very little evidence for long term 
skeletal regeneration of MSC in vivo.  Transplantation of MSC through intravenous 
infusion has resulted in little or no engraftment of cells to bone or bone marrow40 64.  
However, intra-femoral injection of a subset of murine marrow stromal cells has shown 
limited engraftment at the site of injection 4-6 weeks post-transplantation suggesting 
that the quality of the cells injected may be a major determinant of engraftment65 66. 
 
The immunophenotype of MSC 
Assuming that MSC represent a distinct cell population, it is intuitive that they would 
have a specific repertoire of cell surface antigens that would enable identification, 
isolation and purification based on phenotype.  Flow cytometry is a powerful and 
relatively easy to handle approach for phenotyping of cells using fluorescence labelled 
monoclonal antibodies (mAbs) against cell surface antigens.  The cell surface antigen 
profile of MSC has been well explored, and in recent years various combinations of cell 
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surface markers were published for characterising MSC (Table 2, p10 and Table 3, p11) 
67 68.  A particular challenge for the field has been the absence of any specific marker to 
define MSC, although a large number of different determinants have been associated, 
albeit not exclusively, with them (reviewed by Lindner et al., 2010; for human MSC 69). 
 
Defining MSC in vitro adds complexity to their study because the artificial culture 
conditions may introduce experimental artifacts.  It has been proposed that certain 
natively expressed surface markers are modified following explantation, while new 
markers may be acquired.  For example, an MSC line was isolated that uniformly 
expressed HLA-DR (a marker that should not be expressed on MSC by the above 
definition) while also expressing CD90 and CD105, adhering to plastic in culture, and 
being capable of differentiating into osteoblasts, adipocytes, and chondroblasts 70.   
 
Similarly, the expression of CD105, CD73 and CD90 is not uniform and can be 
modulated by in vitro conditioning. The expression or absence of these factors does not 
appear to be inclusive or exclusive of multipotency and discrete subpopulations of MSC 
like cells have been isolated with varying levels of expression 71. Numerous other 
markers have been suggested including PDGFRβ, CD271 72 73, and recently decorin, a 
marker specific to MSC in adipose tissue has been identified 74. A nomenclature that 
focuses on anatomically defined, in vivo populations is preferential to one that is based 
on inherently variable and imprecise in vitro populations. 
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Marker Also known as MSC Pericyte Adventitial  
CD3  
75   
CD9 Tetraspanin-29 
75-78   
CD10 Neural endopeptidase 
14 76 14  
CD13 Alanine aminopeptidase N 
14 76 14  
CD18  
79    
CD29 Integrin beta 1 
75-78 80   
CD34 Mucosialin 
14 81  82 83 
CD44 Receptor for hyaluronic acid 
79 84 14 80 85 
CD49A Half of α1β1 integrin duplex 
75 76 78 79   
CD49B Half of α2β1 integrin duplex 
75 76 78 79   
CD49C Integrin  α 3 
75 76 78 79   
CD49E Integrin  α 5 
75 76 78 79   
CD49F Integrin  α 6 
75 76 78 79   
CD51 Integrin  α V 
79   
CD54 Intercellular adhesion molecule 1 
75 76 78 79    
CD55  
76 78   
CD56 Neural cell adhesion molecule 
(NCAM) 
79   
CD58 LFAA 3 
75   
CD59 Protectin 
76   
CD61 Integrin β 3 
77   
CD63 Lysosomal-associated membrane 
protein3 (LAMP-3) 
77   
CD71 Transferrin receptor 
75-78   
CD73 5’-nucleotidase, ecto 
33 86 87 86 
CD90 Thy-1 
14 81 14 81 14 81 
CD97 Leucocyte antigen 
77   
CD98  
77   
CD99 E2 antigen 
77   
CD104 Integrin β4 
79   
CD105 Endoglin 
33 80 87 83 
CD106  Vascular cell adhesion molecule 1 
(VCAM1) 
84   
CD120A Tumour necrosis factor receptor 
8   
CD124 Interleukin-4 receptor 
8   
CD140 Platelet derived growth factor beta 
(PDGFRβ) 
14 81 14 81  
CD146  Melanoma cell adhesion molecule 
(MCAM) 
14 81 14 81  
CD166 Activated leukocyte cell adhesion 
molecule (ALCAM) 
78 79 88  
CD271 Low affinity nerve growth factor 
receptor (LNGFR) 
89   
CD276  
77   
CD304  
77   
CD324  
79   
CD340  
89   
CD349  
89   
αSMA  
14 81 14 81  
NG2  
81 81 81 
STRO-1   
 87  
Table 2  Markers used for positive selection of MSC  
  [Modified from Murray et al, Cell Mol Life Sci 2014;71(8):1353-74] 
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Marker Also known as MSC Pericyte Adventitial 
CD11a Integrin αL chain 
8 33
   
CD11b Integrin α M chain 
33
   
CD14 Lipopolysacharride (LPS) receptor 






   
CD19  
8 33
   
CD27  
75
   
CD28  
75
   
CD31 Platelet/Endothelial cell adhesion 
molecule 1 (PECAM-1) 








   
CD34 Mucosialin 
33 75 81 84
 




   
CD45 Leucocyte common antigen (LCA) 
33 75 77 78 84
 






   
CD56 Neural cell adhesion molecule (NCAM)  
14 87
  
CD79a Ig- α 
33
   
CD102 Intercellular adhesion molecule 2 
(IAM2) 
79
   





























   
αSMA    
81 83
 
Table 3  Markers used for negative selection of MSC 
 [Modified from Murray et al, Cell Mol Life Sci 2014;71(8):1353-74] 
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MSC isolated from different organs exhibit unique features. 
The equivalency of MSC populations from distinct anatomic origins has not been 
robustly demonstrated. Despite fulfilling the ISCT criteria, differences have been 
observed with respect to the immunophenotype, secreted cytokine profile, and results 
obtained by proteome analysis, depending on the source and the native or cultivated 
state of the MSC population characterized90-92. Cloned human MSC isolated from fat and 
bone marrow default to an adipogenic or osteogenic potential, respectively, suggesting 
that the tissue environment of origin imprints such character.   The ability of MSC to 
differentiate in vitro into adipocytes, chondrocytes, osteoblasts, myoblasts, and of late, 
into haematopoiesis- or osteogenesis- supporting stromal cells has been used to 
stratify the multipotency of these cells as well as to search for markers indicative of 
lineage commitment. While surface antigens like CD105, CD73, and CD29 are conserved 
by most MSC33, others such as Sca-1 (rodents), CD24 93-95, CD140-a & -b, CD146 96, 
CD27197 98, CD338 99 and many others 93 betray the underlying heterogeneity in these 
cells. Some markers like PDGFRα correlated with the adipogenic potential of these cells, 
both in humans and in rodents, while others like CD146 may be associated with greater 
multipotency, and a higher colony-forming efficiency and proliferation rate 100.   
 
Anatomical location of MSC 
With interest focused on multipotency and tissue engineering and repair, the native 
origin and physiological roles in vivo of MSC have been considerably overlooked. As 
such, cells that could be identified only retrospectively in long-term culture were being 
proposed for therapeutic purposes, without true understanding of their native origin or 
function. The real, in vivo counterpart of culture expanded MSC was unknown, and it 
could be argued that based on the ISCT definition, MSC represented a mere artifact of 
culture with no exact equivalent in the living organism. Somewhat surprisingly, the lack 
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of understanding of the in vivo origin of these cells did not constrain their clinical uses 
(305 clinical trials registered on clinicaltrials.gov at the time of writing). However, such 
a retrospective characterization in vitro meant that any clinical exploitation of MSC 
would make use of a heterogeneous population of cells exposed to the hazards of 
extended culture. In search of ways to fully exploit the therapeutic characteristics of 
MSC, researchers sought an improved understanding of the native identity and biology 
of these cells. 
 
The massive stem cell recruitment, expansion, migration and differentiation that can be 
visualised at early embryonic stages wanes with maturity.  As development proceeds 
stem cells become less prevalent and tissue regeneration and repair become 
quantitatively marginal. This makes the documentation of stem cell presence and 
activity in anatomic terms increasingly challenging. It is established that adult tissue 
specific stem cells are located in specialized “niches” in their corresponding tissues of 
origin 101. For example, HSC can be found in the bone marrow 102, epidermal stem cells 
in mammalian hair follicles 103, and neural stem cells in the subventricular zone 104. MSC 
have perhaps proved to be the most elusive of all adult stem cells. 
 
The main cell types suggested to descend from MSC including bone, cartilage, fat and 
muscle are not limited to one anatomical region. Wherever MSC originate they must be 
capable of reaching these tissues throughout the body or be locally available. With this 
in mind, a number of potential explanations have been suggested 105. Firstly, MSC may 
originate from a single organ, from which they migrate towards areas of need in 
response to systemic signals. In support of this, experiments using rats exposed to low-
oxygen conditions suggest that MSC are specifically mobilized into peripheral blood as 
a consequence of hypoxia106, while elevated numbers of MSC were noted in the 
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peripheral blood of patients immediately following traumatic hip injury. However, the 
origin(s) of the mobilized cells remains unclear and it has proved extremely difficult to 
establish MSC cultures from conventional blood either in physiological conditions or 
following stimulation with cytokines 22 107 108. 
 
Conversely, the ability to derive apparently identical MSC from multiple tissues led to 
the hypothesis that these cells share a common in vivo location. A growing body of 
published reports has described perivascular cells which appear indistinguishable from 
vascular pericytes as a possible source of MSC 28 41 109 110, a situation that would explain 
why MSC can be isolated from all organs. Association of these mesenchymal progenitor 
cells with the vasculature would allow them to function as a source of new cells for 
physiological turnover and for the repair or regeneration of local lesions. The 
establishment of MSC-like cultures from blood vessels alone supports this hypothesis.  
More recently another subset of vascular cells, namely adventitial cells, have been 
identified that may behave in a similar manner to pericytes83. 
 
Perivascular stem cells (PSC) 
Recent results have acknowledged the regenerative potential, under certain conditions, 
of a subset population residing in the wall of blood vessels 43 44. Pericytes have been 
recognised as a distinct cellular entity that share a common immunophenotype and 
differentiation potential to mesenchymal stem/progenitor cells 23. In a variety of 
human organs, perivascular mesenchymal progenitor cells can be identified by a 
combination of perivascular (CD146, NG2, PDGFRβ) and MSC (CD29, CD44, CD73, 
CD90, CD105, alkaline phosphatase) markers, as well as lack of haemato-endothelial 
cell markers (CD31, CD34, CD45, CD144, von Willebrand factor (vWF)) (Figure 1, p15). 
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Pericytes have been shown to differentiate into multiple mesodermal lineages in vitro 
including bone 111 112, fat 113, cartilage 110 and skeletal muscle 114 115. Similarly to culture-
expanded bone marrow-derived MSC, T-lymphocyte surveillance shut-down effects 
have also been reported with pericytes 116 117.  
 
Figure 1  Immunodetection of pericytes in human organs and confirmation that pericytes 
natively express MSC markers.   
(A) Myocardium: a capillary EC in transverse section marked by CD34 expression (green) is 
closely surrounded by a CD146+ pericyte (red) (x900).  (B) Skeletal muscle: small vessel 
longitudinal section; PDGFRβ+ perivascular cells (red; red arrows) surrowund vWF+ 
endothelial cells (green; green arrows) (x400).  (C) Skeletal muscle: small vessel transverse 
section; CD146+ pericytes (green) surround CD34+ endothelial cells (red) (x400). (D) Fetal 
pancreas: small vessel longitudinal section; NG2-positive pericytes (green; green arrows) 
surround CD144+ endothelial cells (red; red arrows) (x400). (E) Frozen sections of adult 
human muscle were co-stained with antibodies to CD144 (red) to reveal endothelial cells 
(red arrows) and CD73 (green). Pericytes lining the small blood vessel express CD73 ([H], 
x600, green arrows). (F)  Frozen sections of human adipose tissue were co-stained with 
antibodies to CD34 (green) to reveal EC (green arrows) and CD44 to label pericytes(red, 
[F]). [Modified from Crisan et al.  Cell Stem Cell 2008;3(3):301-13] 
 
Tottey et al. demonstrated that perivascular cells isolated from human fetal muscle 
proliferate at a higher rate under hypoxic condition (6%) than normoxia (21%) and 
that they migrate more rapidly when exposed to degraded extracellular matrix (ECM) 
products 118. This indicates some degree of activation in the presence of injury.  
Perivascular cells can release various cytokines, including basic-fibroblast growth 
factor (b-FGF), a well-known chemotactic and mitogenic agent and vascular endothelial 
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growth factor (VEGF), a regulator of angiogenesis, which can also participate in tumour 
progression 119.  
 
There is now increasing evidence that pericytes can play a natural role as progenitor 
cells in development and in various injured tissues. Perivascular cells represent a 
ubiquitous cell population, distinct from tissue specific progenitors such as myogenic 
satellite cells 120. However, it has also been demonstrated that pericytes resident in 
postnatal skeletal muscle differentiate into muscle fibres and generate satellite cells 
following chemical damage to the muscle121, and that they can contribute directly to 
tooth regeneration by differentiating into odontoblasts42.  
 
Nonpericyte perivascular cells as MSC ancestors 
Cells displaying MSC phenotypic and developmental properties have also been isolated 
from the tunica adventitia of the human pulmonary artery 122. The tunica adventitia was 
long considered an inactive component of blood vessels mainly functioning as 
structural support for the tunica media.  Only recently has it been demonstrated that 
the adventitia plays a crucial role in vascular remodeling and the development of 
vascular diseases including arteriosclerosis and restenosis123. Activation of adventitial 
cells has been described in response to physical stressors including injury 124, vein 
grafting 125, hypoxia 126 and hypertension 127. In these settings adventitial cells may 
differentiate into myofibroblasts that migrate into the inner layers of the vascular wall, 
alter extracellular matrix deposition, and release paracrine factors regulating vascular 
remodeling 128. In apoE-/- mice Hu et al. 125 identified and isolated Sca1+ adventitial cells 
able to differentiate in vitro and in vivo into smooth muscle cells. It has subsequently 
been demonstrated that the differentiation potential of adventitial cells is not restricted 
to myofibroblasts. These observations suggest indirectly that pericytes, exclusively 
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present around capillaries and microvessels, are not the only ancestors of MSC, as 
hypothesized previously 129. 
 
Along a systematic search by flow cytometry for alternative non-pericyte cells at the 
origin of MSC, Corselli et al. identified a subset of CD34+ CD45- CD56- CD146- NG2- 
cells in the tunica adventitia of human arteries and veins 83. These adventitial cells grew 
like MSC in culture and exhibited typical MSC differentiation properties. Interestingly, 
adventitial cells express natively the MSC markers CD44, CD73, CD90 and CD105. No 
potential to give rise to MSC in culture was detected outside the perivascular subsets 
including pericytes and adventitial cells. 
 
Although pericytes and adventitial cells have been described for more than a century, it 
is only recently that the blood vessel wall was demonstrated as a reservoir of 
progenitors. It is now clear that perivascular cells, i.e pericytes and adventitial cells, are 
in vivo counterparts of MSC obtained in culture from various organs 110 130. These 
perivascular cells can be prospectively purified by flow cytometry using a well-defined 
surface marker combination, common in all human organs tested. Importantly, 
pericytes and adventitial cells dissociated from vessel walls contain multipotent 
precursors with robust regeneration properties similar to those of classic 
heterogeneous MSC. 
 
A Perivascular Niche for MSC precursors 
A perivascular niche for MSC-like cells throughout the body is intuitive.  A rich supply 
of mesenchymal progenitors within all vascularised tissues facilitates a swift reparative 
and regenerative response to injury.  A schematic diagram of proposed roles of MSC in 
vivo in normal tissue homeostasis, and in response to injury, can now be proposed 
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(Figure 2, p19). As a result of injury, MSC are dislodged from their attachment domains 
in vessels and become ‘activated’ MSC, which divide and contribute to a regenerative 
microenvironment.  Bioactive factors inhibit immunosurveillance of the damaged 
tissue, preventing autoimmunity, while vascular in-growth is stimulated. Some of the 
MSC, or their progeny, may serve as progenitor cells for the regeneration of the 
damaged tissue, or might stimulate the mitosis of the tissue-intrinsic progenitors that 
replace the damaged tissue. Therefore, these cells can contribute to tissue regeneration 
through direct differentiation into tissue-specific mesodermal lineage cells and/or 
through paracrine mechanisms promoting angiogenesis, immunomodulation and 
survival. PSC have now been extensively characterised, and they exhibit defined 
identity and purity131.  Importantly, purified PSC also exhibit defined potency with 
respect to in vivo chondrogenesis, in vitro and in vivo myogenesis, and in vivo BMP-2 
stimulated osteogenesis14. 
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Figure 2 Following mesenchymal 'activation', pericytes can express a mesenchymal 
phenotype. 
Diagram showing proposed roles of perivascular stem cells (PSC) in normal tissue 
homeostasis and in response to injury. In the latter, pericytes and adventitial cells are 
released from the vasculature, becoming activated mesenchymal stem cells (MSC), which 
proliferate, contribute to regeneration through multipotency, organise a regenerative 
microenvironment, and regulate local immune responses. MSC are also able to support 
haematopoiesis, and contribute to normal tissue turnover.  [Modified from Murray et al, Bone 
Joint J. 2014 Mar;96-B(3):291-8] 
 
 
PSC as regenerative units 
There is accumulating data to confirm that PSC exhibit their MSC characteristics and 
serve as regenerative units in native tissues.  Pericytes have been shown to contribute 
to the turnover of mesenchymal tissues in normal homeostasis and in response to 
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injury through differentiation, while their capacity to regulate local immune 
environments and secrete trophic factors in response to injury is increasingly 
described.   
 
Pericytes can contribute to skeletal myoblasts and satellite cells, and odontoblasts. 
Through the long term culture of human muscle, Dellavalle et al., isolated a pericyte-
like population of cells that showed heterogeneous expression of pericyte markers 
NG2, PDGFRβ and aSMA and more reliably alkaline phosphatase (AP), and were 
negative for myogenic markers120. In appropriate in vitro conditions, a proportion of 
these cells were capable of myogenic differentiation, and following expansion in culture 
and injection into dystrophic mice these pericytes yielded a measurable improvement 
in muscle function120.  Using a tamoxifen inducible Cre recombinase under the control 
of AP, they were able to demonstrate that AP+ pericytes enter myogenesis and 
contribute to maturing myofibres during development as well as in response to injury 
in the early post-natal period121.  Further lineage tracing studies indicate that pericyte 
contribution to myofibres varies among different muscles, ranging from <1% (tibialis 
anterior muscle) to 7% of the fibres (diaphragm) and is enhanced (although only 
modestly) by acute or chronic muscle regeneration. In addition to contributing to the 
myoblast pool, pericytes can also contribute directly to the satellite cell pool, during 
unperturbed, postnatal growth of the mouse. When pericytes are isolated and cultured 
from postnatal skeletal muscle in appropriate conditions, they show the ability to 
undergo skeletal myogenesis although some variation is seen between donors.  Using 
an inducible NG2-Cre system, Feng et al., demonstrated that pericytes contribute to 
regeneration of tooth following injury by differentiating into odontoblasts although 
other populations of cells are also involved42. 
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Implanted pericytes can contribute to myogenesis 
Given the observation that pericytes can differentiate readily in vitro into myoblasts in 
appropriate myogenic conditions, a number of investigators have sought to harness 
their potential as myogenic precursors. Indeed intramuscular injection of freshly sorted 
or cultured PCs derived from human adipose or skeletal muscle regenerated human 
myofibers efficiently in the mouse dystrophic or injured muscle14. It has also been 
shown that intramuscular implantation of dissected human placental villi results in 
crude outgrowth of human cells in dystrophic mice115. In this study cells of human 
origin participated in host muscle regeneration, revealed by the detection of human 
dystrophin-positive (hDys3t) and/or human spectrin-positive myofibers. Many of these 
human myofibers coexpressed human lamin A/C, indicating their sole human origin 
and not intermediate products of cell fusion. Surprisingly, human myofibers were 
located at regions distant (up to 2 cm) to the implantation site, suggesting active 
migration of outgrown human myogenic precursors over long distances 115. 
 
Bioactive factors released by MSC are capable of supporting muscle regeneration 
through angiogenic and anti-apoptotic effects49.  The immunomodulatory properties of 
these cells inhibit immunosurveillance of the injured tissues preventing autoimmunity.  
Clinical and animal studies of MSC indicate that the release of trophic factors is the 
primary contribution of pericytes in tissue regeneration, rather than differentiation and 
engraftment49. 
 
PSC as regenerative units in cell therapy 
Understanding the native anatomical origins of MSC has clinical implications for both 
cell therapy and also manipulation of tissues resident cells in situ.  Cell therapy is the 
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transplantation of human or animal cells to replace or repair damaged tissue. 
Historically, blood transfusions were the first type of cell therapy and are now 
considered routine. Bone marrow transplantation has also become a well-established 
protocol. Bone marrow transplantation and increasingly often peripheral blood 
mononuclear cells (PBMC) are used to treat blood disorders, including anemias, 








Figure 3  MSC can be used and delivered for therapeutic purposes 
In each of these settings MSC may be used with the aim of engraftment, or to harness their 
trophic or immunomodulatory effects. [Modified from Murray et al, Bone Joint J. 2014 
Mar;96-B(3):291-8] 
 
The multipotency as well as the trophic and immunoregulatory effects of MSC have vast 
potential clinical applications, with many treatments already at the stage of clinical 
trials. The mechanisms by which MSC can be used and delivered for therapeutic 
purposes is evolving, with researchers seeking to overcome a dependence on allogeneic 
transplantation and the requirement for ex-vivo expansion (Figure 3, p22).  
Conventional unpurified MSC preparations have significant drawbacks including 
contamination from non-MSC populations and the requirement of in vitro culture to 
enrich the MSC population.  Approaches to delivering cell-based therapies are 
increasingly being guided by regulatory frameworks. Within these frameworks, cells 
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to approval for clinical use while cells that can be directly implanted directly bypass 
much of this legislation. Many of these drawbacks can be addressed with the ability to 
identify and isolate pure populations of MSC precursors as perivascular cells using 
FACS. The practical and therapeutic consequences of understanding the identity and 
anatomical origin of native MSC have therefore been considerable: 
 
(i)  Perivascular stem cells can be sorted to purity 
Whole bone marrow cell suspensions and the stromal vascular fraction (SVF) of 
adipose tissue have been used directly with the aim of harnessing the potential of the 
contained stem cells. However both represent highly heterogeneous cell populations, 
which include non-mesenchymal stem cell types, such as inflammatory cells, 
haematopoietic cells, endothelial cells, and non-viable cells among others 132. Available 
studies using SVF show poor and unreliable tissue formation 133, or lower tissue 
regeneration efficacy relative to cultured MSC 134. In fact, recent studies have suggested 
that the presence of endothelial cells have inhibiting effects on bone differentiation, 
among other lineages 135 136.  Despite the process of enrichment through plastic 
adherence, it is inevitable that preparations will be contaminated by non-MSC 
populations, and the contribution of each contained population to repair process 
cannot be definitively established. However, it is likely that subsets of functionally 
distinct cells exist even within purified populations of PSC and MSC.  Identification of 
MSC subsets with the most desirable characteristics for clinical applications is likely to 
be a major focus of future research. Finally, variability in cell composition presents 
clear disadvantages for regulatory body (for example the FDA (Food and Drug 
Administration)) approval of a future stem cell-based therapeutic for tissue 
engineering, potentially including reduced safety, purity, identity, potency and efficacy. 
With these regulatory hurdles in mind, and notwithstanding the improved potency 
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observed with homogeneous cell populations, the use of purified MSC, i.e pericytes and 
adventitial cells, collectively designated as perivascular stem cells (PSC), has clear 
practical advantages. 
 
(ii)  PSC do not require in vitro selection  
The selection and preparation of MSC through adherence to culture plastic is time 
consuming, and introduces additional risks such as immunogenicity and infection 
through exposure to animal-derived culture products. Investigators have documented 
the influence of MSC culture on genetic instability 137, and tumorigenicity 138 139, 
although these results have been challenged 140. Multipotentiality hence therapeutic 
potency has been shown to diminish with serial passaging, with human BM MSC 
progressively losing their potential for adipogenic and chondrogenic differentiation 
potential as the number of cell divisions increases 141.  Regardless of the protocol for 
culture expansion, MSC undergo replicative senescence in culture limiting their clinical 
applications142.  In addition, expression of adhesion molecules and chemokines, and the 
ability to respond to chemokines decline with time in culture 141.  
 
(iii)  PSC can be isolated in sufficient numbers to negate ex-vivo expansion 
In addition to the advantages of negating the need for in vitro selection of MSC, the 
ability to isolate PSC from adipose tissue in clinically relevant numbers has significant 
therapeutic implications.  Low stem cell numbers and high donor site morbidity limit 
the use of fresh autologous bone marrow 138 143, periosteum 144 and the majority of 
other MSC sources. Adipose tissue represents a largely dispensible source of MSC, that 
are readily accessible through lipoaspiration, even in patients of healthy weight 145. It 
has attracted much attention as a potentially plentiful source of MSC, particularly using 
uncultured cells (SVF or PSC) but also with cells following in vitro expansion. Relative 
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to the lower yield, limited donor sites, and high morbidity associated with bone 
marrow or periosteal harvest, adipose tissue is now a well-documented, easily 
accessible, abundant source of such cells.  James et al. reported the yields from 
lipoaspirate isolated from 60 consecutive donors in cosmetic procedures 112. From 100 
ml of whole lipoaspirate the mean yield of total nucleated cells (SVF) was 39.4x106 
(range 10 x106 to 70 x106).  On FACS sorting, pericytes most frequently represented 
30% or less of total SVF (mean 19.5%) with adventitial cells representing 40% or less 
(mean 23.8%) of total SVF.  When added in combination, the total PSC content most 
commonly fell between 30% and 60% of total viable SVF (mean, 43.2%; median, 
41.7%).  Given this prevalence of PSC, it has been estimated that less than 200 ml of 
lipoaspirate would be sufficient starting material for the clinical application of PSC in 
localized bone repair. For example, 200 ml of lipoaspirate would theoretically yield 31 
million cells, which would be sufficient for healing of a 2-cm mid-diaphyseal femoral 
defect (cell seeding density of 1 million per 0.4 ml) 112 146.  In cases where there is a 
requirement for extremely large numbers of cells (for example GVHD where 1-2million 
cells/kg body weight may be required for infusion) or where the availability of fat for 
lipoaspirate is limited, some expansion in culture is inevitable.   
 
In addition to the requirement for robust trials to demonstrate safety and efficacy of 
PSC for tissue regeneration, a number of practical challenges must also be overcome 
before widespread clinical application of this technology. The number of facilities 
currently set up with flow sorters to produce clinical grade cells in accordance with a 
formal accreditation from State or other body is currently limited. The financial costs of 
clinical grade sorting, taking in account the price of the antibodies (also certified for 
clinical purposes) is high.  However, this may be offset by savings made by the lack of 
requirement for expansion in culture.   The use of the use of an automated clinical 
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grade immunodepletion system has been proposed as a more affordable alternative for 
bulk sorting to FACS.  However, the complex phenotype of PSC, and the requirement for 
both positive and negative selection render this impractical. 
 
Conventionally derived MSC and purified PSC – emerging pre-clinical and clinical data 
There is a rapidly expanding body of pre-clinical data evaluating the potential 
therapeutic benefits of exogenous MSC. The list of MSC-related applications includes a 
broad and diverse range of clinical targets (Table 4, p27)49.  Almost all of these trials 
and preclinical models utilize conventionally derived MSC for their immunomodulatory 
or trophic effects rather than their ability to differentiate in different cell lineages. The 
limited emerging data from animal studies confirm that PSC are at least as effective as 
conventionally derived MSC in terms of clinical effect 131 146.  It is expected that the 
added benefits of prospective isolation and the avoidance of culture will enable these 
treatments to become more accessible to patients from a wider range of conditions.    




Table 4  Potential clinical applications of MSC (non exhaustive list) 




Potential Clinical Application of MSC (non exhaustive list) 
Bone regeneration 
  *Skeletal defect healing147 
  Osteoporosis148 149 
  Osteogenesis imperfecta150 
Cartilage regeneration  
 * Cartilage defect healing147 
  Meniscus injury151 
  *Rheumatoid arthritis152 153 
  *Osteoarthritis154 
Muscle regeneration 
  *Skeletal muscle regeneration155 
  *Cardiac muscle regeneration156 
  Smooth muscle regeneration157 
Tendon Regeneration 
  *Repair of tendon defects158 
Neural regeneration and injury prevention 
  Traumatic brain injury159 
  *Spinal cord injury159 
  *Multiple sclerosis159 
  *Parkinson’s disease159 
  *Multiple system atrophy159 
  *Ischemic stroke160 
Prevention of injury in acute ischemia 
  *Ischemic stroke160 
  *Limb ischemia161 162 
  *Acute lung injury163 
  *Myocardial infarction164 
  *Acute kidney injury165 166 
Immunomodulation 
  *Diabetes, Type I167 
  *Sepsis163 
  *Multiple sclerosis159 
  *Acute lung injury163 
  *Rheumatoid arthritis152 153 
  *Hepatic cirrhosis168-170 
Other 
  *Renal failure163 
  *Skin grafting171 
  *Urinary incontinence172 
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PSC at the origins of fibrosis 
Fibrosis is characterised by persistence of myofibroblasts 
Fibrosis is the pathological persistent accumulation of collagenous extracellular 
matrix173.  Fibrosis can impair tissue function and cause chronic disease in a large 
variety of vital organs and tissues, including skeletal muscle.  Despite the diverse range 
of tissues susceptible to fibrosis, all fibrotic reactions share common cellular and 
molecular mechanisms.  Often starting as a beneficial physiological repair response to 
organ injury with hemostatic, inflammatory and remodelling phases, fibrosis is 
characterised by the persistent activity of matrix remodelling myofibroblasts174. 
Multiple cell types have been proposed to fulfil this myofibroblast precursor role, 
including epithelial cells (via the process of epithelial-mesenchymal transition 
[EMT])175 176, bone marrow-derived cells including fibroblasts177 178 and tissue-resident 
cells179. EMT was initially proposed as a major source of myofibroblasts in fibrotic 
disease, but recent cell fate-mapping studies in multiple organs in rodent models have 
shown that EMT does not directly contribute to the pool of collagen-producing 
myofibroblasts during fibrogenesis in vivo180.  Several recent studies using cutting edge 
murine genetic cell labelling techniques have identified pericytes as major 
myofibroblast progenitors in multiple organs180 181. 
Tracing pericytes in organ fibrosis 
The rapid increase in sophisticated mouse genetic tools has facilitated cellular fate 
mapping in a diverse range of biological processes.  The Cre/loxP system which is 
widely used for this purpose employs the gene for bacterial Cre recombinase (Cre), 
which is linked to a cell- or lineage-specific promoter prior to incorporation in the 
genome of a transgenic mouse.  Fate mapping experiments commonly employ inducible 
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Cre strains which enable temporal and spatial control of Cre expression, as Cre 
expression in these mice only occurs in the presence or absence of exogenous 
compounds (commonly tamoxifen).  Using a range of these techniques a central role for 
pericytes as myofibroblast precursors has been shown in the kidney181, central nervous 
system182, liver183 and lung180. 
Origins of fibrosis in skeletal muscle 
The native source of myofibroblasts in skeletal muscle has been less investigated.  
Pericytes (identified by expression of AP) are increased in biopsies from patients 
affected by different forms of muscular dystrophy, implicating a role for them in the 
fibrotic process184.  The most robust study exploring myofibroblast pre-cursors in 
skeletal muscle was performed by Dulauroy et al.185, who examined the role of 
ADAM12+ cells following muscle injury. Initial studies demonstrated that transient 
expression of ADAM12 identifies a distinct pro-inflammatory subset of stromal cells 
that become activated following injury. The authors then fate-mapped these cells using 
an inducible, tetracycline transactivator based system. This involved the generation of 
triple transgenic mice that expressed tetracycline transactivator under control of the 
ADAM12 locus, Cre under control of the tetracycline transactivator and the conditional 
reporter Rosa26floxSTOP-YFP locus. In these mice, yellow fluorescent protein (YFP) 
labelling of the progeny of ADAM12+ cells was temporally controlled by the 
administration of doxycycline to prevent Cre expression. This allowed the separate 
fate-mapping of fetal and adult ADAM12+ cells following CTX induced muscle injury. 
The genetic strategies employed by the authors, combined with a parabiosis 
experiment, allowed them to demonstrate that the majority of collagen-producing, 
αSMA+ myofibroblasts developing following acute dermal or muscle injury are 
generated from tissue-resident ADAM12+ cells. Furthermore, ablation of ADAM12+ 
cells in skeletal muscle (using mice that also expressed the human diphtheria toxin 
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receptor under control of the ADAM12 locus) markedly reduced the generation of 
profibrotic cells and interstitial collagen accumulation.  The authors were able to 
demonstrate that the ADAM12+ profibrotic progenitors developing in injured skeletal 
muscle originate from ADAM12+ perivascular cells.  
 
Global burden of muscle disease 
The global burden of disease study of 2010 estimates that 1.7 billion people worldwide 
are affected by musculoskeletal disorders, making them the greatest cause of disability 
in terms of disability adjusted life years186.  Muscle is affected by a broad range of 
conditions from congenital dystrophies characterised by wasting, fatty infiltration and 
fibrosis to pathological responses to injury including heterotopic ossification.  As 
progenitors of osteoblasts, adipocytes and myofibroblasts, pericytes are emerging as 
central protagonists in these conditions and as a result represent key cellular targets 
for future therapies. 
Heterotopic ossification 
Myositis ossificans traumatica is characterised by heterotopic ossification 
(calcification) at the site of injured skeletal muscle.  Up to one-third of all patients 
undergoing hip arthroplasty or who have had a severe long bone fracture develop 
heterotopic ossification that can result in pain, swelling and restricted range of 
motion187.  Myositis ossificans progressiva (also known as fibrodysplasia ossificans 
progressiva or FOP) is an extremely rare inherited condition in which ossification in 
muscle and connective tissues and occur spontaneously or following injury188.  
Although the mutation for FOP is known, this is merely a proximate genetic cause – the 
cells that respond by forming bone in acquired and genetic forms of heterotopic 
ossification are not known.  As pre-MSC resident in skeletal muscle with robust 
General Introduction 31 
osteogenic potential, pericytes have emerged as key candidates189.  Understanding why 
these progenitors pathologically express their osteogenic potential in this setting may 
provide insights into future therapies. 
Fibrosis 
In skeletal muscle, fibrosis is often associated with the muscular dystrophies which are 
a molecularly and clinically heterogeneous group of diseases.  Phenotypically these 
diseases are characterized by fatty infiltration of muscle tissue, muscle wasting and 
fibrosis which compromise function and mobility.  In the most severe cases, such as 
Duchenne Muscular Dystrophy (DMD, caused by lack of dystrophin protein), muscle 
loss and fibrosis can cause premature death through respiratory failure190. Patients are 
given corticosteroids which prolong muscle strength and walking capacity in the early 
years, but eventually lead to disabling secondary effects191.  There is no effective clinical 
treatment to combat or attenuate the underlying fibrosis192. 
 
Acute muscle injuries are a common problem in trauma and orthopaedic surgery.  
Skeletal muscle injuries constitute the majority of sports-related injuries in many 
epidemiological studies193 194 and almost all orthopaedic surgical procedures involve 
incision through muscle.  Moderate to severe muscle injuries in athletes may result in 
inability to train or compete for several weeks and have a high tendency to recur195.  
Muscle injuries undergo the healing phases of degeneration, inflammation and fibrosis, 
with established fibrosis resulting in diminished function and susceptibility to re-
injury.  Fibrosis that occurs following surgery can restrict rehabilitation and functional 
outcomes and makes secondary or revision procedures technically challenging.  
Currently there are no European Medicines Agency (EMEA)- or Food and Drug 
Administration (FDA)-approved anti-fibrotic therapies, underscoring the urgent need 
for potent and novel treatments for tissue fibrosis. 
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Architecture of skeletal muscle 
Skeletal muscle makes up about 45% of total human body weight.  As part of the 
locomotor system the primary task of the musculature involves moving and stabilizing 
the skeleton. Therefore, muscles are attached to the bones by collagen-rich tendons. 
Innervation is carried out by the somatic nervous system so that (almost) all skeletal 
muscles may be controlled voluntarily. A motor neuron and its associated muscle fibres 
make up a motor unit. Fine muscles (e.g. outer eye muscles) have small motor units and 
therefore can be controlled more precisely in comparison to gross muscles (e.g. back 
muscles). 
 
A layer of dense connective tissue, called the epimysium surrounds each muscle and is 
continuous with the tendon.  Skeletal muscle is composed of numerous fascicles which 
are surrounded by a connective layer termed perimysium.  These fascicles contain 
bundles of muscle fibres (myofibres) which are themselves separated by connective 
tissue called endomysium.  Each myofibre is a multinucleate syncytium formed by 
fusion of immature muscle cells termed myoblasts and is around 20-100 µm thick and 
up to 20 cm long.  The myofibers of skeletal muscle are long, cylindrical cells that 
possess multiple, peripheral nuclei (Figure 4, p34). 
 
Myofibres can be type 1 or type 2 based on physiologic properties.  Type 1 myofibres 
(slow-twitch or slow-oxidative fibres) have a slow contraction time following electrical 
stimulation and generate less force than type 2 myofibres.  Type 1 myofibres are 
equipped with numerous large mitochondria and abundant lipid for oxidative stress 
and are used for sustained, low level activity.  Type 2 myofibres (fast twitch or fast-
glycolytic fibres) have a rapid contraction time and are specialised for anaerobic 
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metabolism.  As such these fibres contain smaller, less numerous mitochondria, less 
lipid and have larger glycogen stores than type 1 fibres.   The ratio of type 1 and type 2 
myofibres varies between muscles based on function – for example over 95% of the 
fibres in tibialis anterior muscle are of type 2.196  The innervation of a particular muscle 
fibre determines whether it is a type 1 or type 2 fibre.  As such, if the type of motor 
neuron innervating a myofibre is changed, that myofibre acquires a new phenotype 
from its new innervation. 
 
In healthy adult muscle, muscle fibres are of relatively uniform size and shape fitting 
together in a mosaic pattern.  In normal muscle, less than 3% of myofibres should have 
nuclei located in the center of the myofibre (internal nuclei),  with over 97% of nuclei 
located in the periphery of the cell.  In addition to myofibres, the “muscle 
neighbourhood” is composed of satellite cells that reside beneath the basal lamina and 
constitute the major muscle stem cell population. Blood vessels, composed of 
endothelial cells, permeate the interstitial space of the muscle fibers, and in addition to 
providing a blood supply the endothelial cells promote satellite cell proliferation 
through secretion of growth factors and delivery of circulating inflammatory cells.  
Pericytes actively contribute to postnatal muscle growth and regeneration. The 
interstitial space is occupied by mesenchymal progenitors as well as connective tissue 
cells.  Microvessels plunge into and penetrate muscle fascicles with larger vessels and 
nerves organised in neurovascular bundles between perimysium.
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Figure 4  Skeletal muscle architecture 
 (illustration by Iain Murray, based on images from:  Pannerec A, Morazzi G, Sassoon D.  Stem Cells in the hood:  the skeletal muscle niche.  Trends in 




Progenitors in adult skeletal muscle 
It is now recognised that several distinct populations of multipotent cells exist within 
skeletal muscle.  These cells may have myogenic potential, capable of regenerating and 
replacing damaged myofibres, they may contribute to the regenerative response 
through the release of trophic factors, or they may modify the immune response.  These 
progenitor populations may result in aberrant calcification, fatty accumulation or 
deposition of ECM in disease settings.  Many of these populations do not have specific 
markers, with overlapping characteristics and phenotypes, while the nomenclature is 
often unhelpful or misleading.  To minimise confusion these populations are briefly 
summarised below and in Table 5 (p38). 
 
Progenitors with myogenic potential 
Satellite Cells 
The principal stem cell involved in the regeneration of myofibres is the satellite cell197.  
These cells, most reliably identified by expression of paired box transcription factor 
Pax7, are located between the basal lamina and sarcolemma of myofibres remaining 
quiescent until recruited to contribute to myofibres or self-renew198-200.  Lineage 
tracing and serial transplantation studies have conclusively demonstrated that satellite 
cells 201 202 generate myofibres and self-renew, replenishing the existing stem cell 
pool203-206.  The absolute requirement for satellite cells in myogenic repair has been 
demonstrated through genetic ablation of Pax7 cells in adult mice, suggesting that 






Side population cells 
Muscle resident ‘side population’ cells located in the interstitium with myogenic 
potential have been described by several groups.  Subpopulations expressing CD34, 
Sca-1 and Pax7 have been described.  They are able to differentiate into myofibres in 
vitro when exposed to myogenic factors210, when cocultured with myoblasts211, and 
when injected into regenerating muscle212 213.   These cells were first identified by 
Gussoni et al., by the preferential exclusion of Hoechst 33342 and the ability to give rise 
to dystrophin positive myofibres212.  Other than their apparent ability to efflux Hoechst, 
the functional differences between these ‘side population’ cells and the other 
progenitors with myogenic potentials is not entirely clear. 
PICs 
A population of myogenic cells have been identified by the expression of the stress 
mediator PW1.  These PW1+/Pax7- interstitial cells (or PICs) were first isolated by 
Mitchell et al., by FACs sorting on the basis of cell surface antigen expression (CD45-
/Ter119-/Sca1+/CD34+)214.  These cells were capable of acquiring Pax7 and 
differentiating into myoblasts, particularly when in coculture with myoblasts.  In vivo 
studies have confirmed their capacity to regenerate myofibres following 
transplantation into injured muscle, while also contributing to the satellite cell pool and 
self-renewing214. 
Myoendothelial cells 
Skeletal muscle contains a population of cell that co-express myogenic and endothelial 
markers and are capable of regenerating myofibres and differentiating into myogenic, 







Fibro/adipogenic progenitors (FAPs) 
Skeletal muscle progenitors with bipotent fibro/adipogenic potential which do not 
arise from the myogenic lineage have been described by several groups216-218.  Using 
FACS, Joe et al., isolated murine FAPS (CD45-/CD31-/alpha7integrin-/Sca1+/CD34+) 
while Uezumi isolated a phenotypically and functionally equivalent population (CD45-
/CD31-/C2.6-/PDGFRα+).  FAPs spontaneously differentiated into adipocytes and 
fibroblasts in in vitro culture217. The close association of FAPs with regenerating 
myofibres, together with their expression of factors influencing myogenic 
differentiation such as IGF-1 and IL-6 suggests that these stromal cells play a 
supportive role in myogenic differentiation217.  However, FAPs can also give rise to 
ectopic adipocytes that accumulate in degenerating muscles in vivo218.    The fibrogenic 
potential of PDGFRα+ population has also been verified in vivo following 
transplantation of GFP labelled cells into cardiotoxin injured muscle. A contribution of 
this population to aberrant cartilage and bone production in models of heterotopic 
ossification has also been demonstrated using lineage tracing studies based on a Tie2-
driven Cre-dependent GFP reporter.  90% of these cells were PDGFRα+/Sca1+.  FAPS 
are localised to the muscle interstitium, adjacent to myofibre-associated blood vessels 









In vitro In vivo References 













































185 217-220 224  







110 115 120 121 
Table 5  Summary of differing populations of skeletal muscle progenitors. 
(VCAM1, vascular cell adhesion molecule 1; ADAM12, A Disintegrin And Metalloproteinase 12; 
AP, Alkaline phosphatase) 
 
The response to skeletal muscle injury 
Following skeletal muscle injury a series of well-coordinated events takes place that 
serve to repair the damaged tissue (Figure 5, p39). These events are initiated by the 
release of growth factors and cytokines from injured blood vessels and infiltrating 
inflammatory cells. Cytokines promote the migration, proliferation and survival of 
various cell types at the injury site, while inflammatory cells phagocytose cell debris. 
The formation of new muscle fibres begins with the activation of quiescent satellite 
cells that reside beneath the muscle basal lamina. Satellite cells then proliferate 
extensively and commit to the myoblast lineage, either fusing to each other to generate 




(<5%) contribution to the regenerating myofibres.  Basement membranes of 
necrotic myofibres serve as a scaffold to guide the orientation of myofibres generated 
from satellite cells while also guiding the formation of neuromuscular junctions.  The 
basement membrane of necrotic fibres is eventually phagocytosed during the final 
stages of muscle regeneration. In parallel, muscle repair requires the migration and 
activation of tissue resident fibroblasts which produce ECM components.  Following 
minor injury and in the absence of chronic inflammation these ECM components are 
degraded as regeneration and growth of new myofibres proceeds.  New vascular 
networks are also established. Finally, growth and maturation of newly formed muscle 
fibres occurs. Disruption at any of these stages can result in compromised muscle 
regeneration, typically characterized by persistent myofibre degeneration, 
inflammation and fibrosis.  Similarly, in the setting of moderate to severe injury or 
chronic inflammatory events, the persistence of activated myofibroblasts inevitably 
results in excessive ECM accumulation and fibrosis. 
 
 
Figure 5  Stages in the response to muscle injury  
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Adult stem cell niches 
Adult stem cells 
Adult stem cells are found in almost all organs of the postnatal human body where they are a 
source for organ-specific cell replacement either during the normal cell turnover or under 
pathological conditions. They reside within niches that regulate how they participate in tissue 
generation, maintenance and repair 
225 226
. Some adult stem cell types, such as haematopoietic 
stem cells (HSC) or enteric stem cells, have a high proliferation rate in normal tissue 
maintenance, whereas in other organs adult stem cells only divide under certain conditions, 
stimulated by injury, for example. 
 
Stem cell niches consist of both anatomic and functional dimensions, integrating signals that 
mediate the ability of stem cells to remain within the niche, self-renew or exit and 
differentiate 
227
. Niches are capable of modulating stem cell function in response to 
physiological challenges or injury.  This dynamic capability is particularly important to the 
realisation of regenerative medicine. However, niches may also contribute to disease by 
imposing aberrant function on stem cells.    In contrast to ES cells, the differentiation 
potential of adult stem cells is regarded as more restricted, usually to the cells of the tissue in 
which they reside.  This suggests that differentiation of an adult stem cell into a specialised 
cell is dependent on the surrounding tissue.  However, this classical paradigm of tissue-
specific differentiation capacity continues to be debated, and has been challenged by 
observations of a different degree of plasticity in some adult tissues that has resulted in 
differentiation beyond tissue boundaries
228
. 
What makes up a stem cell niche? 
The niche microenvironment serves as a convergence of signaling pathways that balances 
the stem cell response to the needs of the organism.  Here adult stem cells can receive signals  
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from neighbouring heterologous cells, the surrounding ECM, neural connections or from 
paracrine, humoral or metabolic sources. 
(i) Heterologous cell types: Numerous examples of heterologous cell types regulating stem 
cell behaviour within stem cell niches have been described including the regulation of HSC 
by osteoblasts within bone marrow 
229
 and the endothelium in the regulation of hippocampal 
neurogenesis
230
. However, it is not clear whether it is necessary for cell types other than the 
stem cell itself to be present for a niche to function. 
(ii) Extracellular matrix:  The basement membrane of the niche may participate in 
regulation of adult stem cells 
231
. Matrix components can contribute stimulatory, or impose 
inhibitory, influences on the stem-cell pool
232
.  Within skin, β1 integrins are known to 
participate in localisation of the stem-cell population through interactions with matrix 
glycoproteins 
233
.  Similarly, tenascin c alters neural stem-cell number and function in the 
subventricular zone of the nervous system 
234
. 
 (iii) Paracrine and humoral factors:  Soluble factors are known to be key regulators of 
stem cell function.  The influence of wnts and their antagonists, soluble notch modulators, 
FGFs and hedgehog (HH) on various niches have been reported 
225
.  The circulatory system 
is an obvious means of connecting stem cell reservoirs with information from distant sites.   
 (iv) Metabolic: Metabolic products allow stem cells to respond to varying conditions of 




, a cyclin-dependent kinase inhibitor associated with 
senescence is associated with the presence of reactive oxidative species (ROS).   
(v)  Neural: Neural connections have been reported to influence stem cell behaviour235.  For 
example, mice with altered sympathetic nervous system function lack the ability to mobilize 
stem cells from the bone marrow in response to granulocyte colony-stimulating factor 
(GCSF)
235
.   
                                                             
1 also known as  cyclin-dependent kinase inhibitor 2A,  multiple tumour suppressor 1 
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The balance of signals from these sources serves to control the behaviour of adult stem cells 
in terms of quiescence, self-renewal and differentiation 
236
.   This enables the provision of 
cells for turnover or repair while ensuring that the niche pools can be sufficiently replenished 
for futures times of need. A growing number of studies have highlighted the vasculature as a 




Mesenchymal stem cell ancestors reside in the 
perivascular niche 
Sources of MSC are not restricted to the bone marrow as first thought.  Indeed MSC have 
been isolated from multiple tissues (Table 1, p5).  Pericytes are presumptive MSC that reside 
within a perivascular niche in multiple organs.  Based on knowledge of well-characterised 
adult stem cell niches, it is logical that niche components may be involved in their regulation 
(Figure 6, p45).  This appears particularly plausible given the vastly different phenotypes of 
pericytes seen when they reside within this niche or are dissociated from vessel walls.  
Indeed a significant obstacle in identification of the perivascular origin of MSC was the 
reluctance of pericytes to express mesenchymal phenotypes in their native environment
129
.  
However when dissociated in culture the cells readily differentiated down mesenchymal 
lineages.  Although feasible that pericytes acquire MSC potentials on exiting the vasculature, 
it is intuitive that they are natively present and environmentally down regulated.  Studies 
using unfractionated stromal vascular fraction (SVF) have demonstrated poor and unreliable 
tissue formation 
133
 or lower regeneration efficacy relative to prospectively isolated and 
purified MSC 
133
, lending further support to a hypothesis that a cellular component of SVF 
may have an inhibitory effect on differentiating MSC.  Osteogenic and adipogenic 
differentiation is not seen within the perivasculature of healthy tissues where the pericyte/EC 
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relationship is undisturbed.  However, disturbed pericyte/EC relationships have been 
observed in conditions associated with pathological mineralisation and adipogenesis (e.g. 
heterotopic ossification and atherosclerosis)
232 239
.  In addition, the extracellular matrix 
(ECM) proteins, also present within a perivascular niche, have been shown to modify growth 
and differentiation of MSC, with collagen 1, fibronectin and vitronectin treated plates 
enhancing mineralization in vitro
240
.   
 
 
Figure 6  Components of the perivascular niche for MSC-precursors   
Here, adjacent EC, extracellular matrix, paracrine, humoral, metabolic and neural factors 
control the balance between quiescence, self-renewal and differentiation. 
 
Pericytes/Endothelial Interactions – what is known? 
Although the concept of a perivascular niche for MSC precursors is relatively novel, 
interactions between pericytes and EC have been studied extensively in the context of 
angiogenesis.  Knowledge gained in these settings is likely to be relevant to understanding 
the regulation of pericytes in their roles as MSC-precursors. 
 
Genetic mouse models have demonstrated that these two vascular cell types are 
interdependent; primary defects in one cell type have obligated consequences for the other.  
There is growing evidence to suggest that EC can manipulate the migratory and angiogenic 
properties of pericytes while the intimate anatomical relationship between EC and pericytes 
suggests close interactions involving paracrine or juxtacrine signalling.  Pericytes are 
Section 1:  EC accelerate the osteogenic differentiation of pericytes 
  Introduction           
46 
ubiquitously present in blood microvessels where they extend primary cytoplasmic processes 
along the abluminal surface of the endothelial tube.  They are enveloped in a basement 
membrane that is continuous with the EC basement membrane to which both cells contribute 
241 242
.  The majority of the pericyte-EC interface is separated by basement membrane, with 
the two cell types contacting each other at discrete points through peg and socket type 
interactions, occluding contacts, gap junctions and adhesion plaques
243 244
. EC to pericyte 
ratios in normal tissues vary between 1:1 and 10:1 and pericyte coverage of the endothelial 




.  Pericyte density and coverage appear 
to correlate with endothelial barrier properties (i.e. brain>lungs>muscle)
246
, EC turnover 
(large turnover=less coverage)
244
 and orthostatic blood pressure (larger coverage in lower 
body parts)
43
 in keeping with a role of pericytes in regulating capillary barriers, endothelial 




The formation of capillary-like structures during angiogenesis requires a series of well-
orchestrated cellular events allowing EC and pericytes to migrate into the perivascular space. 
In vessel sprouting, angiogenic factors (e.g., VEGF) stimulate EC, which in turn start secrete 
proteases that degrade basement membrane and allow EC invasion. An endothelial column, 
guided by a migrating EC at the very tip then moves toward a VEGF gradient
243
. Studies of 
the corpus luteum indicate that pericytes are also capable of guiding sprouting processes by 
migrating ahead of EC and expressing VEGF
247-249
. Emerging endothelial tubes then secrete 
growth factors, partly to attract pericytes that envelop the vessel wall, and promote vessel 
maturation. Key pathways implicated in pericyte-EC signalling include PDGF/PDGFRβ, 
angiopoietins and tie receptors, sphingosine-1-phosphate signalling, TGFβ signalling, Notch 
and wnt
245 250-252
. It is believed that pericytes, because of their vessel-embracing position, are 
able to transfer angiogenic signals along the vessel length by contacting numerous EC.  
Pericyte recruitment and migration frequently occur in response to pathophysiological events 
such as wound healing, inflammation, or angiogenesis. Increase of pericyte density by 
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activation of PDGF-BB/ PDGFRβ signaling pathways has also been detected during wound 




Endothelial cells influence the differentiation of MSC 
Even without reference to the perivascular niche, a number of investigators have reported 
that EC influence the differentiation of conventionally (culture) derived MSC with divergent 
results (Table 6, p48). 
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Table 6  The influence of EC on the multipotency of tissue specific MSC 
(ASC, adipose-derived stem cells; BMSC, bone marrow MSC, HOP, human osteoprogenitor cells, HUVEC, human umbilical vein endothelial cells; 
HDMEC, human dermal microvascular endothelial cells; EPC, endothelial progenitor cells; HSVEC, human saphenous vein endothelial cells)











Endothelial Cell 3D ASC HUVEC Osteogenesis ↓ paracrine ↑Wnt Rajashekhar135 
Endothelial Cell 3D ASC HUVEC Osteogenesis ↓ juxtacrine ↑Wnt Rajashekhar135 
Endothelial Cell 2D BMSC HUVEC Osteogenesis ↑ Paracrine (Wnt, FGF, PDGF, BMP, 
TGFβ, Notch) 
Saleh254 
Endothelial Cell 2D BMSC HUVEC Adipogenesis - Paracrine - Saleh255 
Endothelial Cell 2D BMSC HUVEC Osteogenesis ↑ juxtacrine - Xue256 
Endothelial Cell 2D BMSC HDMEC Osteogenesis ↑ juxtacrine BMP-2 Kaigler257 
Endothelial Cell 2D BMSC HDMEC osteogenesis - paracrine - Kaigler257 
Endothelial Cell 2D BMSC HDMEC Osteogenesis ↑ juxtacrine N-cadherin Li258 
Endothelial Cell 2D BMSC HDMEC Osteogenesis ↑ paracrine VEGF Grellier259 
Endothelial Cell 2D BMSC HDMEC Osteogenesis ↓ Paracrine Osterix/OSX Meury136 
Endothelial Cell 2D BMSC HUVEC Osteogenesis ↑ juxtacrine Cx43/gap junctions Villars21260 
Endothelial Cell 2D BMSC HUVEC Osteogenesis ↑ juxtacrine - Villars 22261 
Endothelial Cell 2D HOP HUVEC Osteogenesis ↑ juxtacrine - Guillotin262 
Endothelial Cell 2D HOP EPC, HSVEC Osteogenesis ↑ juxtacrine Cx43/gap junctions Guillotin262 
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Regulators of conventional MSC differentiation: overview 
The perivascular niche for MSC represents a relatively novel concept and so there have been 
few studies exploring the regulation of pericyte “MSC” functionality by niche components. 
However, there is also an extensive literature describing signaling pathways recognized to 
control MSC fate decisions (Figure 7, p50).  These include bone morphogenetic protein 
(BMP), Sonic Hedgehog (SHH), Wnt, pparg, Sox9 and Runx2. Interestingly, inducers of 
differentiation along one lineage often inhibit differentiation along the other.  For example, 
the transcription factor peroxisome proliferator-activated receptor gamma (pparg) is a prime 
inducer of adipogenesis that inhibits osteogenesis highlighting the mutual exclusivity of these 
lineages
263
. (BMP) signaling molecules (particularly BMP2, BMP4, BMP6 and BMP7) act as 
major osteogenic inducers and may influence adipocyte differentiation
264
. Downstream 
pathways of an intercellular sonic hedgehog (SHH) signaling molecule have been shown to 
inhibit adipogenesis and induce osteogenesis
265
.  EC are recognized to actively signal through 
a number of these pathways. It is likely that signalling mechanisms responsible for the 
mesenchymal fate of pericytes will be multifactorial and distinct for different lineages.  
Pericytes have many important roles within specific tissues unrelated to their mesenchymal 
phenotype (e.g. control of vascular tone and the production of renin within the kidney).  









Figure 7 Regulators of MSC fate.   
MSC are capable of differentiating into cells of functionally distinct lineages. A number of 
regulators control MSC lineage fate. (Abbreviations: BMP, bone morphogenetic protein; 
C/eBP, CCAAT/enhancer binding protein; GLi, GLi family zinc finger; KLF, Kruppel-like factor; 
MSC, mesenchymal stem cell; MYF, myogenic factor; MyoD, myogenic differentiation 1; 
Nr3C1, nuclear receptor subfamily 3, group C, member 1; PPARγ, peroxisome proliferator-
activated receptor gamma; RUNX2, runt-related transcription factor 2; SOX, sex determining 
region Y-box; SHH, sonic hedgehog homolog; sP7, sp7 transcription factor (formerly known 
as osterix); TGF-β, transforming growth factor β; wwTr1, ww domain containing transcription 
regulator 1 (formerly known as TAZ)). [From Takada I, Kouzmenko AP, Kato S.  Wnt and 
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Section 1 hypothesis and aims 
It is our central hypothesis that interactions with EC modulate the osteogenic differentiation 
of pericytes.   
 
In order to address this hypothesis the following aims were established. 
(i)   Isolate pericytes and demonstrate their mesenchymal phenotype in vitro  
(ii)  Generate two- and three-dimensional models of the perivascular niche 
(iii) Establish the influence of EC on the osteogenic, adipogenic and chondrogenic 
differentiation of pericytes. 
(iv) Establish a potential role for wnt signalling in the EC mediated acceleration of pericyte 
osteogenic differentiation 
 
Why is this of clinical importance? 
Understanding the native regulation of osteogenic differentiation of pericytes in muscle and 
other organs is of significant clinical importance.  Pathological osteogenic differentiation 
contributes to heterotopic ossification in over 40% of patients undergoing total hip 
replacement.  Furthermore, down regulating pericyte multipotency has implications for 
conditions where pathologic pericyte potentials are contributory such as tumorigenesis, 
atherosclerosis and aberrant calcification.  An ability to modulate this process would facilitate 
future therapies.   
 
In addition, this knowledge could also be harnessed where accelerated osteogenesis is 
desirable and treatments are currently limited by inadequate graft material.  Bone disease has 
a major impact on the population as a whole and especially on affected individuals and their 
families.  Osteoporotic fractures alone account for 1.5 million fractures in the US annually 
leading to over 500,000 hospitalizations, with direct costs over $15 billion.  There is great 
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need for improved methods of preventing and treating fractures.  Current stem cell strategies 
depend on the transplantation of cells with additional morbidity of harvesting autologously.    
Stimulation of osteogenic differentiation by pericytes could improve bone mineral density 
and even accelerate normal bone healing to reduce treatment times following fracture.  
Systemic stimulation of pericytes to differentiate into bone could be harnessed in the 
treatment of osteoporosis.  Local targeted stimulation of pericytes could be used to accelerate 
healing and prevent non-union.  The principle of pericyte stimulation could be applied to 
other lineages including cardiomyocyte, myogenic and chondrogenic differentiation with 
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Sorting of Perivascular Cells 
Procurement and storage of tissues 
Human foetal tissues were obtained from elective medical pregnancy interruptions, 
with informed consent from the donor with full ethics committee approval (Lothian 
Research Ethics Committee 10/S1103/45).  The age of the foetus was verified using the 
crown to rump length and foot length prior to dissection carried out using sterile 
scissors and forceps.  Samples were placed in HBSS/5%FBS/1%PS for transfer to the 
laboratory and stored for a maximum of 48 hours prior to use. 
 
Adult whole fat and lipoaspirate were obtained from surgery, upon which they would 
normally have been discarded (Lothian Research Ethics Committee 10/S1103/45).  
Samples were placed in DMEM/20%FBS/1%PS for transfer to the laboratory and stored 
for a maximum of 48 hours prior to use. 
 
Extraction of cellular fraction from human foetal tissues 
Individual tissues (skeletal muscle and placenta) were cut into small pieces (2mm3) and 
digested in collagenase containing medium [DMEM with 0.5mg/ml of each collagenase 
IA-S, II-S and IV-S (Sigma Aldrich)] for 30 min in a shaking water bath (200rpm) at 
37oC.  An equal volume of DMEM/10%FBS/1%PS was added to halt the digestion and 
the total suspension was passed through a sterilized nylon mesh to remove large 
clumps.  The suspension was then passed through a 100µm, 70µm, and 30µm strainers 
consecutively and centrifuged (300 g, RT, 5 min).  The supernatant was discarded and 
the pellet was re-suspended in 5ml red cell lysis buffer (Sigma Aldrich) and incubated at 
RT for 2 min.  40mls of DMEM/10%FBS/1%PS was added and the suspension 
centrifuged (1500 rpm, RT, 5 min).  The supernatant was again discarded and the pellet 
was resuspended in 1ml PBS/5%mouse serum (blocking step) with a 10ul aliquot taken 
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for counting in a haemocytometer using Trypan blue to distinguish non-viable cells.  
After 10 min of blocking, 40mls of PBS/2%FCS was added and the cell solution 
entrifuged at 1500rpm for 5 min in preparation for staining (see below). 
 
Extraction of cellular fraction from whole fat and lipoaspirate 
Whole fat was grated to increase the surface area prior to digestion.  Grated adipose 
tissue or lipoaspirate was transferred to a flask with digestion medium at a volume ratio 
of 1:1.  The digestion medium was composed of DMEM, collagenase type II (1mg/ml 
final concentration) and 3.5% bovine serum albumin (BSA).  Adipose tissue was 
incubated in the digestion medium for 30 min in a shaking waterbath (250rpm) at 37oC.  
An equal volume of DMEN/10%FCS/1%PS was added and the suspension centrifuged 
for 10 min at 1500rpm.  The supernatant was removed with the residual pellet 
resuspended in 50ml PBS/2%FCS.  This cell solution was then passed through a 100µm, 
70µm, and 30µm strainers consecutively and centrifuged (300 g, RT, 5 min).  The 
supernatant was discarded and the pellet was re-suspended in 5ml red cell lysis buffer 
(Sigma Aldrich) and incubated at RT for 2 min.  40mls of DMEM/10%FBS/1%PS was 
added and the suspension centrifuged (1500 rpm, RT, 5 min).  The supernatant was 
again discarded and the pellet was resuspended in 1ml PBS/5%mouse serum (blocking 
step) with a 10ul aliquot taken for counting in a haemocytometer using Trypan blue to 
distinguish non-viable cells.  After 10 min of blocking, 40mls of PBS/2%FCS was added 
and the cell solution entrifuged at 1500rpm for 5 min in preparation for staining (see 
below). 
 
Fluorescence-activated cell sorting of PSC and EC 
In preparation for fluorescence activated cell sorting (FACS), cells were resuspended at 
a concentration of 30x106/ml and incubated with all antibodies at the appropriate 
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dilution (Table 7, p57).  As controls, 5x105 cells were incubated with isotype control 
antibodies in the same conditions.  The cell suspensions were incubated with the 
antibodies on ice and in the dark for 20 min then washed with PBS/2%FBS and 
centrifuged (300 g, RT, 5 min).  The supernatant was then discarded and the cells 




Conjugate Supplier dilution Isotype control antibody 
CD146 
 






1:100 APC-Cy7 – conjugated mouse IgG1 





1:100 PE-Cy7- conjugated mouse IgG1  





1:100 FITC-conjugated mouse IgG1  





1:100 PE- conjugated mouse IgG1  
(1:100; BD Biosciences) 
CD144  
 
PerCp Cy5 BD 
Biosciences 
1:100 PerCp Cy5 - conjugated mouse IgG1 
(1:100;BD Biosciences) 
Table 7  Antibodies and corresponding isotype controls for HUMAN perivascular cell 
purification and analysis 
 
Cells were sorted using a flow cytometer (FACSAria, Becton-Dickinson).  The 
fluorescence compensation settings were optimized using anti-mouse Ig, κ/negative 
control beads plus (BD Biosciences) incubated with the range of FACS antibodies used.  
Unstained cells were used to account for the autofluorescence of samples and 
fluorescently matched isotypes and fluorescence-minus-one samples were used as 
negative controls.  Prior to selection of perivascular cell populations, a side versus 
forward scatter plot was used to remove debris then a height versus width plot was 
used to eliminate doublets.  DAPI [0.1-0.5µg/ml (Invitrogen)] was used to eliminate 
dead cells then cells positive for CD45 and CD56 were negatively gated to remove 
hematopoietic and myogenic cells respectively.  Remaining cells that were positive for 
CD31, CD34 and CD144 were collected as EC. Cells negative for CD31, CD34, CD144 and 
positive for CD146 were collected as pericytes.  Cells negative for CD31, CD144, CD146 
and positive for CD34 were collected as adventitial cells.  The cell surface marker 
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profiles used to distincguish these cell types are summarised in (Table 8, p58).  All cells 
were collected in endothelial cell growth medium [EGM2 (Lonza)].  A portion of the 
selected populations were reanalysed using flow cytometry to confirm purity.  In 
addition, reverse transcription polymerase chain reaction (RT-PCR) was used during 
culture to assess transcription of genes expressed by cells that should have been 
excluded. 
Cell Surface Marker Pericytes Adventitial Cells Endothelial Cells 
CD45 - - - 
CD56 - - - 
CD31 - - + 
CD144 - - + 
CD34 - + + 
CD146 + - + 
Table 8  Cell surface marker profiles used to distinguish pericytes, adventitial cells and 
endothelial cells using FACS.   
Cell culture 
Sorted cells were seeded onto fibronectin coated tissue culture plates, at a density of 
2x104 cells per cm2 and cultured in EGM2 medium in a 37oC, 5% CO2 incubator.  EGM2 
medium was changed after 7 days and then three times/wk until 100% confluence was 
reached.  After an initial passage, pericytes and adventitial cells were seeded on 
uncoated tissue culture plates at 2x104 cells/cm2 in high-glucose 
DMEM/20%FBS/1%PS, and grown until confluent in a 37oC, 5% CO2 incubator.  After an 
initial passage, EC were seeded on fibronectin coated tissue culture plates at 2x104 
cells/cm2 in EGM2, and grown until confluent in a 37oC, 5% CO2 incubator.  On 
subsequent passages the cells were re-plated in larger vessels with the appropriate 
volume of medium (Table 9, p59).  Once confluent in a T75 flask the cells were passaged 
at a ratio of 1:6. 
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Container Surface Area (cm2) Volume of Medium (ml) 
1 well of a 96-well culture plate 0.32 0.370 
1 well of a 48-well culture plate  0.75 0.5-0.8 
1 well of a 24-well culture plate  2 0.8-1 
1 well of a 12-well culture plate  3.8 1.5-2.2 
1 wells of a 6-well culture plate  9.6 2.5-3 
25cm2 culture flask  25 5 
75cm2 culture flask  75 10 
Table 9  Media volumes used for perivascular cell culture 
 
Surplus cells were frozen in FBS/10% DMSO (dimethyl sulfoxide) at a concentration of 
5x105-1x106 cells/ml in cryovials and stored at -80oC prior to transfer to liquid nitrogen 
for long-term storage.  Cells were also resuspended in TRIzol (Invitrogen) and frozen at 
-80oC prior to extraction of RNA. 
Two dimensional coculture of PSC and EC 
Gelatin coated 12-well plates were seeded with HUVEC and cultured in EGM2 until 
confluent.  A single well was sacrificed for counting with pericytes then seeded in 
isolation or in coculture at a ratio of HUVEC:pericyte 4:1.  When overlying pericytes 
reached 80% confluence wells were transferred to differentiation conditions. 
Two-dimensional Transwell co-culture  
In order to determine the influence of EC on pericytes independent of direct contact, EC 
and pericytes were cultured together separated by a semipermeable membrane (0.2μm 
pores) in a Transwell (Corning) system.  Gelatin coated 12-well plates were seeded with 
pericytes and cultured in EGM2 until confluent.  A single well was sacrificed for 
counting.  HUVEC (at a ratio of 4 HUVEC to 1 pericyte) were then seeded onto gelatin-
coated Transwell inserts (Corning) and placed within wells.   After 24hrs of Transwell 
coculture in EGM2, wells were changed to osteogenic medium (Lonza). 
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Three-dimensional coculture of PSC and EC 
For the spheres and pellet assays we used a non-endothelial control cell type in order to 
maintain 3D spheroid size and conditions. We selected human dermal fibroblasts (HDF) 
as controls, representing a related stromal cell type, but lacking both endothelial and 
pericyte characteristics. 
Spheres assay 
Coculture spheroids of pericytes with HUVEC or HDF were generated statically. In brief, 
equal numbers of suspended pericytes and HUVEC as well as equal numbers of both 
pericytes and HDF (15,000 cells each per spheroid) were mixed, centrifuged and 
resuspended in co-culture medium of DMEM: EGM2 (1:1)/ 10% FBS /1%PS. Mixed cells 
were then seeded into non-adherent round-bottom 96-well plates (Fisher) to generate 
overnight pericyte/HUVEC and pericyte/HDF spheroids containing 30,000 cells 
/spheroid. 
Pellet culture  
Pellet cultures were generated and cultured in basal conditions. Approximately 250,000 
pericytes were placed either alone or together with HUVEC or HDF (in 15ml 
polypropylene falcon tubes) and centrifuged to pellet (1500rpm for 5 min).  
Tube assemble (vasculogenic) assay  
Pericytes and HUVEC were fluorescently labelled using red (PKH26, Sigma Aldrich) and 
green (PKH67, Sigma Aldrich) membrane dyes as per manufacturers guidelines.    In 
short, cells were trypsinized, centrifuged to pellet and the supernatant removed. Cells 
were then resuspended in 5μM PKH24 or PKH67 in pre-warmed serum-free basal 
medium for 3 min at 37°C. Labelling was terminated by addition of FBS and any 
unincorporated stain was removed by washing with complete culture medium twice.
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Labelled EC were then suspended whether alone or with labelled pericytes in EGM2 to a 
total concentration of 2x104 cells/ml.  50µl of cell solution was added per well of a 15 
well angiogenesis µ-slide (Ibidi), precoated with a thick layer of Matrigel (BD 
Biosciences) as per slide manufacturer’s guidelines.  The assembly of vascular networks 
over time was captured using fluorescent and brightfield time-lapse imaging (Axio 
Observer, Zeiss).   
Differentiation medias 
Complete osteogenic and adipogenic media were purchased from Lonza. Chondrogenic 
medium was made within our lab from published protocols (DMEM containing 10% 
FBS, 1% PS, 8μl/ml proline, 10μl/ml ITS + Premix [Becton Dickinson; 6.25g/ml insulin, 
6.25g/ml transferrin, 6.25ng/ml selenious acid, 1.25 mg/ml BSA, and 5.35 mg/ml 
linoleic acid], 10μl/ml sodium pyruvate, 1μl/ml transforming growth factor (TGF)‐β3, 
10μl/ml ascorbic acid and 0.1μl/ml dexamethasone).   
Wnt modulators 
To investigate the influence of wnt modulators on cultured cells, osteogenic medium 
was supplemented with ICG (ChemPacific; final concentration 10μM), C59 (Cellagen 
Technology; final concentration 10μM) and CHIR (Axon; final concentration 10μM). 
Pericyte proliferation in coculture  
To determine the influence of EC on the proliferation of pericytes, 40,000 pericytes were 
first seeded into 6 well plates (Corning).  Pericytes were cultured alone, in direct co-
culture with EC or in indirect “Transwell coculture” as described above.  For EC 
coculture, EC were added to wells or Transwells 4 hours after the seeding of pericytes.    
At day 3, 6 and 9, wells were trypsinised and total viable cells counted using a 
haemocytometer with trypan blue used to exclude non-viable cells.  Cells from 
individual wells were then stained with antibody to the EC marker CD144 (BD 
BioSciences) and analyzed using flow cytometry.  The total number of pericytes per 
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coculture well was extrapolated from the total mixed cell count and the pericyte to EC 
ratio on flow cytometry. 
 
Immunohistochemistry 
Histology and preparation of tissues 
Fresh human foetal tissues were frozen in Optimal Cutting Temperature (OCT) 
compound prior to sectioning.  For freezing, tissue was immersed in OCT and lowered 
into a beaker of isopentane (cooled by surrounding the beaker with liquid nitrogen).  
7µm sections were cut using a cryostat at -30oC and mounted on Superfrost slides 
(Thermo Scientific) and fixed in ice-cold methanol:acetone (1:1) for 5 min.  Sections 
were air dried and stored at -80oC prior to immunohistochemistry. 
Detection of perivascular cells in human tissues 
Tissue sections were air dried then stained for the pericyte marker NG2.  Sections were 
washed with PBS/Tween20 pH7.4 (2x5 min) then blocked for 1 h with 5% goat serum.  
After blocking, the cells were incubated with fluorochrome-coupled antibodies 
overnight at 4oC or were blocked to prevent non-specific avidin and biotin interactions 
prior to overnight incubation with the primary antibody at 4oC.  Sections incubated with 
primary antibodies were washed with PBS/Tween20 pH7.4 (2x5 min) prior to 
incubation with the secondary antibody for one hour at RT.  All sections were then 
washed with PBS/Tween20 pH7.4 (2x5 min) and incubated with DAPI (5µg/ml) and 
Alexa-Fluor coupled streptavidin [1 in 1000 dilution (Invitrogen)] for 45 min.  After a 
final PBS/Tween20 pH7.4 wash  (2x5 min) the cells were mounted in fluorescent 
mounting medium (Dako) and allowed to dry for 1 hr.   
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Presence of basement membrane proteins (collagen IV and laminin) within microvessels 
Sections were stained with antibodies against the basement membrane proteins laminin 
and collagen IV.  The optimal concentration of antibodies was determined in titration 
experiments.  Air dried sections were fixed in ice cold methanol/acetone (1:1) for 10 
min, washed with PBS/Tween20 pH7.4 (3x5 min) then blocked for one hour with 5% 
goat serum prior to overnight incubation with the primary antibody at 4oC.  Goat serum 
(Sigma-Aldrich) was used as an isotype control for the polyclonal goat anti-human 
collagen IV (Sigma-Aldrich) antibody 1:400.  Rabbit IgG (Dako) was used as an isotype 
control for the polyclonal rabbit anti-human laminin (Millipore) antibody.   
 
Following overnight incubation, sections were washed with PBS/Tween20 pH7.4 (3x5 
min).  Donkey anti-goat Alexa Fluor 555 (Invitrogen) 1:400 was used as the secondary 
antibody for collagen IV staining and corresponding isotype.  Goat anti-rabbit Alexa 647 
(Invitrogen) 1:400 was used as the secondary antibody for laminin staining and 
corresponding isotype.  Sections were incubated for 1 h at RT in the dark.  Sections were 
then washed with PBS/Tween20 pH7.4 (3x5 min), stained with DAPI (5µg/ml).  
Following a final wash of PBS/Tween20 pH7.4 (3x5 min), sections were mounted with 
fluorescence medium (Dako). 
Considerations for immunohistochemistry in spheres and pellet coculture 
For freezing, spheroids or pellets were removed from wells and immersed in OCT prior 
to freezing as above.  7µm sections were cut using a cryostat at -30oC and mounted on 
Superfrost slides (ThermoScientific) and fixed in ice-cold methanol:acetone (1:1) for 5 
min.  Sections were air dried and stored at -80oC prior to immunohistochemistry as 
above. 
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Considerations for immunohistochemistry in tube assembly (vasculogenic) coculture 
Vascular networks using unlabelled cells were allowed to develop for 4 h following 
seeding before being fixed with 2%PFA for 15 min. Immunohistochemistry for collagen 
IV and laminin was performed as described above.  However, as Matrigel readily 
becomes a liquid when cooled, primary incubations were performed at RT for 1 h 
instead of at 4oC overnight. 
Fluorescence imaging 
Sections were examined using a fluorescence microscope (Nikon Eclipse E800) and 
images were captured using a Zeiss camera.  Fluorescent and brightfield images of 
vascular networks were captured using Axio Observer inverted microscope with a Zeiss 
camera.  Max projection images were generated using Image J. 
 
Histological stains 
Alizarin Red Osteogenesis Assay 
Alizarin red staining for mineralisation was performed using the Osteogenesis Assay Kit 
(Millipore).  In brief, medium was first aspirated and wells washed twice with 2ml PBS.  
Cells were fixed with 10% PFA at room temperature for 15 min and then washed 3 
times with distilled water.  Wells were then covered with Alizarin Red stain solution for 
20 min at room temperature.  Excess dye was then removed and wells washed 4 times 
with distilled water.  Wells were covered with distilled water for visual inspection and 
image acquisition.  Brightfield microscopy was performed using Observer Microscope 
(Zeiss) with images captured on a Zeiss Colour camera.   
 
Quantitative analysis of Alizarin Red staining was performed by determining OD405  
values of a set of known Alizarin Red concentrations and comparing these values to 
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those obtained from unknown samples.  In short, 400µl 10% acetic acid was added to 
each well and incubated at room temperature for 30 min.  The loosely attached 
monolayer was then scraped together with the acetic acid into a 1.5ml microcentrifuge 
tube and vortexed for 30 s.  The sample was then heated to 85oC for 10 min, cooled and 
centrifuged at 20,000 g for 15 min.  400 µl of the supernatant was transferred to a new 
1.5ml microcentrifuge tube and neutralized with 150µl 10% ammonium hydroxide.  
150µl of this sample was then added to an opaque walled, transparent bottom 96-well 
plate and read at OD405.  The sample readings were compared with Alizarin Red 
standards at a high and low range to determine Alizarin Red concentration. 
Oil Red O 
Oil red O can be used to detect lipid droplets produced by adipocytes, due to high 
solubility in lipids.  Cells were fixed with 4% PFA and washed three times with distilled 
water, then once with 60% isopropyl alcohol.  Stock solution (Oil Red O 0.5% (w/v) in 
isopropyl alcohol) was diluted 3:2 in distilled water, allowed to stand for 10 min then 
filtered through a 0.22um filter.  This ‘working’ solution of Oil Red O was added to cells 
and allowed to incubate for 15 min at room temperature.  The cells were then rinsed 
briefly with 60% isopropyl alcohol, then washed three times with water prior to 
imaging.   
von Kossa 
von Kossa staining was carried out to assess mineralisation in the form of phosphate 
crystals.  The principle of this stain is the silver ions react with phosphate and 
precipitate as a metallic silver under bright light, resulting in black staining.  Briefly, 
cells were fixed in 4% PFA, washed three times with distilled water, then incubated with 
5% (w/v) silver nitrate solution before being exposed to a 60 watt light bulb for 10-15 
min.  This allowed staining of any mineralized matrix produced, but not of the 
substrates that also contain calcium phosphate.  Following exposure, cells were washed 
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in distilled water and incubated in 5% (w/v) sodium thiosulphate solution for 5 min to 
remove any unreacted silver nitrate.  Cells were washed three times in distilled water 
and the cells counterstained with DAPI. 
Safranin O 
Safranin O is a dye that binds to glycosaminoglycans, which make up a large proportion 
of extracellular matrix found in cartilage266.   Cells were fixed with 4% PFA for 10mins 
and washed three times with distilled water and once with 1% acetic acid for 10 s.  
Safranin O 0.1% (w/v) solution was added to cells and allowed to incubate for 5 min at 
room temperature.  Then the cells were washed three times with water and 
counterstained with DAPI. 
 
Staining for Cell Viability 
Chloromethylfluorescein diacetate (CMFDA) and propridium iodide (PI) 
To establish the survival of cells within spheroids, a live/dead assay was performed. 
Green CMFDA (5-chloromethylfluorescein diacetate) Cell Tracker (MolecularProbes, 
Invitrogen) was used to visualize live cells, and propidium iodide (PI), a nucleic acid 
stain, was used to identify non-viable cells.  Fluorescence was observed on Z-stack 
analysis of confocal microscopy images.  Max projection images were generated using 
Velocity 3D Image Analysis software. 
Assessment of cell viability within pellets by lactate dehydrogenase (LDH) activity  
Viable cells were identified in cryostat sections (8μm) by means of their LDH activity as 
previously described267 268. Tetrazolium salt methods are well‐established precipitation 
reactions that allow observation of the activity of dehydrogenases. Here, enzyme‐
catalyzed oxidation of lactate, which is a substrate for LDH, releases protons that are 
picked up by the co‐enzyme NAD. The reduced co-enzyme reduces 1‐methoxy‐
Materials and Methods 
Section 1:  EC accelerate the osteogenic differentiation of pericytes 
 
67 
methylsulfate which is an electron carrier that transfers the electrons to the tetrazolium 
salt to generate formazan, a dark, purple, water insoluble precipitate269. Briefly, the 
reaction was performed using 1.75mg/ml nicotinamide-adenine dinucleotide, 60mm 
lactic acid, 3mg/ml nitroblue tetrazolium and 50% polypep in 0.05M glycine (all Sigma 
Aldrich) buffer (pH 8.0). Sections were incubated for 3 h at 37oC in a humidified 




Cells were lysed by repeated pipetting in TRIzol [1ml per 5-10x106 cells (Invitrogen)] 
after which the homogenate was incubated for 5 min at RT.  Chloroform (0.2ml per 1ml 
of TRIzol) was added to the homogenate and the solution was shaken vigorously for 15 s 
then incubated at RT for 3 min.  Samples were centrifuged (12000 g, 4oC, 15 min) and 
the colourless, upper aqueous phase containing RNA was transferred to a fresh tube and 
the RNA was precipitated by mixing with isopropyl alcohol (0.5ml per 1ml TRIzol).  
Samples were incubated at RT for 15 min then centrifuged (12000 g, 4oC, 10 min).  The 
supernatant was discarded and the pellets were washed in 75% ethanol (1ml per 1ml 
TRIzol) then the samples were centrifuged (7500 g, 4oC, 5 mins).  Finally, the pellets 
were air-dried then dissolved in 20µl of RNAse free water an incubated for 10 min at 
55oC.  A spectrophotometer (NanoDrop ND-1000, Thermo Scientific) at a spectrum of 
230-280nm was used to determine RNA concentration and protein contamination.  The 
RNA was stored at -80oC prior to further analysis. 
cDNA synthesis 
RNA was denatured (5min, 65oC) in a reaction mixture containing 1µg RNA, 25ng of 
random primers (Promega) and dNTPs at a final concentration of 0.5mM (Bioline).  The 
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samples were then cooled on ice for 1 min after which 4µl 5xFirst strand buffer and 1µl 
0.1mM DTT were added.  After 2 min, 1µl SuperScript reverse transcriptase was added 
[all reagents provided with SuperScript III reverse transcriptase system kit 
(Invitrogen)].  Samples were incubated at 25oC for 10 min then at 42oC for 50 min and 
finally 70oC for 15 min.  The cDNA was stored at -20oC prior to further analysis. 
Polymerase chain reaction  
The reaction mixture was composed of 4µl MyTaq reaction buffer, dNTPs at a final 
concentration of 0.5mM and 0.2µl Taq polymerase (all Bioline) in addition to 13.6µl 
RNAse free water, 1µl cDNAsample, 0.5µl of forward primer and 0.5µl of reverse primer 
(10µM, Integrated DNA Technologies Inc). Reactions were carried out in a Venti 96 Well 
thermo cycler (Applied Biosystems) using the cycle conditions listed in Table 10, p68.  
Sequences of validated target and reference genes are listed in the Table 11, p68. 
Number of cycles Duration Temperature (oC) 
1 10 min 94 
35 10 s 94 
 30 s 58 
 50 s 72 
1 7 min 72 
Table 10 Thermal cycler program details for PCR  
 
Primer  Sequence 
CD45 F CATGTACTGCTCCTGATAAGA  
 R GCCTACACTTGACATGCATAC  
CD56 F GATTTTGCCTATCCCAGTGCC  
 R CATACTTCTTCACCCACTGCT  
CD31 F GAAGTACGGATCTATGACTCAG 
 R GTGAGTCACTTGAATGGTGCA 
CD144 F TGGAGACTCCTTCAAGCTTCA  
 R GCTTCCACCACGATCTCATAC  
CD34 F CATCACTGGCTATTTCCTGAT  
 R AGCCGAATGTGTAAAGGACAG  
CD146 F AAGGCAACCTCAGCCATGTCG  
 R CTCGACTCCACAGTCTGGGAC  
Beta-actin F CCTCGCCTTTGCGCATCC  
 R GGAATCCTTCTGACCCATGC  
Table 11 Primer sequences used to perform mRNA analysis  
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Agarose gel electrophoresis 
The PCR products were electrophoresed on 1.7% agarose [SeaKem LE agarose (Lonza)] 
gels made with 0.5xTBE buffer (45mM Trisbase, 45mM boric acid, 0.625M EDTA) and 
Gel Red (5µl/100ml).  For sample loading, 2µl PCR product was mixed with 8µl RNAse 
free water and 2µl loading buffer.  The PCR product was electrophoresed at 120V for 80 
min after which the PCR product bands were visualized by exposure to ultraviolet light 
using a UVI pro system (UVItec). 
Quantitative real-time PCR 
The reaction mixture was composed of 4µl 2x Master Mix (Roche), 1.92µl of 2µM 
primers R + L (Applied Biosystems), 0.08µl UPL probes (Roche) and 2µl cDNA (1/10 
dilution).  Reactions were carried out in a LightCycler 480 real time PCR system (Roche) 
using the cycle conditions listed in Table 12 (p69).  Sequences of validated target and 
reference genes are listed in Table 13 (p69). 
 
Program Number of cycles Duration (s) Temperature (oC) 
Pre-incubation 1 10  95 
Amplification 45 10  95 
  30  60 
Cooling 1 30 72 
Table 12  Thermal cycler programme details for qPCR. 
 
Table 13  Primer sequences for qPCR  
 
 
Primer  Sequence 
HPRT F TGACCTTGATTTATTTTGCATACC 
 R CGAGCAAGACGTTCAGCCT 
beta-actin F CCAACCGCGAGAAGATGA 
 R CCAGAGGCTGACAGGGATAG 
Alkaline phosphatase (AP) F TCACTCTCCGAGATGGTGGT 
 R GTGCCCGTGGTCAATTCT 
Osteopontin (SPP1) F CGCAGACCTGACATCCAGTA 
 R GGCTGTCCCAATCAGAAGG 
Collagen 1 (Col 1) F GGGATTCCCTGGACCTAAAG 
 R GGAACACCTCGCTCTCCA 
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Pericytes expressing all known markers of mesenchymal stem cells (MSC) can be sorted 
to homogeneity using fluorescence activated cell sorting (FACS).14 270  Pericytes sorted in 
this way maintain expression of pericyte and MSC markers in long term culture, while 
also maintaining capacity to differentiate into bone, cartilage and fat. 14 146  
 
EC can also be purified from tissues on the basis of cell surface marker expression using 
FACS271 and magnetic activated cell sorting (MACS)272.  However, primary EC isolated in 
this way are known to be extremely sensitive to alterations in culture and regularly lose 
their endothelial phenotype or are overgrown rapidly by more robust cells273. With 
HUVEC, however, the initial isolate is almost exclusively composed of EC and so the 
potential for overgrowth by other populations is more limited. 
 
The aim of this descriptive chapter is to optimise protocols for the isolation and culture 
of pericytes and EC so that they may be used within in vitro coculture models.  To 
increase physiological relevance I set out to use primary EC and pericytes sorted from 
the same tissue and donor for the coculture experiments.  I initially chose adult fat as 
this has been146 274, and continues to be275,  a major focus of our laboratory.  As adult fat 
is widely used in clinical trials as a source of MSC (www.clinicaltrials.gov) I felt that any 
breakthroughs in understanding would be most amenable to clinical translation by 
focussing on this tissue. I chose skeletal muscle as it offered an alternative tissue in 
which pathological expression of MSC potentials (eg heterotopic ossification) has been 
described276. 
 
Unfortunately, there is currently no single cell surface marker that can be used for the 
specific isolation of pericytes144.  Therefore, current protocols utilise a series of 
antibodies allowing for both positive and negative selection of cell populations277 278 
Published protocols for the FACS isolation of pericytes include one positive marker for 
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pericytes (CD146), together with a number of negative selection markers including 
CD34 (to exclude EC and adventitial cells), CD45 (to exclude haematopoietic cells) and 
CD56 (to exclude myogenic cells)277.  As adipose tissue is not thought to contain CD56 
positive myogenic cells, isolation protocols for adipose tissue tend not to include a 
negative selection for CD56277.   
 
Pericytes are damaged by the digestion/sorting process 
From my early experiences of sorting adipose tissue using published protocols from our 
laboratory277, it became clear that pericytes are damaged by the isolation process.  I 
found that yields were low when compared to the prevalence of pericytes that I 
expected from examining tissue sections.  Furthermore, cultures of sorted cells regularly 
did not become established, and if they did, it followed a significant lag period of up to 
20 days.   Furthermore, the yield and integrity of RNA that could be extracted from a 
given number of sorted pericyte events was extremely poor when compared to other 
similar populations such as adventitial cells.  This indicated to me that pericytes were 
particularly susceptible to the isolation process irrespective of whether the cells are 
isolated from adipose tissue (shown in Figure 8, p73) or skeletal muscle.  It was 
therefore important to optimize the isolation process not only to increase yield but also 
to minimize the trauma to which cells are exposed, as this may affect their behavior and 
influence downstream experiments. 
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Figure 8 Adipose derived pericytes are damaged in the isolation process 
While adventitial cells appear as healthy round cells on light microscopy immediately 
following sorting (A), pericyte preparations appeared to contain considerable debris and 
unhealthy cells (B). Despite high RNA integrity of adventitial cell RNA (C), RNA extractions 
with an equivalent number of pericytess yielded almost no intact RNA (D) as indicated by the 
RNA integrity number (RIN) where 10 represents high integrity and 1 indicates completely 
degraded RNA. 
 
Optimisation of isolation protocols to improve yield and 
viability of pericytes from adipose tissue 
The sorting of pericytes from adipose tissue is central to the UCLA Peault group and so 
with the help of my post-doctoral colleague, Dr Reef Hardy, I have refined existing 
protocols for the sorting of pericytes from foetal placenta and skeletal muscle and adult 
fat using fluorescence-activated cell sorting (FACS).  This process is similar irrespective 
of the tissue of origin and for the purpose of optimization we split this into 4 key phases: 
1. Tissue retrieval and storage 
2. Processing and digestion 
3. Sorting 
4. Recovery and culture 
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With refinements to all 4 phases of the process we were able to improve the yield and 
recovery in culture, but were not able to overcome the challenge of poor RNA integrity 
immediately following sorting.  The isolation strategy developed in this way is shown in 
Figure 9, p75. 
Special considerations at each phase 
1.  Tissue retrieval and storage 
In Edinburgh, human foetal tissue samples were from scheduled pregnancy 
interruptions and lipoaspirates were from planned cosmetic procedures.  During my 
time at UCLA I only had access to lipoaspirate samples from scheduled cosmetic 
procedures.  In both Edinburgh and UCLA we had minimal warning that samples had 
become available and no control over the time delay between procedure and delivery of 
sample to laboratory.  To minimise the time period that tissues were at RT, samples 
were always dissected, washed in PBS and stored at 4oC in appropriate media 
immediately on arrival. 
 
2.  Processing and digestion 
We explored the influence of altering the length of enzymatic digestion and changing the 
brand of collagenase on the yield and viability of pericytes from adipose tissue.   
 
Changing the time of digestion reduces pericyte degradation but RNA integrity and 
viability are still poor 
Lipoaspirate from the same sample was exposed to enzymatic digestion for 60, 40, 20 or 
10 min.  Each sample was stained with Annexin V to determine the ratio of apoptotic to 
non-apoptotic cells.  We found that the yield of pericytes was greatest at 30 min.  The 
number of debris and apoptotic events increased markedly with increasing time beyond 
30 min digestion. This was repeated with a total of 3 different donors.     
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Figure 9  Protocol for the sorting of pericytes from lipoaspirate   
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Figure 10  Gating strategy for the sorting of pericytes from human adipose tissue.   
Following double scatter cell selection (A), exclusion of doublets (not shown),  non viable cells 
(B) and CD45+ cells (C). CD146+ and CD34- pericytes are sorted in the gate represented in grey 
(D).  CD34+CD146- adventitial cells are shown in the black gate (D).    The purity of pericyte 
populations sorted on cell surface marker expression (CD45-, CD31-, CD34-, CD146+) was 
confirmed immediately following sorting by running the suspension of purified cells back 
through the flow cytometer (not shown).  (SSC-A, side scatter – area; FSC-A, forward scatter-
area). 
 
Changing brand of collagenase 
We tested three brands of commercially available collagenase, all marketed for the 
isolation of MSC from fat.  For all brands the recommended concentration and 
manufacturers guidelines were used with a digestion time of 30 min.  Each sample was 
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stained with Annexin V to determine the ratio of apoptotic to non-apoptotic cells.  The 
collagenases tested were:  
Sigma (0.5 mg/mL)  
Serva (0.2 mg/mL)  
Liberase (0.08 mg/mL)  
We found that the yield of pericytes from both the Sigma and Serva preparations was 
higher than for the Liberase preparation. 
 
3.  Sorting 
The FACS Aria (Becton Dickinson) is a high through-put, multi laser, multi parameter 
cell sorter. Up to 11 fluorescent parameters can be used to sort up to four populations 
simultaneously at rates of up to 40,000 cells/second. 
 
Sorting pressure and nozzle diameter 
The nozzle diameter and the system pressure used within the cell sorter are important 
to consider, and depend on the size and characteristics of the cells being sorted.  The 
nozzle size should be approximately 5 times that of the cells being sorted.  For example, 
sorts targeting lymphocytes are generally performed with a 70μm nozzle, with the 
100μm nozzle reserved for larger cells.  Increased pressures and a smaller nozzle 
diameter exposes cells to harsher conditions during sorting.  This was reflected in our 
observation that cells sorted using the 100μm nozzle appeared to recover more rapidly 
than those sorted with smaller nozzles. 
 
Appropriate gating to exclude apoptotic cells and debris 
By analyzing my own FACS data and the historical samples from our lab it became clear 
that the majority of cells detected from the machine as CD146+CD34-CD45- cells may 
instead represent debris or apoptotic cells. I was able to ascertain this by back-gating 
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analysis of pericytes showing where they fall when plotted for SSC and FSC (Figure 11, 
p79). It is interesting to note that much of the cellular debris had the exact phenotypic 
profile as pericytes indicating that they could represent remnants of pericytes.  As such, 
unless a very strict initial SSC and FSC gating strategy was used, the percentage of viable 
cells can easily be overestimated.  This would in part explain the poor RNA quality and 
outgrowth of pericytes we observed.  By culturing CD146+CD45-CD34- “pericyte 
events” from different regions of the SSC-FSC back gate we were able to show that most 
apoptotic cells lie towards the SSC axis while most debris events lie clost to the origin of 
both the SSC and FSC axes.  However, a number of apoptotic cells also lay in 
characteristic scatter locations for healthy pericytes, confirming that the identification 
of healthy pericytes can not be based solely on their SSC-FSC profile. 
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Figure 11 The importance of appropriate scatter gating to enrich for healthy pericytes  
In the first example preparation (A), back gating of adipose derived pericytes to a SSC-A 
FSC-A scatter plot reveals that the majority of events lie within areas typically associated with 
apoptotic cells and debris.  Despite the CD34 CD146 plot appearing similar within this next 
sample (B), back gating to a scatter plot reveals that the majority of events lie within the area 
typically associated with viable pericytes.  Note that a large number of debris events remain in 
this second preparation.   
 
 
4.  Recovery and culture 
Coating of culture plates 
The hydrophobic surface of polystyrene plastic is routinely treated using either corona 
discharge under atmospheric conditions or gas-plasma under vacuum so that the 
surface becomes hydrophilic and negatively charged once medium is added279.   Good 
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cell attachment is especially important during recovery of cells from freezing or after 
sorting, as poor attachment can lead to apoptosis and necrosis resulting in slower 
recovery and lost research time.  As such published protocols for the sorting of MSC 
from fat include additional pre-coating of already coated culture plastic with gelatin146 
277.  We compared a number of different biological (gelatin, collagen and fibronectin) 
and non-biological coating (MSC mosaic surface coating, BD) products.  We found that 
the use of all these products improved emergence of colonies and successful outgrowth 
of cells following sorting – we elected to use fibronectin as this was the substrate also 
favoured by EC.  
 
Seeding density 
A number of studies using conventional culture derived MSC have found that the plating 
density is not critical for maintaining a well defined multipotent MSC population280, 
while others found that seeding density influences gene expression patterns281.  We 
found that the outgrowth of cultures of freshly sorted pericytes rarely occurs unless a 
seeding density of at least 20,000cells/cm2 is used.  If the total cell count at sorting 
includes debris and apoptotic cells then the actual number of viable cells seeded per cm2 
will be considerably less than 20,00/cm2.  As such we include in our protocol a further 
cell count using a haemocytometer and trypan blue to confirm the true count of viable 
pericytes to enable accurate seeding at 20,000cells/cm2 . 
 
Analysis of Péault group adipose sorts (2011-2014) 
There is growing enthusiasm for the use of non-cultured MSC and it is therefore of 
clinical interest to establish the yield of perivascular stem cells from lipoaspirate.  
Together with Dr Hardy we set out to establish the yield and frequency of PSC in human 
lipoaspirate (from all samples including my own) to establish patient and processing 
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factors that influenced this yield.  In n=129 donors, 100ml of lipoaspirate yielded a mean 
of 37.8 x106 SVF cells (stromal vascular fraction, or total cells).  The mean percentage 
cell viability among SVF was 82%.  The prevalence of CD45+ haematopoietic cells was 
31.6% of total viable SVF.  Pericytes averaged 8% of total viable SVF (median=6%).  
Adventitial cells represented 31.6% on average of total viable SVF (median=33%).  The 
mean total PSC content was 39.5% (median=41%). No significant change in yield, 
viability, or identity was observed with patient age.  However, as samples were sourced 
from cosmetic lipoaspirate the young demographic analysed (ages ranged from 24 to 
64) may not have been sufficiently broad to detect potential changes within an older 
population. No significant difference was apparent for either cell viability or the 
percentage of pericytes across gender although the percentage of adventitial cells and 
PSC was significantly increased in males.  Menopausal status had no statistically 
significant effects on any cell parameters including yield, viability, or identity.  The 
percentage of haematopoietic cells and PSC was observed to decrease slightly but 
significantly with increasing BMI. Although cell viability and SVF yield exhibited a 20% 
reduction with respect to cold storage time; the decrease in PSC yield was more subtle 
(only 3%), as a result of being partially offset by an ~20% and ~17.5% rise in the 
percentage of adventitial cells and pericytes, respectively. Interestingly, the percentage 
of hematopoietic cells decreased the most (up to 30%) as a function of the duration of 
cold storage. 
 
Pericyte isolation protocols for human skeletal muscle 
I adapted published pericyte isolation protocols considering protocols for the isolation 
of other cell types in skeletal muscle205 282.  I was also able to apply what I had learned 
from my experience with adipose tissue.  Using this protocol (Figure 12, p82) I was able 
to consistently isolate and purify skeletal muscle pericytes from foetal tissues that grew 
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well in culture.  In my preparations the mean viability was 97.23% (SD 0.85%), with 
pericytes contributing 14.04% of all viable cells (SD 3.05%), and adventitial cells 
accounting for 17.36% (SD 2.16%) (n=3). 
 
 
Figure 12 Protocol for the sorting of pericytes from human fetal skeletal muscle  
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Figure 13 Gating strategy for the sorting of pericytes from human skeletal muscle  
Following double scatter cell selection (A), exclusion of doublets (B), non viable cells (C) and CD45+ cells (D), CD146+ and CD34- pericytes are sorted in the 
gate represented in grey (E).  CD34+CD146- adventitial cells are shown in the black gate (E).    The purity of pericyte populations sorted on cell surface 
marker expression (CD45-, CD56-, CD31-, CD34-, CD146+) was confirmed immediately following sorting using FACS reanalysis (not shown).  
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Pericytes maintain their sorted immunophenotype in long-
term culture  
Once sorted to homogeneity pericytes have been described to “maintain their phenotype” in 
long term culture14 283.  I found that these cells indeed maintained their sorted phenotype (ie 
CD146+, CD34-, CD56-, CD45-) as assessed by FACS analysis and RT-PCR (Figure 14, p84).   
 
 
Figure 14 Confirming pericyte purity in long-term culture 
Pericytes sorted from human adipose tissue adhere and proliferate in culture (A,B).  The purity of 
sorted cells was confirmed using RT-PCR (C) and FACS analysis (D,E). (yellow, antibody stain; 
blue, isotype; red, unstained). 
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Cultured pericytes demonstrate tri-lineage differentiation 
potential 
PEricytes sorted from adipose tissue and muscle also maintained their osteogenic and 
adipogenic potentials over serial passaging.  My experiences support reports in the 
literature that  several factors influence pericyte differentiation.  These include confluence 
when differentiation factors are introduced, passage of pericytes, and history of previous 
over confluence in culture.   
Osteogenic differentiation 
In the presence of osteogenic differentiation factors pericyte cultures were capable of 
osteogenic differentiation as assessed by Alizarin Red and von Kossa staining for calcium 
deposits.  Differentiation should be started with cells at 80% confluence; cells at lower 
confluence demonstrated limited capacity for differentiation while more confluent cells 
rapidly lifted from culture wells. 
Adipogenic differentiation 
When adipogenic differentiation is initiated with cells at high density (90-100% confluence) 
cultured pericytes are capable of differentiating into adipocytes as assessed by Oil Red O 
staining for lipid droplets. 
Chondrogenic differentiation 
Despite forming characteristic pellets when cultured in 15ml tubes in chondrogenic media, 
Safranin O and Alcian blue staining of pellet sections for evidence of chondrogenic 
differentiation into cartilage has so far been inconclusive (Figure 15, p86).   
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Figure 15 Multi-lineage potential of pericytes 
Pericytes cultured in osteogenic medium for 14 days stained positively for mineralization by 
Alizarin Red staining (A). At 21 days of culture in adipogenic conditions, widespread lipid droplet 
formation was detected with Oil Red O (B). Weak Alcian Blue staining of pericyte pellets cultured 
in chondrogenic conditions was suggestive of the presence of proteoglycans at 21 days (C). 
 
Isolation of primary EC  
To increase physiological relevance I set out to use primary EC sorted from the same tissue 
and donor.  I have established a protocol for sorting and culture of EC although I have been 
unable to establish sustainable cultures of these cells.    
 
EC from human adipose tissue, muscle and placenta (CD45-, CD56-, CD34+, CD31+) 
exhibited characteristic cobblestone appearance with contact inhibition until passage 5.  
Purity was assessed by FACS analysis and RT-PCR (Figure 16, p87).  When seeded onto 
Matrigel they formed vascular network structures (Figure 17, p87). However, beyond 
passage 5, these cells lost their characteristic phenotype. As these would not maintain their 
phenotype for the duration of differentiation experiments HUVEC were used as an 
alternative.   
 
A B C 
x5 x40 x10 
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Figure 16 Confirming phenotype and purity of sorted EC  
EC sorted from skeletal muscle (CD31+, CD34+) using FACS exhibit characteristic ‘cobblestone’ 
phenotype in culture at passage 3 when viewed at x10 (A) and x20(B) magnification.  RT-PCR 
confirmed the purity of cells at passage 3 (C).  When analysed at passage 3 using FACS they 
represented a homogenous population staining positively for directly conjugated antibodies to 








Figure 17 EC form vascular network like structures on Matrigel 
(A, seeding; B, 4 h; C, 8 h). 
 
A B C 
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The perivascular niche consists of pericytes, EC and their enveloping basement membrane.  
The initial aim of this chapter is to establish models of pericyte-endothelium interactions to 
use as a basis for investigating the influence of EC on the differentiation potential of 
pericytes.  The assays for osteogenic, adipogenic differentiation last a minimum of 7-14 days 
while chrondrogenic differentiation resquires up to 4 weeks.   Stability in long-term culture 
is therefore a prerequisite.  It was also important to show that the final constituent of the 
perivascular niche: the basement membrane, was produced in these settings.  In this 
chapter I explore two and three dimensional models of the perivascular niche. 
 
Two-dimensional model of the perivascular niche 
Pericytes were seeded at varying ratios onto confluent HUVEC (Figure 18, 90).  HUVEC 
formed a monolayer with proliferation limited by contact inhibition, while overlying 
pericytes formed a homogenous multilayer when cultured in EGM2 for up to three weeks. 
HUVEC and pericytes were able to survive as distinct populations in this culture setting 
(Figure 19, p91). 
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Figure 18 Light microscopy of 2D coculture  
HUVEC were grown to a confluent monolayer (A). Pericytes were seeded in monoculture (B) and 
at varying ratios in coculture (C, shown 4:1 HUVEC:pericyte). At day 9, HUVEC remained in a 
monolayer (D), while pericytes proliferated without contact inhibition to form multiple layers (E), 
which overgrew HUVEC in coculture (F).    
  
x20 x20 x20 
x20 x20 x20 
Modelling the perivascular niche 
 




Figure 19 Flow cytometry analysis of cocultured cells 
Two distinct populations of pericytes (red boxes) and HUVEC (green boxes) survived 2D 
coculture at 9 days. Irrespective of whether cells were seeded at a ratio of 1:1 (HUVEC: 
pericyte)(A), 2:1(B), 4:1(C) or 8:1(D), pericytes were more numerous on analysis. 
 
Despite discrepancies in growth kinetics it was important to ensure that all pericytes were 
in contact with EC for the duration of culture.  Pericyte growth was more restrained by 
culturing the cells in basal medium (DMEM10%FCS1%PS) rather than EGM2.  In these 
conditions pericytes were more likely to be exposed to underlying HUVEC initially although 
HUVEC coverage decreased when culture extended beyond ten days in basal medium: at 
two weeks HUVEC coverage had diminished to 50%.  To maintain EC presence within 
cocultures, cultures were supplemented with additional EC every two days. 
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Three-dimensional spheres assay  
To improve physiological relevance by removing the influence of adherence to culture 
plastic, three dimensional perivascular niche models were developed.  To generate self-
assembly spheres, pericytes in isolation and in coculture with HUVEC at a 1:1 cell ratio were 
propagated for 7 days in non-adherent U-shaped bottom 96 well plates.  Cocultures of 
pericytes and fibroblasts served as controls.  Under optimal growth conditions, spheroids 
were formed overnight.  Pericytes in isolation formed distinct spheroids with cells 
expressing pericyte markers diffusely spread throughout the spheroid at 3 days (Figure 20, 
p93).  At day 7, cells within the core did not express the pericyte marker NG2 that may 
reflect a change in phenotype or loss of viability.  Despite both cell types being introduced 
simultaneously as a single cell suspension, HUVEC and pericytes were shown to self-
assemble and form organized structures with HUVEC assuming a predominantly peripheral 
distribution initially and with time forming increasingly substantial networks throughout 
the 3D structure (Figure 21, p93). The spheroids did not progressively increase in size over 
time – in contrast they appeared to become more compact.  
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Figure 20 Immunohistochemistry of pericyte spheroids.  
Fluorescent images of NG2 labelling of pericytes within spheroids at day 1 (A,D), 3 (B, E) and 7 
(C, F).  Over time, NG2 expression diminished within the core of spheres in keeping with 
increased numbers of dead cells (see Figure 1.12 below) 
 
 
Figure 21 Immunohistochemistry of pericyte-HUVEC spheroids. 
Pericyte-HUVEC spheroids at day 1 (A,D), 3 (B,E) and 7 (C,F).  CD144 positive HUVEC were 
observed predominantly around the periphery of coculture spheroids at day 1.  By day 7, HUVEC 
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Viability in 3D spheres 
It was necessary to establish whether cells remained viable in this setting as cells, 
particularly within the centre of the spheroids, may have reduced access to nutrients and 
oxygen.  A fluorescence viability assay using CMFDA and PI was performed and visualized 
under confocal microscopy at day 1, 3 and 7 following sphere assembly.  At day 1 the 
majority of cells were viable (green), with the number of dead cells increasing over time, 
particularly within the core of cocultured spheres (Figure 22, p94). 
 
Figure 22 Viability assay of cells within 3D spheres using confocal microscopy  
CMFDA labelling indicates viability (green) with PI labelling indicating non-viable cells (red).  
Confocal images taken of intact spheres containing pericytes (A), pericytes and HUVEC in equal 
numbers (B) and pericytes and fibroblasts in equal numbers (C).  Cross sections indicating cell 
viability within the core of spheres containing pericytes (D), pericytes and HUVEC in equal 
numbers (E) and pericytes and fibroblasts in equal numbers (F).   
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Three dimensional Pellet Culture 
Pellet cultures are the most widely used setting for performing chondrogenic 
differentiation.   The culture of MSC in non-adherent pellets containing approximately 2x105 
cells in chondrogenic conditions is an effective method of inducing chondrogenic 
differentiation.  We sought to establish whether this model could be modified to enable 
coculture with EC (Figure 23, p95). 
  
Figure 23 NG2 and CD144 immunohistochemistry of pericyte-HUVEC pellets 
Antibody staining at day 21 (A-C) together with appropriate isotype control (D).  CD144 positive 
HUVEC were observed throughout the coculture pellet with the highest concentration of pericytes 
found at the pellet surface.    
 
Viable cells were identified in cryostat sections (8μm) by means of their LDH activity (dark 
blue) (Figure 24, p96).  The highest concentration of viable cells was seen at the surface of 
the pellets with relatively fewer viable cells present within the core. 
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Figure 24 Cell viability within pellet cultures 
LDH staining of pellet cultures of pericytes (A), pericytes plus HUVEC (B) and pericytes plus 
fibroblasts (C) 
 
Three dimensional tube assembly (vasculogenic) assay  
Fluorescently labelled pericytes and HUVEC were seeded at varying ratios onto Matrigel 
and visualized over time in an incubation chamber.  HUVEC in monoculture began forming 
networks immediately, reaching maximal complexity at 4 hours before collapsing within 8 
hours.  Pericytes in monoculture associated into clumps and did not form networks.  In 
coculture, pericytes and HUVEC both contributed to vascular networks that expanded over 
time reaching maximal organization at 4 hours before collapsing at eight hours (Figure 25, 
p97). 
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Figure 25 Pericytes contribute to 3D networks when cocultured with HUVEC on Matrigel 
Single cell suspensions of pericytes (green) and HUVEC (red) were seeded onto a thick layer of Matrigel and visualized using fluorescence and 
brightfield microscopy.  Immediately after seeding at a ratio of pericyte:HUVEC of 1:1 cells immediately began forming vascular networks (A) 
which had developed in complexity at 2hrs (B) and 4hrs (B) and subsequently collapsed at 6hrs (C) and 8hrs (D).  A similar pattern was seen in 
wells seeded at pericyte:HUVEC ratios of 1:2 (images F-J) and 1:4 (images K-O).  In monoculture, pericytes formed clumps that did not form 
distinct networks (images P-T)
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Production of basement membrane proteins by pericytes 
and endothelial cells in coculture  
Serial titrations of antibodies to the human basement membrane proteins collagen IV and 
laminin on human fetal placental sections revealed an optimum antibody concentration of 
1:100 for both antibodies.   At these concentrations the expected distribution284 of basement 
proteins was optimally observed in histological tissue sections with no background staining 













Figure 26 Distribution of collagen IV and laminin within fetal placental villous. 
Laminin (A) and type IV collagen (C) are expressed in all placental basal membranes and villous 
stroma. The trophoblastic basement membranes and endothelial basal membranes are sharply 
demarcated and display high intensity. Laminin and collagen IV are also localised, but to a lesser 
degree, in the villous stroma, but is not evident in the epithelial layer.   There was no positive 
staining within the isotype controls of both laminin (B) and collagen IV (D). 
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We used immunohistochemistry to determine the presence of laminin and in our in vitro 
models.  For the 3D vasculogenic assay, a pericyte:HUVEC ratio of 1:2 was used due to the 
stability and organisation of networks at this ratio.  Due to cross-reactivity of human 
antibodies to mouse derived proteins in Matrigel we were unable to assess for laminin 




    
 
 
Figure 27 Staining of collagen IV and laminin on unseeded Matrigel 
The anti-collagenIV monoclonal antibody did not label any proteins within Matrigel (A).  However 
the anti-laminin antibody bound to mouse derived proteins within Matrigel (B). 
 
Both collagen IV and laminin were produced in 2D and 3D monoculture of pericytes and EC 
with deposition being proportional to the time in culture.  Although not formally quantified, 
the production of basement membrane in coculture appeared greater that would be 
expected for the sum of individual productions in monoculture (Figure 28, p100 and Figure 
29, p101).   
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Figure 28  BM production in pericyte-EC coculture.   
The production of BM proteins at day 5 of 2D coculture (A-D), 3D spheroid coculture (E-H) and in 3D tube assembly (vasculogenic) coculture of 
pericytes and HUVEC (I-L).  At day 5 collagen IV and laminin were distributed throughout 2D cocultures and spheroid cocultures.  Note that there was 
significant binding of anti-laminin antibody to mouse derived proteins present in in Matrigel (K).
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Figure 29  BM production in pellet coculture.   
Basement membrane production at day 21 in pellets containing pericytes alone (A-D), pericytes and HUVEC (E-H) and pericytes and fibroblasts.
Influence of endothelial cells on pericyte differentiation 
 







 Chapter 1.5  The influence of endothelial cells 
on the osteogenic, adipogenic and 
chondrogenic differentiation of pericytes   
 
Influence of endothelial cells on pericyte differentiation 
 
Section 1:  Endothelial cells accelerate the osteogenic differentiation of pericytes 
 
103 
Adult stem cell niche components provide signals that control the balance between 
quiescence, self-renewal, and differentiation236. A significant obstacle in identification of the 
perivascular origin of MSC was the reluctance of pericytes to express mesenchymal 
phenotypes – except for cell surface markers - in their native environment129. Although 
feasible that pericytes acquire MSC potentials on exiting the vasculature, it is intuitive that 
they are natively present and environmentally downregulated. Regulation of EC behavior by 
pericytes (and vice versa) has been extensively documented in the context of 
angiogenesis241 285. However, to our knowledge, no studies have evaluated the influence of 
perivascular niche components on the differentiation potential of pericytes.  The influence 
of EC on the multipotency of tissue specific MSC has been explored with divergent findings 
(Table Chapter 1).  However, the unique  relationship between pericytes and EC within the 
context of a stem cell niche remains poorly understood. 
 
The initial aim of this chapter was to examine whether coculture with EC influences the 
osteogenic differentiation of pericytes.  Secondly, the influence of EC on the adipogenic and 
chondrogenic differentiation of pericytes will be explored. 
 
Endothelial cells accelerate the osteogenic differentiation of 
pericytes in vitro 
To establish the influence of coculture with EC on the osteogenic differentiation of pericytes 
in two dimensions, pericytes were seeded onto a confluent monolayer of HUVEC in EGM2 as 
described above.  When pericytes reached 80% confluence, cells were exposed to either 
basal medium or basal medium supplemented with osteogenic factors.   There was no 
evidence of differentiation by day 21 in cells cultured in basal media (Figure 30, p104) 
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confirming that pericytes do not spontaneously differentiate down the osteogenic lineage 
either in monoculture or in the presence of EC. 
 
 
Figure 30 Pericyte-EC coculture in basal conditions 
There was no evidence of osteogenic differentiation as detected by Alizarin red for mineralization 
when HUVEC (A-C), pericytes (D-F) or cocultures of these cells G-H) were cultured in basal 
medium.   
 
In osteogenic conditions, there was no differentiation seen in wells containing EC alone 
(Figure 31, p105).  Although considerable variation was seen between pericyte 
preparations, mineralization was evident in pericyte monoculture wells from week 2.  
Coculture wells demonstrated accelerated osteogenic differentiation with complete 
coverage of differentiated pericytes by week 2.  To explore the influence of direct contact, 
the experiment was repeated with cells separated by a semi-permeable membrane 
(Transwell or indirect system).  Pericyte differentiation remained increased in wells 
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containing EC Transwells indicating that EC mediated acceleration of pericyte 
differentiation is not dependent on direct contact (Figure 31, p105).  This effect was seen 
using either HUVEC or HAMEC with either adipose or skeletal muscle derived pericytes 
(n=3 of each). 
 
 
Figure 31  Pericyte-EC coculture in osteogenic conditions 
HUVEC, adipose derived pericytes and cocultures of these cells were cultured in osteogenic 
conditions for 21 days.  There was no evidence of mineralization within wells containing HUVEC 
alone (A-D). The osteogenic differentiation potential of pericytes (E-H) was enhanced in the 
presence of HUVEC (I-L).  This effect was maintained when pericytes and HUVEC were 
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The degree of osteogenic differentiation was quantified through spectrophotometric 
analysis of eluted Alizarin Red stain (Figure 32, p107).   There was a significant increase in 
osteogenic differentiation at d 7 and 14 in cocultures with HUVEC and human adipose 
microvascular EC (HAMEC) (p<0.05,  n=3).  Although there was a trend to increased 
differentiation in indirect coculture wells, this did not reach statistical significance.  
 
Quantitative RT-PCR was used to compare the expression of osteogenic genes in pericyte 
monocultures and in indirect Transwell coculture with EC. The relative expression of the 
osteogenic genes alkaline phosphatase (AP) and osteopontin (OPN/SPP1/bone 
sialoprotein/BSP) was increased at d 14 when pericytes were cocultured with HUVEC 
Transwells (Figure 33, p108).  However, we were unable to detect differences in collagen 1 
(COL1) between pericyte monoculture and indirect coculture wells at any timepoint.   
 
In this set of experiments I used Transwell cocultures to establish whether the accelerating 
effect on pericytes osteogenic differentiation by EC was contact dependent.  This method 
permits molecular “crosstalk” and is generally considered the gold standard.  However, 
applicability is limited in 3D and the system is extremely expensive.  An alternative method 
is the use of conditioned media.  The soluble factors present in culture supernatant can be 
delivered directly, as supernatant concentrate or as fresh frozen.  While this permits ease of 
use in 3D there is no “crosstalk” between cells, and factors may be affected by the 
transfer/freezing process. 
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Figure 32 Quantification of osteogenic differentiation of muscle derived pericytes was performed through spectrophotometric analysis of eluted 
Alizarin red  
HUVEC cocultures (A),   HAMEC cocultures (B), comparison between HUVEC and HAMEC in indirect coculture (C) and comparison between 
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Figure 33 Expression of osteogenic genes by muscle pericytes in Transwell coculture with EC 
Time course expression of the osteogenic genes AP (A), SPP1 (B) and Col1 (C) by pericytes in 
monoculture and pericytes in transwell coculture with EC.  For each gene, values are given as the 
expression levels relative to pericyte monocultures at day 0 (Results shown as ± SEM;n = 3; 
endogenous control HBRT; *p<0.05)  
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Coculture with endothelial cells does not increase the 
proliferation rate of pericytes 
EC have been shown to influence the rate of proliferation of human retinal pericytes286 and 
pericytes from other sources285.  We explored the possibility that an increase in 
proliferation of pericytes in coculture with EC might explain, in part, their accelerated 
osteogenic differentiation.  Pericytes were seeded in equal numbers in monoculture, direct 
coculture with EC, and indirect (Transwell) coculture with EC.  Wells were harvested at day 
3, 6 and 9 and the number of pericytes ascertained using a combination of cell counting and 
FACS to confirm the proportion of pericytes.  We found that the growth curves of pericytes 
in these three settings were very similar and the population doubling times (PDTs) were 
not significantly different.  Pericytes exhibited a PDT of 22.06hrs (SD 1.137), 23.55hrs (SD 
7.430) and 22.84hrs (SD 1.721) in monoculture, coculture and indirect coculture 
respectively (figure 1.5.5). 
 
Figure 34  Proliferation of pericytes in coculture with EC.   
Growth curves of pericytes in monoculture, direct coculture and indirect coculture with EC (A).  
There was no significant difference in population doubling times of pericytes in monoculture, 
direct coculture or indirect coculture with EC. (Results shown as ±SEM; n=3; NS p>0.05). 
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The influence of endothelial cells on the osteogenic 
differentiation of pericytes in vivo 
In vivo osteogenesis experiments using MSC are most frequently accomplished using the 
ectopic bone formation assay14 287.  In this assay, human MSC are seeded onto gelfoam or 
mixed with hydroxyapatite and implanted into intramuscular or subcutaneous pockets in 
immunocompromised288 289 or immunocapable290 rodents.  Assessment for bone is done 
using serial radiographs and by micro CT.   
 
To investigate whether EC would also accelerate the osteogenic differentiation of pericytes 
in an in vivo setting, gelfoam sponges were inserted into the gluteofemoral muscles of 
C57BL6 mice loaded with HUVEC alone, pericytes alone, pericytes and HUVEC or only PBS 
as a control. BMP2 was loaded onto the gelfoam sponges to stimulate osteogenesis.  Serial 
radiographs were taken at weekly intervals for six weeks post implantation at which point 
mice were culled and the legs harvested for micro CT analysis of ectopic bone. 
 
With n = 4 animals per experimental group there were no statistically significant differences 
in ectopic bone volume (BV) and bone density (BD) between any of the groups (p<0.05) (
Figure 35, p112).  This in vivo study was limited by the huge variability seen within 
experimental groups and the low sample size used.   
 
The muscle pocket model of ectopic bone growth has a number of limitations which may 
have affected the results. The cytokine used to induce osteogenesis in this setting – BMP – is 
potent and can mask subtle differences in differentiation between groups.  This is 
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highlighted by the degree of osteogenesis seen in animals who did not receive cells.  
Furthermore this model can have considerable variability between animals as subtle 
alterations in implant placement (for example in an avascular plane compared to a vascular 
body of muscle) can influence osteogenic differentiation.  Despite practicing gelfoam 
placement on cadaver animals in advance it is likely that my relative inexperience with the 
surgical model may have contributed to the variability. 
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Figure 35  In vivo ectopic bone formation assay 
Huge variation in ectopic bone formation was seen both within and between treatment groups 
with four representative patterns of bone growth observed: (A) no ectopic bone growth, (B) low 
ectopic bone growth, (C) high ectopic bone growth (D) high ectopic bone growth fused to the 
femur. No significant differences in ectopic bone volume were seen using skeletal muscle derived 
pericytes with HUVEC (E) and HAMEC (F), or using adipose derived pericytes with  HUVEC (G) 
and HAMEC (H).  (Results shown as ± SEM; n=3; NS p>0.05) 
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Influence of coculture with endothelial cells on the 
adipogenic differentiation of pericytes 
We set out to determine whether the effects on pericyte differentiation potential in two 
dimensional coculture were lineage specific. Pericytes were seeded onto a confluent 
monolayer of HUVEC in EGM2 medium as described above.  When pericytes reached 80% 
confluence, cells were exposed to either basal medium or basal media supplemented with 
adipogenic factors. There was no evidence of differentiation by day 21 as detected by Oil 
Red O staining of lipid droplets in basal medium.  In adipogenic conditions, lipid droplets 
were visible in pericyte cultures from day 7 increasing to day 21 (Figure 36, p114).  There 
were no lipid droplets in HUVEC monocultures. Subjectively, there was less evidence of 
pericyte adipogenic differentiation in coculture with HUVEC – a difference most marked at 
Day 7 and Day 14 (n=3). 
 
The area fraction of wells staining positively for Oil Red O was determined using image 
analysis software. Dye taken up by lipid droplets was eluted and measured using a 
spectrophotometer (Figure 37, p115).  Despite subjective differences in the number of lipid 
droplets within wells, neither of these methods were sufficiently sensitive to detect 
differences.   
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Figure 36  Pericyte adipogenic differentiation in coculture with HUVEC 
In adipogenic conditions, lipid droplets were visible in pericyte cultures from day 7 increasing up to day 21 (A-D).  There was no lipid droplet 
formation in HUVEC monocultures (E-H).  Subjectively, there was less evidence of pericyte adipogenic differentiation in coculture with HUVEC – a 
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Figure 37  Quantification of pericyte adipogenic differentiation in coculture with HUVEC   
Cultures were stained with Oil Red O to identify lipid droplets.  The dye taken up by lipid 
droplets was eluted and the concentration of dye eluted was used to quantify differentiation.  
Despite subjective differences in the levels of differentiation (for example from Day 0 to Day 
21 pericytes) this dye elution method was not able to detect any statistically significant 
differences between wells.  Furthermore there was considerable background dye quantified in 
this method as shown by the readings at Day 0 before adipogenesis was initiated and by the 
ongoing high readings in the EC only wells. 
 
Influence of coculture with endothelial cells on the 
chondrogenic differentiation of pericytes 
The influence of EC on conventional MSC or pericyte chondrogenic differentiation has 
not previously been reported.  However, many of the early transcriptional changes are 
common to both osteogenesis and chondrogenesis.  We were therefore intrigued to see 
if EC also had an effect on chondrogenic differentiation.  Pericytes alone and cocultured 
with HUVEC or fibroblasts (cellular control) were centrifuged to form pellets.  Over the 
subsequent 48hrs pellets develop into spherical micromasses that are agitated daily to 
prevent them from adhering to the tubes (figure 1.5.9). 
 
Pellets composed of pericytes alone and pellets with pericytes and EC cultured in 
chondrogenic medium for 21 days formed compact spherical structures.  The pellets 
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containing EC alone did not form stable pellets with cells dispersing with even slight 
agitation.  Irrespective of the cell content, debris were present in all wells at day 21 that 
were distinct from the pellet itself.  On histological analysis, pellets showed a highly 
compact central core that became increasingly compact with time in chondrogenic 
medium and stained positively for Alcian blue and safranin O (Figure 38, p117).  This 
core was surrounded by a peripheral ring of flat, elongated cells suspended in 
extracellular matrix.  Pellets cultured in basal conditions for 21 days formed a spherical 
structure that was less compact and stable on sectioning than pellets exposed to 
chondrogenic medium.  Furthermore, there appeared to be a less pronounced 
peripheral ring of elongated cells.  In these control samples, there was evidence of 
proteoglycans as determined by Alcian blue and safranin O staining although the level of 
staining was not clearly different to cells exposed to chondrogenic medium. 
 
Our findings support the chondrogenic capacity of pericytes under appropriate 
environmental cues without conclusive findings of a possible regulatory effect by EC.  
Due to the prolonged time required to culture freshly sorted cells and the expense 
involved in the assay, experiments were performed with a single EC type (HUVEC) and 
pericytes from adipose tissue (n = 3).  The staining evident in our experimental samples 
was considerably weaker than that from the positive control tissues (foetal cartilage) 
(Figure 39, p118).  It is possible that the collagen matrix formed in our chondrogenic 
pellets represents a very early stage in cartilage development where the proteoglycan 
content is still relatively low. Additional proteoglycan stains such as toluidine blue could 
be used, or antibodies against chondrogenic proteins such as collagen type II, type X, 
and type IX and aggrecan could be used41 291  A straight forward method that could have 
been performed to assess formation of matrix in pellets would have been to measure 
pellet cellularity and weight and proteoglycan content41.  It is known that oxygen 
tension regulates chondrocyte differentiation and promotes cartilage matrix 
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formation292 293.  This may go some way to explain the zones of variable ECM production 
seen within pellets. 
 
Figure 38  Chondrogenic pellet structure   
(A) This histological section of a pericyte pellet exposed to chondrogenic medium for 21 days 
illustrates typical appearances with a central core with marked proteoglycan deposition (blue) 
and a peripheral ring with flatter, more elongated cells. (B) histological section of pericyte 
pellet exposed to chondrogenic medium for 21 days stained with safranin O.  Foetal cartilage 
(positive control) stained with Alcian blue (C) and safranin O (D).
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Figure 39  Safranin O analysis for proteoglycans within chondrogenic pellets.  
Pericyte monocultures at day 7 (A), day 14 (B) and day 21 (C) in chondrogenic medium and at day 21 in basal medium (D). Pericyte-HUVEC cocultures at 
day 7 (E), day 14 (F) and day 21 (F) in chondrogenic medium and at day 21 in basal medium (G). Pericyte-fibroblast cocultures at day 7 (H), day 14 (I) and 
day 21 (J) in chondrogenic medium and at day 21 in basal medium (K).
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There is an extensive literature describing signalling pathways recognised to control 
MSC fate decisions263 294.  These include bone mophogenetic protein (BMP), sonic 
hedgehog (SHH), wnt, pparg, sox9 and runx2263 294.  EC are recognised to actively signal 
through a number of these pathways295.   
 
Wnt proteins are cysteine rich secreted glycol-lipoproteins that regulate a vast array of 
biological processes including development, cell proliferation and motility, and cell fate 
determination296-298. Wnts bind to serpentine receptors of the frizzled (FZD) family on 
the plasma membrane to initiate several distinct cascades classified as either canonical 
or non-canonical, depending on whether β-catenin is involved (Figure 40, p121) 299. So 
far, 19 wnt ligands have been identified in mammals300.  Classically, wnt1, 2, 3, 3a, 8 and 
8b are regarded as the canonical wnts, and wnt4, 5a, 5b, 6, 7a and 11 as the non-
canonical wnts301 302. In the absence of a canonical wnt signal, cytosolic β-catenin is 
rapidly phosphorylated, ubiquitinated, and degraded. wnt-FZD binding in the presence 
of LRP5 or LRP6 results in inactivation of the β–catenin phosphorylation complex, so 
that β-catenin accumulates in the cytosol. β–catenin then translocates to the nucleus, 
binds transcription factors of the Tcell factor (TCF) family and promotes transcription of 
target genes303.   Non-canonical wnt signaling and the molecules involved have been less 
well characterized, although their interactions are known to be diverse. 
 
Wnt signalling is closely controlled by several groups of negative regulators that 
interfere either with receptor-ligand binding or with intracellular signalling.  Secreted 
FZ-related peptides (sFRPs) and wnt inhibitory factor (WIF-1) compete with FZD for 
wnt ligand binding while dickkopf (Dkk) and Sclerostin target and antagonize LRPs 
(transmembrane proteins with which FZ proteins usually interact) to block wnt 
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signalling304-306.  Certain cytoplasmic proteins interfere with wnt signalling to block the 
β–catenin dependent pathway.  APC, axin1 and axin2, scaffold proteins of the β–catenin 
destruction complex, are required for the degradation of β–catenin.  CKIα and GSK3β 
phosphorylate β–catenin, leading to its degradation.  NKD (Naked Cuticle) 1 and -2 
interact directly with Dv1 enabling Dv1 to favour the wnt/PCP pathway by stimulating 
JNK activity, while simultaneously preventing Dvl from activating the canonical Wnt 
pathway.  Similarly, NLK activates the non-canonical pathway and simultaneously 
inhibits the canonical pathway by antagonizing TCF/LEF1298.  
 
 
Figure 40 The mode of action of the wnt modulators C59, CHIR and ICG is highlighted in red. 
 
A potential role for wnt signalling 
 
Section 1:  Endothelial cells accelerate the osteogenic differentiation of pericytes 
 
122 
MSC express a number of wnt ligands, including wnt2, wnt4, wnt5a, wnt11 and wnt16 
and several wnt receptors, including FZD 2, 3, 4, 5 and 6 as well as various co-receptors 
and wnt inhibitors307.  Once secreted, wnt proteins become attached to extracellular 
matrix or the cell surface to function in an autocrine or paracrine manner308.  Wnt 
signalling plays a vital role in the regulation of self-renewal and in adipogenic, 
chondrogenic, and osteogenic differentiation in MSC309-311, although the mechanisms by 
which this pathway exerts its effects are still not fully understood.   
 
The lineage specification and the early differentiation potentials of MSC are controlled 
by both canonical and non-canonical wnt pathways307 312, although again with divergent 
findings.  The first study linking wnt signalling to adipogenesis demonstrated that 
expression of wnt10b decreases during adipogenesis in vitro and that ectopic secretion 
of wnt10b inhibits adipogenesis by suppressing adipogenic transcription factors 
including pparg and CCAAT/enhancer binding protein-alpha (C/EBPα)313.  Since then 
wnt6, wnt10a and wnt10b have been shown to inhibit adipogenesis and stimulate 
osteoblastogenesis through a β–catenin-dependent pathway314.  However, it has also 
been suggested that canonical signalling suppresses osteogenic differentiation298.  In the 
presence of wnt3a, MSC undergoing osteogenesis exhibit reduced matrix mineralization 
and alkaline phosphatase activity and an increased expression of bone related 
markers312. 
 
Although numerous studies have described the role of wnt signalling on MSC isolated by 
traditional means, few studies have addressed these processes in native MSC, namely 
pericytes.  Pericytes express several wnt receptors, including LDL receptor–related 
proteins 5 and 6, and Frizzled 1 to 4 and 7, 8, and 10, 315. Wnt/β-catenin signalling 
inhibits adipogenic differentiation while enhancing chondrogenic differentiation when 
stimulated by lithium 315.  In these investigations, lithium enhanced chondrogenesis in 
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pericyte pellet cultures in the presence of transforming growth factor-β3, as 
demonstrated by increased sox-9 expression and glycosaminoglycan accumulation into 
the matrix. In contrast, transduction of pericytes with a recombinant adenovirus 
encoding dominant-negative T-cell factor-4 (RAd/dnTCF), which blocks wnt/β-catenin 
signalling, inhibited chondrogenesis, leading to reduced sox-9 and type II collagen 
expression and less glycosaminoglycan accumulation. Adipogenic differentiation of 
pericytes in both pellet and monolayer cultures was reduced, as demonstrated by 
decreased staining with Oil Red O and reduced pparg expression. This effect was 
negated by transduction of pericytes with RAd/dnTCF.  
 
EC display endogenous activation of the canonical wnt signalling pathway and express 
multiple ligands, receptors, and secreted modulators of wnt signalling.  A systematic RT-
PCR analysis of expressed wnt signalling components has been performed on HUVEC.  
Of the nineteen human wnts identified to date, only wnt 2b, 3, 4, 5a, 5b, 6, 7a, 11, 14 and 
15 were expressed by fresh or cultured HUVEC295.  However these cells also secrete the 
wnt regulators Dkk1, Dkk2, Dkk3, SFRP1, SFRP3 and SFRP5295. 
 
The aim of this short chapter was to explore a potential role for wnt signalling in the EC 
influence on pericyte osteogenic differentiation.  We evaluated the subcellular localisation of 
β-catenin to explore whether EC derived factors influenced canonical wnt activation of 
pericytes. 
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Wnt modulators may influence the osteogenic 
differentiation of pericytes in  coculture with endothelial 
cells 
HUVEC, pericytes and cocultures of these cells were cultured in osteogenic conditions 
supplemented with wnt modulators for 14 days (Figure 41, p125).  CHIR promotes wnt 
signalling through the inhibition of GSK3 which acts to degrade β–catenin. ICG 
selectively binds to CBP preventing its interaction with β–catenin and therefore 
inhibiting transcription through both the canonical and non canonical pathways.   At 14 
days, monocultures and cocultures supplemented with the wnt agonist CHIR 
demonstrated increased differentiation when compared with controls (DMSO).  
Conversely, monocultures and cocultures supplemented with the wnt inhibitor ICG had 
less osteogenic differentiation at 14 days than controls. 
 
The abolition of osteogenic differentiation in the presence of ICG, a specific inhibitor of 
wnt signalling, confirms that wnt signalling is necessary for the osteogenic 
differentiation of pericytes.  In addition the enhanced osteogenic activity of pericytes in 
cultures supplemented with CHIR is in keeping with previous studies on MSC.  Overall 
these findings indicate that increased wnt signalling enhances osteogenesis while 
inhibition of this pathway is associated with reduced osteogenic activity.  However, this 
experiment does not provides direct evidence that the EC influence of pericyte 
osteogenic differentiation is mediated through wnt pathways – the pro-osteogenic 
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Figure 41  Coculture of pericytes and EC in the presence of the Wnt modulators 
The osteogenic differentiation of pericytes in monoculture is accelerated in the presence of 
the wnt agonist CHIR and abolished in the presence of the wnt inhibitor ICG (A, B).  In direct 
coculture, the osteogenic differentiation of pericytes in CHIR is similar to that of DMSO 
controls while the presence of ICG tempers osteogenesis (C,D).  In indirect coculture with 
HUVEC pericyte differentiation is increased in the presence of CHIR and reduced in the 
presence of ICG (G,F). (Results shown are mean ± SD; n=3) 
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Nuclear translocation of beta β-catenin was not seen in 
pericytes exposed to EC Transwells or EC supernatant 
β-catenin is the central component of the wnt canonical pathway, and is regarded as a 
hallmark of wnt pathway activation.  In the absence of a wnt signal, free cytoplasmic β-
catenin is phosphorylated by serine/thionine kinases, casein kinase1alpha (CK1alpha) 
and GSK3β in a large APC/axin scaffolding complex that targets β-catenin for 
degradation.  In the presence of wnt, the destruction complex is disrupted and 
dissociation of GSK3β prevents phosphorylation of β-catenin.  The increased stability of 
β-catenin following wnt activation leads to its translocation in the nucleus and induces 
transcriptional activation316.  BCL9 is involved in signal transduction through the wnt 
pathway by promoting β-catenin's transcriptional activity. 
 
We evaluated whether EC influenced the nuclear translocation of β-catenin by exposing 
pericytes to a number of different culture conditions including EC Transwells and EC 
supernatant.  The addition of CHIR was used as a positive control as this is known to 
activate canonical wnt signaling.  Cultures fixed at 6hrs and 48hrs and fluorescently 
stained for β-catenin and BCL9.  Using Image J image analysis software, we were unable 
to detect any change in subcellular location of fluorescence with β-catenin or BCL 9 or in 
the number of cells expressing BCL9 in the nucleus following exposure to CHIR.  
Furthermore, we were unable to detect any changes in fluorescent staining between 
pericytes exposed to EC supernatant/Transwells over controls with either β-catenin 
(Figure 42, p127) or BCL9 (Figure 43, p127). 
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Figure 42  β-catenin and staining in pericytes exposed to wnt activators and EC Transwell. 
  Diffuse cytostolic fluorescence was seen following anti-β-catenin staining despite exposure to 
the wnt agonist CHIR or exposure to EC Transwell. 
 
 
Figure 43  BCL9 and staining in pericytes exposed to wnt activators and EC Transwell.   
Nuclear fluorescence was seen in a number of cells cultured in basal conditions following anti-
BCL9 staining.  However the number of cells expressing BCL9 in their nucleus and the intensity of 
this staining did not quantifiably increase following treatment with the wnt agonist CHIR or in 
Transwell coculture with EC.
Discussion 
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The ability for mesenchymal stem cells (MSC) to differentiate into osteocytes, 
chondrocytes and myocytes holds great promise for tissue engineering. Emerging data 
demonstrate that MSC derive from perivascular locations in vivo where their ancestors 
reside as pericytes and adventitial cells within an adult stem cells niche consisting of 
endothelial cells (EC) and the enveloping basement membrane. However, the factors 
that regulate mesenchymal activation and osteogenic differentiation of these cells in vivo 
are unknown.  The intimate contact between pericytes and EC suggests the existence of 
heterotypic cell-cell “crosstalk” that regulates pericytes in their local microenvironment. 
Knowledge of mechanisms mediating mesenchymal activation and osteogenic 
differentiation of pericytes may facilitate therapeutic exploitation of MSC in vivo where 
accelerated bone regeneration is desirable or in conditions characterized by 
pathological osteogenic differentiation. We hypothesized that EC influence the 
osteogenic potential of pericytes.  We studied this hypothesis using in vitro cell culture 
models of the perivascular niche making use of histological, immunohistochemical, flow 
cytometric and molecular biology techniques. 
 
Pericytes were sorted to homogeneity (CD146+/34-/45-/56-) from human adult 
adipose tissue and fetal muscle using FACS.  Sorted pericytes maintained a characteristic 
spindle shaped morphology and maintained their sorted phenotype (CD146+/34-/45-
/56-) in long-term culture (up to passage 10).  Additionally, sorted pericytes exhibited 
trilineage differentiation in vitro when cultured under appropriate conditions. Pericytes 
and EC integrated, and contributed basement membrane proteins (collagen IV and 
laminin) in 2D cocultures. Pericytes and EC formed vascular networks in 3D coculture. 
In the absence of osteogenic factors (basal conditions), there was no osteogenic 
differentiation at day 21 in EC monocultures, pericytes monocultures, and cocultures of 
the two cells.  In osteogenic conditions, there was no evidence of mineralization within 
wells containing EC alone, while there was complete differentiation of the pericyte 
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monoculture well. The osteogenic differentiation of pericytes was accelerated in 
coculture with EC. A significant pro-osteogenic effect was maintained when pericytes 
and EC were physically separated, being able to communicate only by soluble factors, as 
determined by qPCR for AP and SPP1 at day 14 (the increase in qPCR for Col1 and 
Alizarin Red staining for mineralisation did not reach statistical significance). Both 
HUVEC and HAMEC accelerated osteogenesis, with no significant difference between 
their effects. EC, pericytes and cocultures of these cells cultured in osteogenic conditions 
supplemented with the wnt modulators for 14 days.  At 14 days, pericyte monocultures 
and cocultures with EC supplemented with the wnt agonist CHIR demonstrated 
increased differentiation when compared to cultures without CHIR.  Conversely, 
cocultures supplemented with the wnt inhibitor ICG had reduced osteogenic 
differentiation at 14 days.  This data suggests that in osteogenic conditions, EC 
accelerate the osteogenic differentiation of MSC pre-cursors, and that this effect may be 
mediated through wnt signalling.   However, the potential role for wnt signialling in this 
setting requires further investigation. 
 
Pericytes and EC can be sorted from multiple human 
tissues although endothelial cells rapidly lose 
characteristic phenotype in culture. 
In order to explore the influence of EC on pericytes, I first purified homogenous 
populations of pericytes and EC using FACS.  FACS sorting is an attractive method of cell 
isolation as it can perform rapid selection of cells based on multiple fluorochromes.  The 
capacity for this platform to select cells based on positive and negative expression of 
surface markers means that multiple populations can be sorted simultaneously on a 
standard FACS.   In this thesis I initially focused on the sorting of pericytes and EC from 
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adult fat and human fetal skeletal muscle.  Our twin laboratories at the University of 
Edinburgh and at the University of California, Los Angeles (UCLA) are involved in a large 
early translational project funded by the Californian Institute for Regenerative Medicine 
(CIRM) that aims to establish an autologous adipose derived perivascular stem cell 
based therapy for bone regeneration.  My involvement in the project in Edinburgh and 
during an 8 month attachment at UCLA was primarily in the optimization of FACs 
sorting protocols from fat.  However, the techniques and principles of sorting from fat 
are extremely transferrable and provided an excellent platform for the sorting of 
perivascular cells from human and mouse skeletal muscle used in this thesis. 
 
I found that pericytes can be reliably sorted to homogeneity using FACS from both fat 
and skeletal muscle.  By optimizing published protocols I was able to culture pure 
populations of pericytes revealing some particular pitfalls associated with gating of 
pericytes.  Although I have been able to isolate populations of CD31+CD34+CD146+ EC 
that retain characteristic appearance and phenotype for the initial passages – these 
populations universally change phenotype or are over grown by more robust 
contaminating populations by passage 5.  
 
Notwithstanding the problems I have had with maintenance of an EC phenotype in 
culture, there are several limitations of using primary EC isolated from skeletal muscle 
and adipose tissue using FACS.  Firstly, EC sorted from these tissues are not well 
characterised and show significant heterogeneity in behaviour between individuals and 
preparations271.  They are slow to proliferate and their characteristics change with each 
passage in culture317.  It is likely that with each passage a subpopulation of cells is 
selected, based on their ability for ex vivo culture, until they eventually die out.318  It is 
also possible that these cells “age” rapidly in culture becoming rapidly senescent 
through accelerated telomere shorting as demonstrated with MSCs142.  As such there is a 
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strong case for using well characterised EC sources to improve consistency and to 
ensure that the set up is sensitive enough to pick up subtle experimental phenotypes.  In 
addition, current EC sorting methods cannot distinguish between micro and 
macrovascular EC and sorted populations would likely contain a mixture of both. Macro- 
and microendothelial cell matrix differs significantly319  and it was important to 
establish whether the macro- or microvascular source of EC influences cell-cell 
interactions with pericytes. I therefore used well characterised commercially available 
EC preparations in this thesis: Human Umbilical Vein Endothelial Cells or HUVEC 
(macrovascular EC) (Lonza) and Human Adipose Derived Microvascular Endothelial 
Cells (HAMEC) (ScienCell).  I found that HUVEC and HAMEC were indistinguishable in 
terms of appearance in culture, cell surface marker expression and in their influence on 
pericyte proliferation and differentiation. 
 
Strengths and weaknesses of perivascular niche models 
The 2D and 3D models of the perivascular niche generated in this thesis have a number 
of strengths and limitations (Table 14, p134).  There are a number of prerequisites for 
perivascular models used in the setting of osteogenic differentiation of pericytes in 
coculture with EC.  Firstly, all three components of the perivascular niche must be 
present: pericytes, EC and their enveloping extracellular matrix or basement membrane.  
As the process of osteogenic differentiation can take from 2-3 weeks, the model must be 
stable for the duration of this period.  Although the in vitro tube assembly assay more 
closely recapitulates the local cellular and structural environment seen in microvessels, 
the networks collapse within 24 h and retrieval of the cells from Matrigel can be 
challenging in this setting.  While the 3D in vitro spheroid model arguably provides more 
physiological relevance than 2D coculture, particularly as the influence of stiff culture 
plastic matrix is removed, the natural structural relationship of vessels is not recreated 
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and further variables such as the influence of limited access to nutrients of cells in the 
core are thought to influence cell behaviour135.  Furthermore, Transwell coculture and 
the histological processing of tissue are technically challenging.  It was therefore 
decided to proceed using a simple 2D in vitro model, where the  contact between the two 








2D in vitro model  
Strengths 
- Simple 
- Contact between cell types can be 
easily defined 
- IHC can be performed in culture plates 
- Cells easily dissociated for isolation of 
populations 




- Contact with culture plastic may 
modify pericyte/EC behaviour 
- Natural structural relationship not 
recreated 
- Differentiation dependent on 
confluence 
- Confluence of pericytes when starting 
influences capacity to differentiate 
3D in vitro spheroid model 
Strengths 
- 3D culture more closely recapitulates 
local cellular environment 
- Allows physiological self-assembly 
phenomena 
- Amenable to sectioning 




- Natural structural relationship not 
recreated 
- Difficulty transferring to a Transwell 
system 
- Subsequent isolation of cell 
populations challenging 
- Freezing, sectioning and staining of 
small spheres technically challenging 
- Contact between cell types not easily 
defined 
3D in vitro tube assembly (vasculogenic) assay 
Strengths 
- 3D culture more closely recapitulates 
local cellular and structural 
environment 




- Networks collapse within 24 h 
- Retrieval of cells challenging 
- Difficulty visualizing at >20x as large 
optical distance required to 
accommodate Matrigel layer 
- Unable to freeze due to 
thermosensitivity of Matrigel 
Table 14  Strengths and weaknesses of 2D and 3D perivascular niche models  
 
In addition to the challenges specific to the structure of each model, establishing 
conditions in which pericytes are capable of osteogenic differentiation and EC survive 
proved to be a considerable challenge.  Pericytes are routinely cultured in DMEM 
(20%FBS,1%PS) while EC are conventionally grown in EGM214 215.  Survival of EC drops 
dramatically in DMEM (20%FBS,1%PS), and further still in the presence of 
differentiation factors.  Conversely, pericytes cultured in EGM2 proliferate rapidly 
becoming a multilayer overgrowing underlying EC.  Titrations of media combinations 
were performed to optimize coculture conditions.  Increasing the EGM2 proportion 
improved EC viability yet resulted in rapid overgrowth of pericytes.  Furthermore, 
diluting differentiation media with EGM2 diminished the differentiation of pericytes.  
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We therefore elected to use conventional commercial differentiation medium (Lonza) 
supplemented with fresh EC every second day to ensure a constant presence of viable 
EC in culture.  Optimisation of differentiation conditions in this way was performed in 
the settings of osteogenesis, adipogenesis and chondrogenesis. 
 
Quantifying differentiation 
Functional stains to detect products of osteogenic, adipogenic and chondrogenic 
lineages are widely published and were therefore used in this thesis14 216 320.  In 
particular, Alizarin Red staining for mineralisation provides a clear visual 
representation of the extent of osteogenic differentiation that can also be quantified 
using image analysis software.  Elution and spectrophotometric measurement of these 
dyes provides a useful means of quantifying differentiation320. 
 
The differences in osteogenic differentiation seen with Alizarin Red staining and elution 
and von Kossa staining were not reflected by significant rises in osteogenic transcripts 
detected by RT qPCR. However, there was a clear trend indicating increased AP, SPP1 
and Col1 in transwell EC coculture over pericyte monoculture. OPN, AP and COL1 were 
selected because of their early expression321 322. Overall, the genetic profile obtained 
points towards an accelerated osteogenic commitment of pericytes in the presence of 
EC.     
 
We used relative quantification to determine fold differences in target gene expression 
normalized to an internal reference (housekeeping) gene.  HPRT (hypoxanthine-guanine 
phosphoribosyltransferase) was selected as a reference gene as our group has found it 
to be stably expressed across skeletal muscle.  The use of multiple stable reference 
genes is generally accepted as the method of choice for RT-qPCR data normalisation and 
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this could have improved the reliability of our data323 324.  The presence of EC-derived 
reference gene within coculture wells means that accurate comparison of pericyte 
differentiation between monocultures and cocultures could not be made. However, 
differentiation in pericyte monocultures and pericytes in Transwell culture with EC 
could be made as EC populations were separated throughout and excluded for the 
analysis.  We considered a number of strategies that would enable us to accurately 
compare monocultures and cocultures using qPCR.  One potential method would be to 
use pericytes transfected with fluorescent proteins.  The transfected pericytes could 
then be purified from EC using FACS or MACS immediately prior to RNA extraction.  
However, many cells are lost through the sorting process and the experiment would 
need to be performed with a prohibitively large number of cells.  Furthermore the 
differentiated cells are encased in mineralised matrix limiting their amenability to 
trypsinization and resuspension as single cells prior to sorting. 
 
EC mediated up regulation of pericyte osteogenesis 
supported by previous studies 
The acceleration of pericyte osteogenic differentiation by EC is in keeping with previous 
studies using MSC (Table 6, p48), but is the first report of this effect in MSC 
precursors254-256 325. Overall, two main mechanistical dialogues have been reported: a 
paracrine effect through VEGF, BMP-2, IGF production and a juxtacrine mechanism by 
gap junctional activity 259 326. Our data indicate that EC mediated up regulation of 
pericyte osteogenic potential is independent of direct contact.  We demonstrate that the 
presence of EC (separated by Transwell) appears to increases the osteogenic 
differentiation of pericytes although this did not reach significance in a number of 
outcome measures.  Experiments culturing pericytes using EC supernatant could be 
performed to investigate if this process requires “crosstalk” between cells or whether 
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the presence of EC produced cytokines is sufficient to produce this effect.  The nature of 
this effect could be further characterised by exposing the pericytes to EC Transwells for 
defined periods during the differentiation process to establish whether EC “prime” 
pericytes for differentiation or whether they exert an effect throughout the process. 
 
Endothelial-Mesenchymal transition is not responsible for 
increased osteogenesis in coculture wells 
The importance of EC plasticity in the development and progression of disease is 
increasingly recognized327.  Although pericytes and resident stem cells within muscle 
have been shown to contribute to forms of heterotopic ossification328 329, vascular 
endothelial cells have recently emerged as a candidate for the cellular origin of 
heterotopic cartilage and bone in the rare condition Fibrodysplasia ossificans 
progressive (FOP)330.   Up to 50% of the cartilage and bone cells found in FOP 
heterotopic lesions appear to be of endothelial origin based on Tie2-Cre lineage tracing 
and expression of various endothelial markers (Tie2, Tie1, vWF, VE-cadherin)328. 
 
Endothelial-mesenchymal transition (EndMT) is characterized by loss of cell-cell 
adhesion and a strong change in cell polarity, generating elongated spindle-shaped cells.  
Expression of endothelial markers such as CD31, VE-cadherin, Tie1 and vWF is reduced 
whereas mesenchymal markers such as FSP-1, αSMA and N-cadherin increase.  The 
newly formed cells are highly invasive and motile and give rise to various tissue types in 
embryonic development and disease. 
 
We considered the possibility that the increase in osteogenic differentiation in our 
cocultures resulted from EndMT resulting in a secondary source of osteogenic cells.  
However, a number of observations make this unlikely in this setting.  EC maintained 
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their characteristic cobblestone appearance in culture irrespective of the medium used 
(EGM2, basal and osteogenic) while maintaining their CD31+CD34+ phenotype.  
Furthermore, there was no evidence of osteogenic differentiation as assessed by Alizarin 
Red and von Kossa staining in EC wells. Finally, the increase in pericyte differentiation 
seen in the Transwell setting, where EC are physically separated suggests that EndMT is 
not responsible for the observed increase.  
 
In vivo coculture (muscle pocket) unable to confirm in 
vitro findings 
I used a common method of in vivo osteogenesis to investigate whether this 
phenomenon occurred in an in vivo setting. However, there was considerable variability 
within biological replicates and we were unable to draw any meaningful conclusions.  
The muscle pocket model of ectopic bone growth has a number of limitations which may 
have affected the results. The cytokine used to induce osteogenesis in this setting – BMP 
– is potent and can mask subtle differences in differentiation between groups. 
Furthermore this model can have considerable variability between animals as subtle 
alterations in implant placement (for example in an avascular plane compared to a 
vascular body of muscle) can influence osteogenic differentiation.  Despite practising 
gelfoam placement on cadaver animals in advance it is likely that my relative 
inexperience with the surgical model may have contributed to the variability.  If given 
the opportunity to repeat this experiment I would increase considerably the number of 
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The effects of EC are lineage specific 
Our results indicate that EC accelerate the osteogenic differentiation of pericytes but we 
were unable to demonstrate objectively an influence on adipogenic differentiation135.  A 
growing body of results suggests that osteogenic and adipogenic lineages are mutually 
exclusive331-333,334.  In addition to implications on bone tissue engineering, this 
observation is relevant to bone homeostasis, where a decline in osteoblasts and a 
parallel increase in adipocytes is thought to underlie osteoporosis 335. Chemotherapy is 
known to induce a shift in the bone marrow MSC population towards a more adipogenic 
genotype with higher capacity to differentiate into adipocytes336.   Despite this, various 
pathways, activated by external stimuli that induce differentiation seem to play dual 
roles. For example, BMP signaling - one of the main inducers of osteogenic 
differentiation in MSC - may also be involved in adipogenic differentiation264. 
 
Complex niche interactions and absent environmental 
cues prevent differentiation in healthy tissues 
Although EC may produce factors in vitro that accelerate the osteogenic potential of 
pericytes, florid osteogenic differentiation throughout perivascular locations is not 
observed in vivo in healthy tissues. This may be due to a lack of environmental cues 
directing lineage fate and native pericyte-EC interactions that maintain quiescence.  Our 
findings confirm that pericytes do not spontaneously differentiate in basal media, 
requiring lineage specific factors to direct differentiation.  The osteogenic factors used to 
induce differentiation artificially in vitro are likely to have in vivo equivalents present 
only in certain conditions (e.g. injury or growth).  It is intuitive, and in keeping with 
literature describing the behaviour of other adult stem cells230 234 that pericyte 
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differentiation potential natively exists and is environmentally repressed.  Here, 
interactions that require intimate cell-cell contact may maintain stem cell quiescence 
until this interaction is disrupted by appropriate signals.   
 
An emerging paradigm?  
In light of our findings and findings reported by others we propose a paradigm of 
multilevel control of pericyte behaviour by EC.  We propose that pericytes are 
maintained in a ‘quiescent state’ through native cell-cell interactions with EC.  In 
response to injury factors, pericytes are ‘activated’ with respect to MSC potentials, 
becoming sensitive to environmental cues that initiate osteogenic differentiation and 
secondary factors produced by EC that accelerate osteogenesis (Figure 23).  The native 
pericyte-EC interaction that maintains dormancy and the soluble factors that 
subsequently accelerate osteogenic factors represent key mechanistic targets. 
Mechanism 1: Native pericyte-EC interaction maintaining quiescence 
Pericyte ‘quiescence’ within their native perivascular niche is observed in healthy 
tissues where natural pericyte/EC relationships are undisturbed.  Similar niche 
quiescence is observed within other adult stem cell niches229 230.    Pathological 
osteogenesis/adipogenesis is observed in pathological conditions where the 
microvascular structure is disturbed indicating that pericytes may have been ‘activated’ 
with respect to MSC potentials. Furthermore, pericytes have been shown to be capable 








Figure 44 Proposed paradigm outlining the influence of EC on the mesenchymal ‘activation’ 
and osteogenic differentiation of pericytes.   
Quiescent pericytes reside within their perivascular niche where complex interactions with EC 
maintain them in a dormant state (A) despite the presence of EC produced soluble factors 
accelerating osteogenesis.  In response to injury factors pericytes are dislodged from the EC 
binding domains to become activated with respect to MSC characteristics (B).  ‘Activated’ 
pericytes are sensitive to environmental cues directing lineage differentiation and in the case 
of osteogenesis to soluble factors accelerating osteogenesis (C). The behavior of pericytes is 
likely to be modified by long-term culture (D).  The native cell-cell interaction maintaining 
dormancy is not recreated in 2D in vitro coculture where the unopposed EC paracrine effect 
stimulates accelerated osteogenic differentiation.  It is not yet clear whether this native cell-
cell interaction maintaining dormancy can be recreated in 3D models of the perivascular niche 
(E). 
 
Mechanism 2: Endothelial paracrine effect stimulating osteogenesis 
Following ‘activation’ pericytes become sensitive to local lineage specific factors that 
may be up regulated as part of the injury response – including soluble factors produced 
by EC. Although a dual effect of EC on pericyte differentiation appears contradictory – it 
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may be harnessed to maximize the response to injury.  While it is important to maintain 
pericyte quiescence when their mesenchymal phenotypes are not desired, it is equally 
important to ensure their effects are maximized when their ‘activation’ is beneficial.   
 
While we have observed EC mediated upregulation of pericyte osteogenic 
differentiation through soluble factors we have so far been unable to recreate the native 
cell-cell interactions responsible for maintaining dormancy.  It is most likely that 2D 
culture limits the relevant interactions necessary for downregulation.  Alternatively, the 
initial pericyte detachment from EC may result in irreversible activation, resulting in a 
downstream subset of pericytes that have so far not been identified as distinct from in 
situ pericytes.  Finally it is feasible that EC have no inhibitory effect on pericytes – the 
lack of pericyte differentiation observed in healthy tissues occurs as relevant cues for 
differentiation are not present. 
 
A potential role for wnt signalling 
I have performed preliminary experiments to explore a possible role for wnt signalling 
in the EC acceleration of pericyte osteogenic differentiation.  This was based on 
literature describing production of wnt ligands by EC295 and the known pro-osteogenic 
and anti-adipogenic effects of wnt activation294 337 338.  In the presence of the wnt 
inhibitor ICG, pericytes in monoculture were not able to differentiate down the 
osteogenic lineage confirming that wnt signalling is critical to this process.  The addition 
of EC to ICG supplemented wells appeared to overcome this inhibition to some degree.  
ICG selectively binds to CBP preventing interaction with β-catenin in the nucleus and it 
may be that the increase in wnt ligand load associated with EC coculture was sufficient 
to overcome this inhibition.  The addition of the wnt agonist CHIR mirrored the pro-
osteogenic effect seen with the addition of EC to pericyte monocultures while the 
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addition of CHIR to coculture wells increased further osteogenic differentiation.  It is not 
clear whether this reflects distinct mechanisms accelerating the osteogenic 
differentiation of pericytes or whether EC exert their effect through the wnt pathway. 
More detailed mechanistic studies are required. 
 
Nuclear translocation of β-catenin is a defining feature of canonical wnt signalling.  In 
order to demonstrate activation of wnt pathways in pericyte coculture with EC we set 
out to show that the concentration of nuclear β-catenin was higher in pericyte coculture 
with EC.   Even in the presence of the wnt agonist CHIR (positive control) we were 
unable to detect an increase in nuclear β-catenin.  This may indicate a technical problem 
with the experimental set up or that our antibodies were not sensitive enough to 
evaluate subtle changes in expression.  It would be preferable to conduct this 
experiment in direct cocultures as pro-osteogenic effects are known to be dramatic, 
although this would have precluded accurate microscopic evaluation. Finally, lack of 
nuclear translocation of β-catenin in our studies may indicate that EC do not activate 
wnt through the canonical pathway or that the degree of activation seen with indirect 
coculture is not sufficiently dramatic to detect using this system.  
 
There are a number of experiments that I could have performed to further characterise 
the role of wnts in the EC mediated acceleration of pericyte osteogenesis.  Despite 
published reports of the wnt secretome of EC it will be important to confirm that EC 
secrete wnt ligands.  This could be established by performing an ELISA to confirm the 
presence of wnt ligands in EC supernatant.  Furthermore, any difference in wnt gene 
expression in the presence (using Transwell system) and absence of pericytes might 
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A further experiment can be envisioned to confirm that EC modify pericyte 
differentiation through wnt signalling.   EC could be pre-treated with C59 (a wnt 
modulator that prevents the secretion of all wnt ligands through inhibition of porcupine 
(figure 1.6.1)) prior to coculture with pericytes.  Inhibition of the pro-osteogenic effect 
by the pre-treated pericytes would confirm that EC exerted their effect through wnt 
signalling.   C59 is the only wnt modulator studied here that influences the production of 
wnt ligands (CHIR and ICG act downstream of receptor binding).  Therefore, addition of 
CHIR and ICG to EC prior to coculture - without exposing the pericytes to these 
modulators - would be unlikely to influence pericyte differentiation.
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SECTION 2:  αV INTEGRIN DEPLETION IN 
PDGFRβ+ PERIVASCULAR CELLS REGULATES 
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TGFβ1 has a central role in the development of fibrosis 
Fibrotic disease represents one of the largest groups of disorders for which there is no 
effective therapy and thus fibrosis treatment represents a major unmet medical need.  It 
is well established that myofibroblasts are the main cellular effectors of fibrosis339.  
These phenotypically modulated fibroblasts acquire expression of contractile proteins 
such as αSMA, and when activated, produce large amounts of extracellular matrix 
proteins. TGFβ is considered to be the master control cytokine in the activation of the 
fibrotic response174.  TGFβ induction and activation is consistently observed in 
experimental models of tissue fibrosis340, while TGFβ overexpression induces marked 
fibrotic changes179.  Also of consequence is the ability of TGFβ to decrease the 
production of enzymes that degrade the ECM, such as collagenase, while increasing 
production of proteins that inhibit ECM-degrading enzymes such as TIMPs and 
plasminogen activator inhibitor (PAI)-1.  
 
The TGFβ superfamily includes the bone morphogenetic proteins and the TGFβ 
subfamily which are involved in distinct signalling pathways.  The TGFβs are some of the 
most pleiotropic peptides known, whose functions include critically regulating tissue 
homeostasis and repair, immune and inflammatory responses, ECM deposition, cell 
differentiation and growth341.  The three structurally similar isoforms – TGFβ1, TGFβ2 
and TGFβ3 are encoded by three different genes.  Although the isoforms signal through 
the same surface receptors and have similar cellular targets, each isoform is expressed 
in a distinct tissue specific manner.  TGFβ1 is almost ubiquitously found in mammalian 
tissues, while TGFβ2 and 3 are expressed in a more limited manner.  While similar 
effects with each isoform are observed in vitro, genetic mouse studies have 
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expressed in fibrotic tissues, although the development of tissue fibrosis in multiple 
human organs has primarily been attributed to TGFβ1341. 
 
TGFβ activation 
TGFβ is stored in the ECM as a latent complex consisting of a C-terminal TGFβ and an N-
terminal latency associated peptide (LAP), which is bound to the latent TGFβ binding 
protein (LTBP) by disulphide bonds.  The attachment of TGFβ to the binding proteins 
shields its active epitopes, preventing interactions with the TGFβ receptors.  In most 
tissues, significant amounts of latent TGFβ are “stored” in the matrix.  As such, activation 
of TGFβ signalling is primarily regulated by conversion of latent TGFβ to active TGFβ.  
One of the best characterised mechanisms of TGFβ activation requires binding of αv 
integrins to an RGD sequence in the prodomain and exertion of force on this domain, 
which is held in the ECM by latent TGFβ binding proteins.  Although TGFβ synthesis and 
expression of its receptors are widespread, activation is localised to the sites where 
TGFβ is released from latency. Mice with integrin binding RGD motif mutated to RGE 
recapitulate all major phenotypes of TGFβ1-null mice, including multi-organ 
inflammation and defects in vasculogenesis, thus demonstrating the essential role of 
integrins in TGFβ activation.  Integrin binding alone is not sufficient for TGFβ activation 
– contractile force exerted by integrins across the latent TGFβ binding protein (LTBP)-
prodomain complex is hypothesised to change the conformation of the pro-domain and 
to free TGFβ for receptor binding (Figure 45, p149). 
 
When active TGFβ is liberated it binds to a heterodimeric receptor complex consisting of 
one TGFβ type 1 receptor molecule, termed activin-linked kinase (ALK) 5, and one TGFβ 
type II receptor.  In the canonical TGFβ pathway, ligand binding leads ALK5 to 
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is translocated to the nucleus, activating transcription. TGFβ has also been shown to 
signal via additional pathways, including p38 mitogen-activated protein kinase (MAPK), 
the Ras/MAPK kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway, the 
c-abl pathway and Jun kinase (JNK). These signaling pathways modify gene expression 
in a promoter-selective fashion. It is therefore likely that additional signaling pathways 
are abnormally activated in myofibroblasts in a manner independent of the canonical 




Figure 45 Schematic of the structure and activation mechanism of proTGFβ1 
ss, disulphide bonds [From Shi M, Zhu J, Wang R et al.  Latent TGFβ structure and 
activation.  Nature 2011;474:343-348] 
 
Although αv integrins are one of the only mechanisms of TGFβ activation demonstrated 
in vivo343, a number of other methods have been reported in vitro including physical 
processes such as acidification, extreme temperature changes, and oxidation.  In 
addition, TGFβ can also be activated by a number of proteases, including plasmin, 
tryptase, thrombin, elastase, matrix metalloproteinase (MMP)-2, and MMP-9, and by 









Integrins are allosteric2 receptors that signal across the plasma membrane in both 
directions.   They are the major metazoan receptor for cell adhesion to extracellular 
matrix proteins and are essential for cell-cell adhesion.  They make transmembrane 
connections to the cytoskeleton and activate many intracellular signalling pathways 
(Figure 46, p151).  Integrins are αβ heterodimers; each subunit crosses the membrane 
once, with most of each polypeptide in the extracellular space and two short cytoplasmic 
domains.  Integrins also serve as transmembrane mechanical links from those 
extracellular contacts to the cytoskeleton inside cells. 
 
Integrin alpha v (αv) is known to associate with the β chains 1, 3, 5, 6 and 8.  The 
expression of αv on myofibroblasts is thought to be critical to fibrosis339.  Myofibroblasts 
express several αv containing integrins and as contractile cells, are capable of exerting 
force on tethered ligands.  The crystal structure of the small latent complex of TGFβ has 
recently been solved and confirms that mechanical force generated by actomyosin 
cytoskeleton and transmitted by integrins is a common mechanism for activating 
TGFβ345.  In vitro studies have shown that αv integrins can use alternative αv containing 
integrins to activate TGFβ346.  Furthermore, several integrins that share the αv subunit 
including αvβ1, αvβ3, αvβ5, αvβ6 and , αvβ8 can recognise the same RGD peptide motif 
and activate TGFβ in some instances343 347-350. 
                                                             
2 Allosteric regulation is the binding of an enzyme or other protein by binding to an 









Figure 46 Integrins are transmembrane heterodimers.   
The extracellular ligand binding site binds extracellular matrix while the cytoplasmic domain 
attaches to the cytoskeleton. 
 
 
Figure 47  The integrin receptor family 
Integrins are αβ heterodimers; each subunit crosses the membrane once, with most of each 
polypeptide (>1600 amino acids in total) in the extracellular space and two short cytoplasmic 
domains (20-50 amino acids).  The figure depicts the mammalian subunits and their αβ 
associations.  8 β subunits can associate with 18 α subunits to form 24 distinct integrins.  
These can be considered in several subfamilies based on evolutionary relationships, ligand 
specificity and, in the case of β2 and β7 integrins, restricted expression on white blood 
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Henderson et al.,  were the first to show that the specific targeting of the αv subunit in 
fibrogenic myofibroblasts effectively reduces developing and established fibrosis in 
liver, kidney and lungs351.  They used this system to delete the integrin αv subunit 
because of the suggested role of multiple αv integrins as central mediators of fibrosis in 
multiple organs.  In this section we set out to establish whether the activation of 
pericytes to myofibroblasts through αv integrins was conserved in skeletal muscle, and 
whether the targeting of αv integrins represented a potential therapeutic target in the 
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Hypothesis and aims 
 
Hypothesis  
1.  αv integrin expression on PDGFRβ+ perivascular cells regulates skeletal muscle 
fibrosis. 
 
In order to address this hypothesis the following aims were established: 
(i) Demonstrate that PDGFRβ-Cre effectively targets recombination in quiescent and 
activated skeletal muscle pericytes. 
(ii) Show that selective αv integrin depletion in skeletal muscle PDGFRβ+ perivascular 
cells regulates skeletal muscle fibrosis. 
(iii) Show that blockade of αv integrins by a novel small molecule (CWHM12) attenuates 
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Graphical Abstract  
 
  
Materials and methods 
 




 Chapter 2.1 Materials and methods 
Materials and methods 
 




 mTmG (TdTomato-EGFP)352 mice were obtained from the Jackson Laboratory and 
crossed with Pdgfrb-Cre353 mice.  Itgavflox/flox354 mice and Itgb8flox/flox355 mice were 
obtained from Neil Henderson and all were maintained on C57BL/6 background. Mice 
used for all experiments were 8–12 weeks old and were housed under specific 
pathogen–free conditions in the Animal Barrier Facility of the University of Edinburgh. 
All experiments were approved by the Institutional Animal Care and Use Committee of 
the University of Edinburgh and the Home Office. 
Genotyping 
In preparation for PCR, ear clips were lysed overnight at 55oC in 200µl Direct PCR lysis 
Reagent (Peqlab) with 4µl Proteinase K (Sigma Aldrich).  Samples were subsequently 
centrifuged at 1000rpm for 10 minutes.  40µl of supernatant was heated for a further 45 
minutes at 85oC to inactivate the Proteinase K.  The PCR reaction mixture was composed 
of 5µl 5xQ solution, 2.5µl 10xBuffer, 0.5µl dNTP(10mM), 0.8µl forward and reverse 
primers, 0.2µl Qiagen Taq and 14.5µl RNAse-free water (all Qiagen). Reactions were 
carried out in a Venti 96 Well thermo cycler (Applied Biosystems) using the cycle 
conditions listed in (Table 15, p156).  Sequences of validated target and reference genes 
are listed in (Table 16, p157).  Genotyping gels demonstrating αvflox/flox and β8flox/flox are 
shown in (Figure 48, p157) and (Figure 48, p157) respectively 
 
Number of cycles Duration Temperature (oC) 
1 5 min 94 
30 30 sec 94 
 45 sec 57 
 2 min 72 
1 10 min 72 
1 To end 12 
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Primer  Sequence Amplicon size 
Cre F TGC CAC GAC CAA GTG ACA GCA 375bp 
 R AGA GAC GGA AAT CCA TCG CTC  
αV F CAC AAA TCA AGG ATG ACC AAA fl/fl = 600bp  
 R TTC AGG ACG GCA CAA AGA CCG WT = 350bp 
β8  F GAGATGCAAGAGTGTTTACC fl/fl = 350bp 
 R CACTTTAGTATGCTAATGATGG WT = 300bp 
mTmG F (WT) CTCTGCTGCCTCCTGGCTTCT Mut = 250bp 
 R (WT) CGAGGCGGATCACAAGCAATA WT = 330bp  
 R (Mut) TCAATGGGCGGGGGTCGTT  
Table 16 Primer sequences used to perform genotyping PCR  
 
 
Figure 48 Genotyping gel demonstrating αv
flox/flox
 expression  
 
 








Muscle Fibrosis model 
We injected 50μl of 20μM cardiotoxin (CTX) Naja Mossambica Mossambica (Sigma 
Aldrich) directly into the midbelly of the tibialis anterior (TA) muscles of 8-10 week old 
sex-matched mice.  50μl of PBS was used in control animals.   TA muscles were 
harvested at multiple time points following CTX injection.   
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Muscle Regeneration Model 
Muscle damage was induced by injection of 50 ml of 20μM cardiotoxin Naja Mossambica 
Mossambica (Sigma Aldrich) directly into the midbelly of TA muscle. To assess muscle 
damage, mice were given an intraperitoneal injection of Evans blue dye (25 mg/kg) at 
day 7, 24 h prior to sacrifice216. 
Primary cell isolation and fluorescence activated cell sorting (FACS) 
Mouse skeletal muscle was excised, minced with scissors and digested in 
collagenase/dispase solution [DMEM/20%FBS/1%PS/0.5mg/ml of collagenase II-S and 
dispase (Sigma)] for 30 minutes at 37oC with shaking (200rpm).  An equal volume of 
DMEN/20%FBS/1%PS was added to halt the digestion and the total suspension was 
passed through a sterilized nylon mesh to remove large clumps.  The suspension was 
then passed through a 100µm followed by a 70µm strainer and centrifuged (300 x g, RT, 
5mins).  The supernatant was discarded and the pellet was re-suspended in 10ml red 
cell lysis buffer (Sigma Aldrich) and incubated at RT for 2 minutes.  An equal volume of 
DMEN/20%FBS/1%PS was added and the suspension centrifuged (300 x g, RT, 5mins).  
The supernatant was again discarded and the pellet was resuspended in 1ml 
PBS/2%FBS.  The cell suspension was then passed through a 40µm strainer.  Cells were 
counted using a haemocytometer using tryphan blue to distinguish non-viable cells.   
 
(i)  Isolation of eGFP cells from mTmG reporter 
Following live/dead staining with dapi (Invitrogen), live single eGFP positive cells from 
mTmG;PDGFRβ-Cre mice were sorted using a FACSAria (BD Biosciences). Fluorescence 
compensation settings were optimized using anti-mouse Ig, κ/negative control beads 
plus (BD Biosciences) incubated with the range of FACS antibodies used.  Unstained cells 
were used to account for the autofluorescence of samples and fluorescently matched 
isotypes were used as negative controls.     
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(ii) Isolation of pericytes from non-reporter tissue 
When sorting non-reporter tissues an anti-PDGFRβ antibody was used to identify 
PDGFRβ+ perivascular cells.  A number of markers used in the identification of pericytes 
(CD146) and exclusion of non-pericyte cells (CD31, CD144, CD45, CD56, CD34) were 
used to confirm the purity of sorted cells.  In brief, cells were resuspended at a 
concentration of 30x106/ml and incubated with all antibodies at the appropriate 
dilution (Table 17, p160).  As controls, 5x105 cells were incubated with isotype control 
antibodies in the same conditions.  The cell suspensions were incubated with the 
antibodies on ice and in the dark for 20 minutes then washed with PBS/2%FBS and 
centrifuged (300 x g, RT, 5mins).  The supernatant was then discarded and the cells 
resuspended in 1ml PBS/2%FBS. Cells were sorted using a FACSAria (BD Biosciences).  
Fluorescence compensation settings were optimized using anti-mouse Ig, κ/negative 
control beads plus (BD Biosciences) incubated with the range of FACS antibodies used.  
Unstained cells were used to account for the autofluorescence of samples and 
fluorescently matched isotypes were used as negative controls.  Prior to selection of 
PDGFRβ+ perivascular cell populations, a side versus forward scatter plot was used to 
remove debris then a height versus width plot was used to eliminate doublets.  DAPI 
[0.1-0.5µg/ml (Invitrogen)] was used to eliminate dead cells.  
 
Sorted cells were seeded onto tissue culture plates, at a density of 2x104 cells per cm2 
and cultured in EGM2 medium in a 37oC, 5% CO2 incubator.  After 24hrs, EGM2 medium 
was changed to DMEN/10%FBS/1%PS which was then refreshed three times/wk until 
100% confluence was reached.  After an initial passage, perivascular cells were seeded 
on tissue culture plates at 2x104 cells/cm2 in high-glucose DMEN/10%FBS/1%PS, and 
grown until confluent in a 37oC, 5% CO2 incubator. 
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FACS analysis of cultured cells 
In preparation for flow cytometric analysis, cells were resuspended at a concentration of 
30x106/ml and incubated with all antibodies at the appropriate dilution (Table 17, 
p160).  As controls, 5x105 cells were incubated with isotype control antibodies in the 
same conditions.  The cell suspensions were incubated with the antibodies on ice and in 
the dark for 20 minutes then washed with PBS/2%FBS and centrifuged (300 x g, RT, 
5mins).  The supernatant was then discarded and the cells resuspended in 1ml 
PBS/2%FBS.  Cells were analysed using a flow cytometer (Fortessa, Becton-Dickenson).  
The fluorescence compensation settings were optimized using anti-mouse Ig, κ/negative 
control beads plus (BD Biosciences) incubated with the range of FACs antibodies used.  
Unstained cells were used to account for the autofluorescence of samples and 
fluorescently matched isotypes and fluorescence-minus-one samples were used as 




Fluorochrome Supplier Dilution Isotype Control antibody 
PDGFRβ PE Biolegend 1/50 PE Rat  IgG2b κ 
PDGFRβ APC eBioscience 1/50 APC Rat IgG2b κ 
PDGFR APC BD Bioscience 1/50 APC Rat IgG2b κ 
PDGFR PE eBioscience 1/50 PE Rat  IgG2b κ 
CD146 PE Biolegend 1/100 PE Rat  IgG2b κ 
CD146 Alexa Fluor 488 BD Bioscience 1/100 Alexa Fluor 488 Rat IgG2b κ 
CD56 APC Abcam 1/100  
CD56 PECy7 BD Bioscience 1/100 PE-Cy7 Rat IgG2b κ 
CD146 PerCPCy5.5 BD Bioscience 1/100 PerCPCy5.5 Rat IgG2b κ 
CD31 APC eBioscience 1/50 APC Rat IgG2b κ 
CD90.2 PerCPCy5.5 Molecular 
probes 
1/100 PerCPCy5.5 Rat IgG2b κ 
CD34 Alexa Fluor 700 BD Bioscience 1/100 Alexa Fluor 700 Rat IgG2b κ 
CD34 FITC BD Bioscience 1/100 FITC Rat IgG2b κ 
CD45 PerCPCy5.5 BD Bioscience 1/100 PerCPCy5.5 Rat IgG2b κ 
CD45 PE-Cy7 BD Bioscience 1/100 PE-Cy7 Rat IgG2b κ 
Table 17 Antibodies and corresponding isotype controls for MOUSE perivascular cell 
purification and analysis  
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Immunohistochemistry and Immunofluorescence 
For immunofluorescence staining, skeletal muscle tissue was fixed in 4% 
paraformaldehyde overnight at 4oC, immersed in graded sucrose solutions, embedded in 
OCT (Tissue Tek) and stored at -80oC. Tissue sections were air dried and then stained 
for pericyte and non-pericyte markers (Table 18, p162).  Sections were washed with 
PBS/Tween20 pH7.4 (2x5mins), incubated with Avidin (Thermo Scientific) for 15 
minutes, washed with PBS/Tween20 pH7.4 (2x5mins), then incubated with Biotin 
(Thermo Scientific) for 15 min.  Sections were washed with PBS/Tween20 pH7.4 
(3x5mins) before being blocked for one hour with Protein Block (Dako).  After blocking, 
the cells were incubated with primary antibodies overnight at 4oC.  Sections incubated 
with primary antibodies were washed with PBS/Tween20 pH7.4 (3x5mins) prior to 
incubation with the Biotinilated antibody (1/1500) for 1 h at RT. All sections were then 
washed with PBS/Tween20 pH7.4 (3x5mins) and incubated with Alexa-Flour coupled 
streptavidin (1/1000) (Invitrogen) for 45 min.  After a final PBS/Tween20 pH7.4 wash  
(3x5mins) the cells were mounted in DAPI fluorescent mounting media (Vector) and 
allowed to dry for 1 h.  Digital morphometric measurements of GFP expression and 
PDGFRβ immunostaining were performed using Image J. Ten random fields from each 
section were analyzed at a final magnification of 63X. 
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Antibody Specificity Fluorochrome Supplier Dilution 
PDGFR Alexa Fluor 647 Abcam 1/50 
PDGFR Alexa Fluor 647 Abcam 1/50 
SMA Alexa Fluor 647 Sigma Aldrich 1/1000 
CD146 Alexa Fluor 647 Abcam 1/100 
NCAM/CD56 Alexa Fluor 647 Abcam 1/100 
CD31 Alexa Fluor 647 Abcam 1/100 
CD90.2 Alexa Fluor 647 Abcam 1/50 
CD34 Alexa Fluor 647 Abcam 1/100 
Pax7 Alexa Fluor 647 Developmental Studies 
Hybridoma Bank 
1/3 
Table 18 Antibodies and isotype controls used for immunohistochemistry of skeletal muscle 
sections. 
 
IHC on Cultured Cells 
Cells cultured of glass microscope cover slides (Labteck Chamber Slides) were washed 
with PBS/Tween20 pH7.4 (3x5mins) prior to fixation with 4% PFA for 10 min.  Slides 
were then washed with PBS/Tween20 pH7.4 (3x5mins) and IHC performed as 
described for frozen sections.  
Histological stains and analysis 
5μM sections were stained with picrosirius red or antibody and results quantified using 
Nikon Elements software. Ten random fields from each section were analyzed at a final 
magnification of 40X.  
Molecular physiology 
RNA extraction 
Isolation of RNA from sorted and cultured cells was performed using the RNeasy 
Micro Kit (Qiagen) and standard protocols.  350µl of Buffer RLT (containing 10µl of B-
ME per 1ml of buffer) was added to cell pellets (not more than 5x105 cells). 350µl of 
70% ethanol was added to the homogenate and transferred to an RNeasy MinElute spin 
column placed in a 2ml collection tube and centrifuged at 12,000xg for 15 s.  The flow 
through was discarded before 350µl Buffer RW1 was added to the RNeasy MinElute spin 
column and centrifuged for 15 s at 8000 x g (10,000 rpm) to wash the spin column.  The 
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flow-through was discarded.  The membrane was then incubated with10 µl DNase I 
stock solution in 70 µl Buffer RDD for 15 min at RT.  350 µl Buffer RW1 was added to the 
RNeasy MinElute spin column and centrifuged for 15 s at 8000 x g. Samples were 
washed with RPE buffer and then 80% ethanol by spinning for 2 min at <8000g. RNA 
was dried by spinning for 2 min at 13,000g. RNA was eluted in 14µl RNase free water. 
RNA concentration was determined using a Nanodrop from Thermofisher. 
 
cDNA synthesis 
RNA was denatured (5 min, 65oC) in a reaction mixture containing 1µg RNA, 25ng of 
random primers (Promega) and dNTPs at a final concentration of 0.5mM (Bioline).  The 
samples were then cooled on ice for 1min after which 4µl 5xFirst strand buffer and 1µl 
0.1mM DTT then, after 2 min, 1µl SuperScript reverse transcriptase [all provided with 
SuperScript III reverse transcriptase system kit (Invitrogen)].  Samples were incubated 
at 25oC for 10 min then at 42oC for 50 min and finally 70oC for 15 min.  The cDNA was 
stored at -20oC prior to further analysis. 
 
Polymerase chain reaction  
The reaction mixture was composed of 4µl MyTaq reaction buffer, dNTPs at a final 
concentration of 0.5mM and 0.2µl Taq polymerase (all Bioline) in addition to 13.6µl 
RNAse free water, 1µl cDNAsample, 0.5µl of forward primer and 0.5µl of reverse primer 
(10µM, Integrated DNA Technologies Inc). Reactions were carried out in a Venti 96 Well 
thermo cycler (Applied Biosystems) using the cycle conditions listed in (Table 19, 
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Number of cycles Duration Temperature (oC) 
1 10 min 94 
35 10 sec 94 
 30 sec 58 
 50 sec 72 
1 7 min 72 
Table 19 Run protocol for PCR  
 
Agarose gel electrophoresis 
The PCR products were electrophoresed on 1.7% agarose [SeaKem LE agarose (Lonza)] 
gels made with 0.5xTBE buffer (45mM Trisbase, 45mM boric acid, 0.625M EDTA) and 
Gel Red (5µl/100ml).  For sample loading, 2µl PCR product was mixed with 8µl RNAse 
free water and 2µl loading buffer.  The PCR product was electrophoresed at 120V for 80 
minutes after which the PCR product bands were visualized by exposure to ultraviolet 
light using a UVI pro system (UVItec). 
Quantitative real-time PCR (qPCR) 
qRT-PCR Total RNA was isolated using an RNeasy Micro kit as described above (Qiagen). 
cDNA was analyzed by SYBR-Green real-time PCR with Lightcycler thermocycler 
(Roche) and normalized to β-actin expression (cycle conditions are listed in Table 20, 
p165). Primers used were as follows: β-actin forward: TGTTACCAACTGGGACGACA, β-
actin reverse: GGGGTGTTGAAGGTCTCAAA; 18S forward: TAGAGGGACAAGTGGCGTTC, 
18S reverse: CGCTGAGCCAGTCAGTGT; Itgav forward: CCGTGGACTTCTTCGAGCC, Itgav 
reverse: CTGTTGAATCAAACTCAATGGGC; PDGFRβ forward: 
TCCAGGAGTGATACCAGCTTT, PDGFRβ reverse: CAGGAGCCATAACACGGACA; GFAP 
forward: CGGAGACGCATCACCTCTG, GFAP reverse: TCTCGGAGGCATAGGAGCG; α-SMA 
forward: GTCCCAGACATCAGGGAGTAA, α-SMA reverse: TCGGATACTTCAGCGTCAGGA; 
Col1A1 forward: GCTCCTCTTAGGGGCCACT, Col1A1 reverse: 
CCACGTCTCACCATTGGGG; Col 3A1 forward: AACCTGGTTTCTTCTCACCCTTC, Col 3A1 
reverse: ACTCATAGGACTGACCAAGGTGG; TGFβ1 forward: CTCCCGTGGCTTCTAGTGC, 
TGFβ1 reverse: GCCTTAGTTTGGACAGGATCTG; MMP-2 forward: 
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CAAGTTCCCCGGCGATGTC, MMP-2 reverse: TTCTGGTCAAGGTCACCTGTC; MMP-3 
forward: ACATGGAGACTTTGTCCCTTTTG , MMP-3 reverse: 
TTGGCTGAGTGGTAGAGTCCC; MMP-9 forward: CTGGACAGCCAGACACTAAAG, MMP-9 
reverse: CTCGCGGCAAGTCTTCAGAG; MMP 13 forward: 
CTTCTTCTTGTTGAGCTGGACTC, MMP 13 reverse: CTGTGGAGGTCACTGTAGACT; TIMP-
1 forward: TGCAACTCGGACCTGGTCATA, TIMP-1 reverse: 
CGCTGGTATAAGGTGGTCTCG; PPARγ forward: GGAAGACCACTCGCATTCCTT, PPARγ 
reverse: GTAATCAGCAACCATTGGGTCA; Itgb1 forward: 
CTACTTCTGCACGATGTGATGAT, Itgb1 reverse: TTGGCTGGCAACCCTTCTTT; Itgb3 
forward: CCACACGAGGCGTGAACTC, Itgb3 reverse: CTTCAGGTTACATCGGGGTGA; Itgb5 
forward: GAAGTGCCACCTCGTGTGAA, Itgb5 reverse: GGACCGTGGATTGCCAAAGT; Itgb8 
forward: CTGAAGAAATACCCCGTGGA, Itgb8 reverse: ATGGGGAGGCATACAGTCT.  Melt 
curve analysis was performed to ensure the specificity of the amplified product.   
 
Program Number of cycles Duration (sec) Temperature (oC) 
Pre-incubation 1 10  95 
Amplification 35 10  95 
  30  60 
Cooling 1 30 72 
Table 20 Thermal cycler programme details for qPCR 
 
Myofibroblast activation in αv depleted PDGFRβ+ cells in vitro   
Control and Itgavflox/flox PDGFRβ-Cre PDGFRβ expressing cells were isolated, seeded at 
20,000 cells/cm2 and cultured for 5 days on tissue culture plastic.  Cells were then 
harvested and processed for qPCR analysis. 
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In vitro CWHM 12 and CWHM 96 studies  
PDGFRβ expressing cells were isolated from WT mice, seeded at 20,000 cells/cm2 and 
cultured for 5 days on tissue culture plastic in the presence of 10μM CWHM 12 and 
10μM CWHM 96 (control).  Cells were then harvested and processed for qPCR analysis. 
In vivo CWHM 12 and CWHM 96 studies  
For all studies CWHM 12 and CWHM 96 were solubilized in 50% DMSO (in sterile 
water) and dosed to 100mg/kg/day. Drug or vehicle (50% DMSO) were delivered by 
implantable ALZET osmotic minipumps (Durect, Cupertino, CA). For cardiotoxin 
induced fibrosis, pumps were inserted subcutaneously either before the cardiotoxin 
injection or one week following the injection.  Muscles were harvested after 21 days. 
Transgenic mice and muscle injury models 
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Mouse models in musculoskeletal research 
The accessibility of genetic manipulation has made the mouse the most commonly used 
laboratory animal and their use is now often favoured over rats for musculoskeletal 
research. The sequencing and analysis of the mouse genome has allowed many genes to 
be targeted and studied using this technology. 356 357   In this thesis I combine mouse 
transgenic technology with conventional models of injury to dissect molecular 
mechanisms driving the response to muscle injury and the development of fibrosis.  
 
Modifying genes in mice provides a unique approach to unravel gene function at a 
cellular and molecular level, as well as elucidating the role of genes in normal 
physiology and the development of pathology. Numerous disease models have been 
established that provide insight into that pathogenesis of disease while facilitating the 
development of therapies. Central to these advances has been the ability to modulate 
gene expression, by increasing, decreasing or eliminating expression completely. Cells 
can be genetically labeled with fluorescent proteins, or proteins that facilitate targeted 
lineage depletion.  These alterations can be made cell type-specific and even inducible or 
reversible.  The most widely used system is the Cre-LoxP system, but the use of 
alternative systems is becoming more widespread.  
 
Numerous injury models have been proposed to examine skeletal muscle regenerative 
mechanisms, including physical, chemical and biological injury.  In choosing the most 
appropriate animal model for research a number of key factors need to be taken into 
consideration.358  These include:  1 – appropriateness of the model as an analogue of the 
disease being studied, 2- transferability of the information from the model to the clinical 
scenario, 3 – genetic uniformity where applicable, 4 – background knowledge of 
biological properties, 5 – cost and availability, 6 – generalisability of the results, 7 – ease 
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and adaptability to experimental manipulation, 8 – ecological considerations, 9 – ethical 
and societal implications.   
 
In this thesis I utilize a PDGFRβ-Cre driver to target perivascular MSC precursors.  I use 
fluorescent reporters of Cre activity to define the extent of recombination and gene 
knockdown to investigate genes central to the development of skeletal muscle fibrosis. 
The aim of this chapter is to outline the transgenic systems utilized in the project and 
the breeding strategies used to generate them.  I will also describe mouse models used 
to investigate muscle regeneration and fibrosis, outlining their strengths and limitations. 





Cre-Lox technology is based on the ability of the P1 bacteriophage recombinase (Cre) to 
direct site-specific DNA recombination between pairs of LoxP sites359.  Such 
recombination in a Cre-Lox mouse can permanently activate or inactivate a gene of 
interest.  Cre-Lox experiments typically require two transgenic animals: a Cre strain and 
a LoxP strain (Figure 50, p171).  The Cre strain contains a Cre recombinase transgene 
under the control of a tissue specific promotor, whereas a LoxP strain contains two LoxP 
sites that flank a genomic segment of interest, the “floxed” locus. Cre recombinase can 
initiate deletions, inversions, and translocations of a floxed locus depending on the 
location and orientation of the LoxP sites in a Cre-Lox mouse360.  The floxed loci can be 
designed to allow permanent inactivation or activation of the gene of interest. The cell-
type specificity of Cre depends on the availability of tissue-specific or cell-specific 
promotors.  Tissue-specific Cre expression can be combined with time specific activity. 
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Cre strains have been widely used in skeletal muscle for lineage tracing and permanent 
gene activation or deletion121 216. 
 
To control the timing of Cre activity, fusion proteins have been generated between Cre 
and the ligand-binding domain of steroid hormone receptors.  A fusion between Cre and 
a mutated ligand-binding domain of the oestrogen receptor (CreERT2) is the most 
commonly used variant.  ERT2  binds powerfully to 4-hydroxy tamoxifen (4OH-T), the 
active metabolite of the synthetic steroid tamoxifen but weakly to endogenous 
oestrogens. The CreERT2 has been widely used in musculoskeletal research, although the 
extent of recombination and the most effective dosing strategy must be determined 
empirically for each CreERT2 mouse strain.  These so-called “inducible systems” are 
essential for lineage tracing studies but their use in gene knockdown is limited by their 
efficiency of recombination, which is generally lower than with constitutive Cres. I use a 
constitutive Cre system in this thesis as high recombination efficiency is essential for my 
key application – gene knockdown.  
 
 Off-target effects of the Cre recombinase have been reported in several tissues including 
muscle361. These off-target effects may be due to endogenous cryptic LoxP that cause 
cytotoxic chromosomal rearrangements when activated. However, not every Cre strain 
has off-target effects, and this variation is likely to result from differences in levels of Cre 
protein expression. The off-target phenotypes resulting from Cre toxicity can make the 
interpretation of some experiments particularly challenging361. The use of inducible Cre 
systems limit the amount of time Cre spends in the nucleus and may decrease Cre 
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Figure 50 Schematic of the Cre-Lox system 
(A) Cre, or CreER, is expressed from a cell or tissue-specific promoter. (1) Cre is active in 
every cell in which it is expressed. Levels of activity depend on expression levels. (2) CreER 
is not active and is excluded from the nucleus until tamoxifen is administered. This allows for 
temporal control and reduces nonspecific effects of Cre. (B) Cre catalyzes recombination 
between its recognition (LoxP) sites, resulting in permanent genetic rearrangement, which is 
inherited by daughter cells. The most common arrangement of LoxP sites are (1) flanking a 
critical exon of an endogenous gene to mediate loss of function or (2) flanking a 
transcriptional STOP to mediate reporter gene expression and/or overexpression. In this 
case, a ubiquitous promoter is usually used to drive the gene of interest, but the transcript is 
disrupted by the LoxP-flanked transcriptional STOP. After Cre-mediated deletion of the stop, 
the gene of interest is permanently expressed. [Modified from Rawlins et al., The a”MAZE”ing 
world of lung specific mouse transgenics.  Am J Respir Cell Mol Biol 2012;46(3):269-82] 
 
 
Reporters of Cre activity 
Reporters of Cre activity are important for defining the spatial and temporal extent of 
Cre-mediated recombination.  This is generally achieved using a Cre reporter transgene 
in which a fluorescent marker (e.g. GFP, TdTomato) is expressed following Cre-mediated 
recombination.  The descendants of stem and progenitor cells can be traced by crossing 
a Cre mouse with a reporter mouse strain permanently expressing a reporter gene after 
activity.  Genes are generally inserted into loci that are expressed robustly in most cell 
types and that are targeted with high efficiency e.g. ROSA26.   
 
It can be helpful to label both recombined and non-recombined cells. Double fluorescent 
marker systems allow for visualization of recombined and nonrecombined cells 
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allowing the delineation of structure without additional staining.  Furthermore, double 
reporting can be beneficial in FACS sorting where the ability to both positively and 
negatively select for populations can improve purity.  In this thesis I use the mTmG 




Figure 51 Schematic diagram of the mTmG construct before and after Cre-mediated 
recombination.  
mTmG consists of a chicken β-actin core promoter with a CMV enhancer (pCA) driving a 
LoxP-flanked coding sequence of membrane-targeted tandem dimer Tomato (mT) resulting in 
tdTomato expression with membrane localisation.  After Cre-mediated intra-chromosomal 
recombination, the mT sequence is excised allowing the pCA promoter to drive expression of 
membrane-targeted enhanced green fluorescent protein (mG).   
 
Gene knockout vs knockdown 
It is important to be aware of the distinction between gene “knockout” and 
“knockdown”.  With knockout mice, a gene is eliminated or a functional domain of the 
protein is deleted.  This can be achieved through random mutation using chemical or 
gene trap mutagenesis, or through gene targeting362.  Homologous recombination allows 
researchers to completely remove one or more exons from a gene, resulting in the 
production of truncated protein or no protein at all.  The phenotype of knockout mice 
can be very complex because all tissues may be affected and embryonic lethality is 
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common.  In this thesis I explore the role of αv integrins in muscle fibrosis.  However, 
because of the ubiquitous expression of αv and its key role in a wide range of cellular 
processes, traditional knockout systems result in embryonic lethality.  A conditional 
gene modification using Cre-Lox technology allows the gene of interest to be knocked 
out in a targetable subset of cells or at a particular time circumventing lethality.  
Furthermore the capacity for population specificity increases mechanistic insight 
afforded by knockdown systems.  I will therefore make use of knockdown technology for 
this thesis. 
 
Mouse Lines and Breeding Strategies 
I use trio breeding (e.g. one male and two females) in all of my breeding strategies. 
Continuous trio breeding groups can result in a higher breeding efficiency by permitting 
breeding at the first post-partum estrus and facilitating pup survival through cross 
fostering. It is convention to breed the Cre strain through the male, as this has been 
proposed to reduce Cre toxicity.  However this practice has no scientific basis.   
 
PDGFRβ-Cre 
PDGFRβ-Cre mice (Tg(PDGFRβCre)♯Rha), which express Cre recombinase under 
control of a fragment of the gene encoding PDGFRβ, were previously developed to 
specifically target pericytes353.  These mice were developed by Ralph Adams at the 
London Research Institute, by microinjecting a transgene containing a genomic PDGFRβ 
promotor fragment to a Cre recombinase and a polyA sequence into 129/B6 zygotes.  
Founder lines were then maintained on a mixed 129;B6 background.  It has been shown 
that under the control of the PDGFRβ promotor, Cre inactivates LoxP flanked genes in 
mouse pericytes with high efficiency in the liver, lung and kidney351 363.  We were 
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therefore optimistic that a high recombination efficiency would be seen in skeletal 
muscle. 
PDGFRβCre; mTmG 
In order to visualise recombined and non-recombined cells under the control of the 
PDGFRβ promotor I used the mTmG reporter mouse.  To generate this strain I crossed a 
PDGFRβ heterozygous mouse (WT background) with an mTmG homozygous mouse 
purchased from Jackson Laboratory (Figure 52, p174).  This strategy yields 50% Cre 
positive mTmG heterozygous and 50% cre negative mTmG heterozygous mice.  The Cre 
positive mice were used for visualisation of PDGFRβ+ cells and cell sorting, while Cre 
negative mice were used as controls in calculating background fluorescence and 
compensation in FACS.  Genotyping was performed using conventional PCR and gel 
electrophoresis. 
 
Figure 52 Breeding strategy for mTmG;PDGFRβCre  
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PDGFRβCre; αv flox/flox 
Using Itgαv flox/flox mice354, αv integrins were deleted under the control of the promotor 
for PDGFRβ.  Itgavflox/flox;PDGFRβCre strains were generated by crossing PDGFRβ Cre 
positive αvflox/flox with Itgαv flox/flox (Figure 53, p175).  This strategy resulted in 50% Cre 
positive αv homozygous experimental animals and 50% Cre negative littermates that 
could be used as experimental controls. 
 
Figure 53  Breeding strategy for αv;PDGFRβCre  
 
To visualize recombination in Itgαvflox/flox;PDGFRβ-Cre mice we developed a breeding 
strategy to introduce the mTmG allele into PDGFRβ expressing cells (Figure 54, p176).  
This strategy requires three breeding steps to ultimately result in 50% Cre positive and 
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Figure 54  Breeding strategy for αv;mTmG;PDGFRβ-Cre 
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Itgβ8flox/flox;PDGFRβ-Cre mice were generated in a similar way (Figure 55, p177). 
 
Figure 55  Breeding strategy for β8;PDGFRβ-Cre  
 
Mouse models of skeletal muscle regeneration and 
fibrosis 
Numerous injury models have been proposed to examine skeletal muscle regenerative 
mechanisms, including physical, chemical and biological. A number of models have been 
used to specifically examine skeletal muscle fibrosis (Table 21, p178), the most dramatic 
of which are the muscular dystrophies.  However, skeletal muscle fibrosis can occur 
where the treatment of the muscle is extremely simple.  This includes the mechanisms of 
skeletal muscle injury used in the assessment of muscle regeneration such as the 
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 Model Animal (muscle) Sample References 
Mechanical Laceration Mouse (gastrocnemius) 364 365 
 Puncture Mouse (TA) 366 
 Chronic Stretch Rabbit (EDL) 367 
 Immobilization Mouse (soleus), Rat (TA, 
soleus, gastrocnemius) 
368 
 Hind limb 
suspension 
Rat (soleus) 369 
 Tenotomy Mouse (supraspinatus), 






Cardiotoxin Mouse (TA) 185 364 
 Glycerol  216 
 Botulinum toxin Rat (TA) 374 
 hrTGFβ1 Mouse (TA) 364 
 BaCl2 Mouse (TA, 
gastrocnemius) 
375 
Genetic Desmin KO Mouse 364 
 Mdx Mouse (diaphragm, biceps 
femoris) 
376 
Ageing  Rat (EDL, soleus) 377 
Table 21 Models of in vivo skeletal muscle fibrosis  
 
Physical injury  
Generating skeletal muscle injury using cold, crushing, surgical wounding, mincing and 
free grafts have all been used to study regeneration and fibrosis.  
Cold 
Localized exposure to a low temperature (e.g. by using liquid nitrogen) of a well-defined 
area of skeletal muscle has been used experimentally to induce a limited area of 
necrosis. In this model, regeneration of the necrotic muscle (with no viable cells 
remaining) is entirely dependent on precursor cells from the surrounding viable skeletal 
muscle tissue.   
Crush 
 Crush injury of skeletal muscle tissue causes necrosis resulting in a focal reduction of 
the satellite cells, invasion of macrophages and phagocytosis of the necrotic tissue.  
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Surgical wounding (i.e. transection) of muscle tissue produces a clean lesion, which in 
humans is usually followed by scarring at the site of injury. On either side of the incision, 
the transected myofibers often undergo abortive attempts at regeneration, and the 
regenerated ends commonly become embedded in connective tissue. 
Minced tissue model 
Using the minced muscle model of muscle regeneration, a skeletal muscle piece is 
chopped into small fragments destroying all the myofibres and neurovascular 
connections.  The tissue is then transplanted subcutaneously or intramuscularly. This 
minced muscle can regenerate up to 30% of its original mass, but the process is often 
accompanied by excessive fibrosis. Minced muscle grafts eliminate the problem of 
inhomogeneous distribution when studying the participation of stem cells in the 
regeneration process.  
Free transplantation 
Free transplantation consists of removing a skeletal muscle completely from its bed and 
replacing it orthotopically. In the standard graft, the tendons are surgically restored, but 
revascularization and re-innervation are allowed to occur spontaneously. The center of 
the tissue becomes ischemic and over a few days regeneration occurs along a centripetal 
gradient.  
Chemical injury  
Numerous chemical compounds have been described that cause severe skeletal muscle 
damage following intramuscular administration. Most widely used are the snake toxins 
(cardiotoxin or CTX, and netoxin) although other chemicals such as barium chloride 
(BaCl2), bupivacaine, aldehydes, chloroquine (specific to type I myofibers), glycerol 
(promotes the replacement of myofibers by adipocytes), vincristine and hypertonic 
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solutions as well as solutions of varied temperature (hot or cold) and pH (acid or 
alkaline) have also been employed.  
Cardiotoxin 
Intramuscular CTX injection induces local myofibre necrosis, which is rapidly followed 
by recruitment of inflammatory cells, clearance of cellular debris, and regeneration of 
injured muscle.218 The lesions caused by CTX are extremely reproducible and the 
process closely mimics the response to injury also seen following crush and freeze 
injury.  Intra-peritoneal Evans Blue dye injection is a simple, safe and sensitive method 
for detection of increased myofibre permeability and ongoing inflammation.378 It has 
been used to evaluate the overall efficacy of the regenerative response, as the dye 
accumulates in damaged muscle fibres.216  The cardiotoxin model is an attractive model 
to delineate factors that influence the capacity for muscle regeneration.  In particular, 
the reproducibility of this model facilitates the detection of subtle phenotypes in 
transgenic mice. 
Glycerol 
Muscle injury can also be induced by injection with glycerol, which has been reported to 
induce destabilisation of the cytoplasmic membranes followed by cell death, eventually 
resulting in fatty degeneration of the injected muscle.  This model has been used to 
evaluate the efficacy of gene therapy for muscle disorders379. 
Biological injury 
Examples of biological injury include forced exercise, denervation, de-vascularization 
and ischemia-reperfusion.  Forced or eccentric physical exercise induces focal damage of 
the myofibres. Devascularization-denervation represents a mild form of skeletal muscle 
injury that can be used to study myofibre type specification.  Ischaemia-reperfusion 
injury (e.g. by temporary clamping) results in transient ischaemia.  Reperfusion is 
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rapidly followed by infiltration of inflammatory cells in the damaged area and skeletal 
muscle regeneration.    
Genetic models of skeletal muscle fibrosis 
Genetic models of the muscular dystrophies which have cyclic degeneration and 
regeneration produce the most dramatic fibrosis.  In different types of dystrophy, ECM 
area fraction increases as much as ten-fold, and the associated muscle increases in 
stiffness.  These models are highly complex, since cellular infiltration, muscle atrophy, 
fibre size variability, and regenerating fibres accompany fibrosis and fill the tissue area.  
Since this type of fibrosis is extreme and clinically relevant, studies of muscle fibrosis 
and of the potential therapeutic interventions for its prevention are often performed 
using dystrophic models. 
Measures of muscle fibrosis 
As a general rule fibrosis is characterised by abnormal accumulation of ECM.  However, 
time and severity are important contributors to fibrosis.  For example muscle fibrosis 
can be seen in nearly all models of muscle injury, but this is often transient and thought 
to stabilize the contractile apparatus while normal adaptive or regenerative responses 
proceed.  In contrast, long-term accumulation of ECM interferes with function and does 
not resolve under normal physiological conditions. 
 
Typically, skeletal muscle assays quantify the cross-sectional area fraction of ECM by 
excluding muscle fibres using image-processing tools reporting the amount of ECM as 
‘area fraction’.  A limitation of this approach is that if muscle fibres atrophy and ECM 
remains the same, ECM will occupy a greater fraction of the muscle cross section.  This 
approach also gives no information about isoforms and cross-linking, which can also 
affect function.  For normal muscle the ECM area fraction is typically around 5%, but this 
value can increase dramatically in diseased or injured states. In addition to the 
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increased fractional area of ECM in fibrotic muscles, because the pathological response 
often includes fibre degeneration and regeneration, muscle fibrosis is also accompanied 
by a large increase in muscle fibre size variation.   
 
Skeletal muscle fibrosis can also be expressed in terms of the total amount of collagen 
present in the tissue, as measured by the content of hydroxyproline, a major component 
of collagen derived from hydroxylation of the amino acid proline by prolyl oxidase.  
While this assay has been used for decades, expression of collagen mass relative to a 
known muscle protein is only rarely reported.  In the majority of studies of skeletal 
muscle, collagen contents (typically expressed as micrograms of collagen per wet or dry 
muscle mass) of experimental and control groups are compared.  While this content 
provides some insight into a tissue's response to treatment, in the few cases where 
collagen content has been quantified along with skeletal muscle mechanical stiffness, 
the two values only show weak correlation.  Thus the method used to quantify fibrosis 
in skeletal muscle will depend on whether one uses a morphological assay such as area 
fraction, a biochemical assay such as collagen content, or a functional assay such as 
stiffness.  It is not possible to quantitively interchange results of assays although they 
usually change in the same direction.   
 
Optimisation of the CTX model of muscle injury and fibrosis 
In this thesis I use a CTX model to study both regeneration and fibrosis within skeletal 
muscle.  The CTX model is extremely simple and highly reproducible216 380 and is 
emerging as the method of choice for producing injury in high impact publications 
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For the CTX fibrosis model, I have adjusted a protocol published in Nature Medicine in 
2012 by Dulauroy et al., (Figure 56, p183).  In my model mice are anaesthetised using 
inhaled isoflurane, given subcutaneous bupivacaine as analgesia before an 
intramuscular injection of 50ul of 20nM CTX (Naja mossambica mossambica, Sigma) 
into the right tibialis anterior muscle.  50ul of PBS is injected into the contralateral limb 
as an internal control.  The mice are then recovered, checked hourly for the first 4 hrs 
and then daily until day 21.  The mice are then culled by cervical dislocation and the 
tibialis anterior muscles harvested and analysed. 
 
Figure 56  CTX fibrosis model 
Tibialis anterior muscles are harvested 21 days following IM (TA) injection of CTX (A).  
Extracellular collagen can be visualised using Picrosirius Red in which collagens stain bright 
red and background tissues stain pale yellow (B, magnification 40x).  Anti-collagen 1 antibody 
can also be used to detect ECM (C, magnification 20x). 
 
Models using intramuscular cardiotoxin injections have also been used to investigate 
muscle regeneration216.  In this model mice are subjected to a 50μl IM injection of 20nM 
CTX into the mid-portion of tibialis anterior muscle.   Animals receive an IM injection of 
50μl PBS on the contralateral side as a vehicle control.  To evaluate the overall efficacy 
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of the regenerative response, mice are given an intraperitoneal injection of Evans blue 
dye, which accumulates in damaged muscle fibres.  I performed a series of titration 
experiments to determine the optimum dose of Evans blue at day 8 that would allow 




Figure 57 CTX skeletal muscle regeneration model 
(A) CTX induces local muscle necrosis, which is rapidly followed by recruitment of 
inflammatory cells, clearance of cellular debris, and regeneration.  To evaluate overall 
efficiency of the regenerative response Evans Blue can be administered intraperitoneally, 
accumulating in damaged muscle fibres.  WT mice exhibit a robust regenerative response, 
resulting in the restoration of intact, regenerating fibres as evidenced by minimal Evans Blue 
staining at 8 days.  The dose of Evans Blue was titrated establishing that 6.25mg/kg was the 
optimum dose to produce minimal Evans blue staining at day 8 following injury (B).
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Chapter 2.4 PDGFRβ+ perivascular cells 
contribute to skeletal muscle fibrosis 
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The origin of myofibroblasts contributing to skeletal muscle fibrosis following injury is 
not clear, although a number of putative progenitor populations have been implicated 
including so-called fibro-adipogenic progenitors (FAPs)381 and pericytes382. 
 
PDGFRβ is known to label mesenchymal cells within the perivasculature that are 
important in fibrosis affecting the liver351, lung351 and kidney181.  We therefore used a 
PDGFRβ-Cre system to target pro-fibrotic cells in skeletal muscle.  These mice, which 
express Cre recombinase under the control of a fragment of the gene PDGFRβ, were 
previously developed to specifically target pericytes in experiments investigating 
angiogenesis353. 
 
The first aim of this chapter is to describe validations performed to show that PDGFRβ-
Cre effectively targets PDGFRβ+ perivascular cells.  Using PDGFRβ-Cre I then show that 
PDGFRβ+ perivascular cells contribute to the myofibroblast pool both following injury 
in vivo and in vitro. In order to visualise recombined and non-recombined cells we used 
double-fluorescent reporter mice that express membrane-targeted tdTomato before 
Cre-mediated excision and membrane-targeted GFP after excision352.  The double 
reporting enabled us to assess tissue morphology – particularly important in fibrosis – 
and also to determine contamination after isolating the cells. 
 
PDGFRβ-Cre efficiently targets PDGFRβ+ perivascular cells 
In uninjured skeletal muscle, pericytes are found in a perivascular location in close 
contact with underlying endothelial cells - morphologically resembling pericytes in 
other organs14.  Adventitial cells expressing CD34+CD31-CD146-CD45- reside in the 
outer layer (tunica adventitia) of arteries and veins.  Both pericytes and adventitial cells 
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fulfill the defining criteria for MSC383, and are considered to represent in vivo sources of 
mesenchymal progenitors49 129. Together, these two populations have been termed 
“perivascular stem cells”384 385.  Using mTmG reporter mice, we found that PDGFRβ-Cre 
induced highly efficient recombination in cells in perivascular locations.  We performed 
immunohistochemistry using antibodies targeting PDGFRβ and assessed for co-
localisation using confocal microscopy to confirm appropriate targeting of PDGFRβ+ 
populations by PDGFRβ-Cre (Figure 58, p188).  Furthermore, flow cytometric analysis of 
eGFP expressing cells confirmed co-expression of PDGFRβ  (Figure 59, p189). 
 
To evaluate the specificity of recombination in perivascular MSC we co-stained 
uninjured muscles from mTmG;PDGFRβ-Cre mice for α-SMA and CD146 (both well 
characterized markers of skeletal muscle pericytes14), and CD34 (well characterized 
marker of adventitial cells83 384). Virtually all of the reporting cells expressed one set of 
these markers (Figure 60, p191). αSMA was seen only in larger blood vessel walls in 
uninjured skeletal muscle (Figure 60, p191). To further assess specificity of PDGFRβ-Cre 
recombination, we stained uninjured control and fibrotic skeletal muscle from 
mTmG;PDGFRβ-Cre mice with antibodies to CD31 (endothelial cells), CD56 (myogenic 
cells), Pax7 (satellite cells), myosin fast and slow (myofibres).   Very few of the reporting 
cells expressed any of these markers (Figure 60, p191).  Flow cytometric analysis of 
GFP+ cells reflected findings on immunohistochemistry and confocal microscopy 
(Figure 61, p192) while also demonstrating that a subset of PDGFRβ+ Cells express 
PDGFRα (Figure 62, p193) – a marker previously described to identify pro-fibrogenic 
progenitors in muscle219.  
 
 
PDGFRβ+ perivascular cells contribute to muscle fibrosis 




Figure 58 Immunofluorescence micrographs of skeletal muscle from mTmG;PDGFRβ-Cre mice co-staining with anti-PDGFRβ antibody 
(a)  Virtually all cells (97.49% SEM 0.46, n = 8) staining for PDGFRβ antibody expressed eGFP (b) and virtually all (95.28% SEM 1.08, n = 8) reporting cells 
stained positively for PDGFRβ antibody (c).
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Figure 59 FACS sorting of eGFP reporting pericytes from mTmG:PDGFRβ-Cre mouse 
skeletal muscle. 
(A) Cells were identified on the basis of size and granularity prior to selection for singlets (B), 
viable cells (C) and the expression of eGFP (D).  (E) Co-staining with anti-PDGFRβ antibody 
at the time of sorting confirmed co-expression of eGFP reporting cells (pink line represents 
stained sample, black line indicates isotype control).
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Figure 60  PDGFRβ-Cre mediates specific recombination in perivascular cells.  
Immunofluorescence micrographs of skeletal muscle sections from mTmG;PDGFRβ-Cre reporter mice (n = 4) stained for pericyteS (CD146, αSMA), 
adventitial cells(CD34) (A), endothelial cells (CD34, CD31, CD146) and myogenic cells (myosin fast and slow) with endogenous eGFP reporting in green (B). 
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Figure 61  Flow cytometric analysis of purified eGFP+ cells from mTmG:PDGFRβ-Cre mice.  
Cells were stained the indicated antibodies.  The mean percentage co-localisation is indicated within each box plot (n = 3)
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Figure 62 A subset of PDGFRβ perivascular cells express PDGFRα  
(a) FACs analysis of PDGFRα expression levels in eGFP cells from mTmG;PDGFRβ-Cre 
reporter mice at the time of sorting.  (b) FACs analysis of eGFP expression levels in PDGFRα 
cells from mTmG;PDGFRβ-Cre reporter mice at the time of sorting.  (c) Proportional venn  
diagram showing the expression of PDGFRα cells on eGFP cells sorted from 
mTmG;PDGFRβ-Cre reporter mice. 
 
 
eGFP labels a small proportion of myofibres in injured 
skeletal muscle of mTmG;PDGFRβ-Cre mice 
Dellavalle et al., reported that pericytes resident in postnatal skeletal muscle 
differentiate into muscle fibres and generate satellite cells. We set out to quantify the 
proportion of myofibres reporting eGFP in uninjured muscle.  Expression of eGFP 
indicates that a cell currently expresses GFP, or has expressed PDGFRβ at any point in 
its ontogeny.  Ten confocal miscroscopy aribitrary fields were taken from n = 8 mice to 
establish the percentage of myofibres expressing eGFP in uninjured tibialis anterior 
muscles for mTmG;PDGFRβ-Cre mice.  While the majority of fields contained no eGFP+ 
myofibres, a number of fields contained clusters of eGFP+ reporting cells.  The mean 
percentages of eGFP myofibres was 2.1% (Figure 63, p194).  No eGFP+ myofibres 
stained positively for the PDGFRβ antibody. 
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Figure 63 Expression of eGFP by myofibres. 
Ten confocal miscroscopy aribitrary fields were taken from n = 8 mice to establish the 
percentage of myofibres expressing eGFP in uninjured tibialis anterior muscles for 
mTmG;PDGFRb-Cre mice.  While the majority of fields contained no eGFP+ myofibres (A), a 
number of fields contained clusters of eGFP+ reporting cells (B).  The mean percentages of eGFP 
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PDGFRβ+ perivascular cells proliferate in response to 
skeletal muscle injury and contribute to fibrosis in vivo 
 
To evaluate the contribution of PDGFRβ+ perivascular cells to the myofibroblast pool 
following injury we observed the distribution of eGFP cells in the skeletal muscles of 
mTmG;PDGFRβ-Cre mice in a time course following injury (CTX injection) and control 
procedure (PBS injection) (Figure 64, p195). 
 
 
Figure 64 Skeletal muscle injury timecourse in mTmG;PDGFRβ-Cre mice  
Tibialis anterior muscles are harvested and observed under confocal microscopy at day 4, 8 
and day 21 following CTX injection. 
 
We found that PDGFRβ-Cre induced highly efficient recombination in a distribution 
appropriate for PSC in control muscles.  In response to injury, the field coverage of eGFP 
+ cells increased markedly with eGFP cells settling in a distribution characteristic of 
myofibroblasts at day 21. The level of field coverage by eGFP+ cells appeared to plateau 
at day 21 with no difference in field coverage seen in CTX injured muscles between day 
21 and day 60 (Figure 65, p196).
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Figure 65 PDGFRβ+ perivascular cells proliferate and adopt the appearance of myofibroblasts following skeletal muscle injury.  
(A) Immunofluorescence micrographs of skeletal muscle sections harvested from mTmG;PDGFRβ-Cre reporter mice 4 days following control (PBS) or IM 
CTX injection. Scale bars, 30 μm. (B)  Immunofluoresence micrographs of skeletal muscle sections harvested from mTmG;PDGFRβ-Cre reporter mice 8 days 
following control (PBS) or CTX IM injection. Scale bars, 30 μm. (C) Immunofluorescence micrographs of skeletal muscle sections harvested from 
mTmG;PDGFRβ-Cre reporter mice 21 days following control (PBS) or CTX IM injection. Scale bars, 30 μm. (D) Field coverage of PDGFRβ+ perivascular 
cells at day 4, 8 and 21 following control (PBS) or CTX IM injection and at day 60 following CTX IM injection.
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To further characterise PDGFRβ expressing cells in these settings we purified eGFP 
positive cells by cell sorting from uninjured control and fibrotic muscles of mTmG; 
PDGFRβ-Cre mice.  Quantitative PCR (qPCR) of mRNA obtained from live eGFP positive 
cells showed marked induction of genes associated with the transition of quiescent PSC 
to the activated myofibroblast phenotype with injury including PDGFRβ, αSMA, TGFβ1, 
TIMP1, MMP2, MMP9, MMP13, Col1A1 and Col3A1 (Figure 66, p197). 
 
 
Figure 66 Gene expression profile of freshly sorted eGFP positive cells from skeletal muscle 
at day 10 following control (PBS) or CTX IM injection.   
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PDGFRβ+ perivascular cells transition to a myofibroblast 
phenotype in vitro 
 
To establish whether PDGFRβ+ perivascular cells were capable of adopting a 
myofibroblast like phenotype in vitro, eGFP positive cells isolated by FACS from 
uninjured mTmG;PDGFRβ-Cre mouse muscles were cultured for up to 14 days to 
induce myofibroblast activation.  All of the cells in these sorted cultures expressed the 
myofibroblast marker αSMA (Figure 67, p199).  qPCR of mRNA obtained from the 
cultured cells demonstrated a rise in the characteristic myofibroblast markers PDGFRβ, 
α-SMA, Col1A1 and TIMP1 (Figure 68, p200).  The rise was also marked, but less 
dramatic when cells were cultured in EGM2 medium (Figure 69, p201) 
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Figure 67  PDGFRβ+ perivascular cells become activated myofibroblasts in vitro 
Immunofluorescence staining of eGFP positive cells sorted from uninjured skeletal muscle of 
mTmG;PDGFRβ-Cre reporter mice and plated in tissue culture plastic for 7 days.  Left panel 
shows eGFP (green), middle panel shows αSMA (red), right panel shows merged images.  
Scale bars, 50μm.   
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Figure 68 PDGFRβ+ perivascular cells transition to a myofibroblast phenotype in culture 
(DMEM10%FCS1%PS medium) 
qPCR analysis of PDGFRβ, αSMA, Col1A1 and TIMP1 in freshly sorted eGFP+ cells from 
mTmG;PDGFRβ-Cre reporter mice and from eGFP+ cells cultured for 7 and 14 days.  Data 
are mean ± SEM. *P < 0.05, **P < 0.01, ***p<0.001, ****p<0.0001 (Student’s t-test). 
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Figure 69  PDGFRb+ perivascular cells transition to a myofibroblast phenotype in culture 
(EGM2 culture medium) 
qPCR analysis of PDGFRβ, αSMA, Col1A1 and TIMP1 in freshly sorted eGFP+ cells from 
mTmG;PDGFRβ-Cre reporter mice and from eGFP+ cells cultured for 7 and 14 days.  Data 
are mean ± SEM. NS = not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001  
(Student’s t-test).
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 Chapter 2.5 Selective αv integrin depletion in 
PDGFRβ+ perivascular cells regulates skeletal 
muscle fibrosis 
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Secreted transforming growth factor–β (TGFβ) is arguably the major pro-fibrogenic 
cytokine and a central mediator of fibrosis in multiple organs.  The binding of active 
TGFβ1 to high affinity TGFβ1 receptors in the plasma membrane of myofibroblast 
precursors induces TGFβ1 signaling, which generates contractile (remodeling) cell 
features by promoting αSMA neoexpression and secretory cell functions such as 
collagen production.  Although antagonists of TGFβ1 and the TGFβ1 receptor inhibit 
myofibroblast activation in cell culture and suppress induced fibrosis in skin, lung, 
kidney and liver in animal models, these strategies bear the risk of adverse effects on 
immunity and carcinogenesis via effects on inflammatory cells and epithelium that are 
also regulated by TGFβ1173 174 386. 
 
TGFβ is secreted as a latent complex that is present at high concentrations and directly 
cross-linked to the extracellular matrix.  Much of the regulation of TGFβ function in 
tissues is based on extracellular activation of this latent complex387 388.  Two of the three 
mammalian TGFβ isoforms (TGFβ1 and TGFβ3) can be activated by members of the 
integrin family that interact with a linear arginine-aspartic acid (RGD) motif present in 
an N-terminal fragment of the TGFβ gene product called the latency-associated peptide. 
 
Myofibroblasts express several αv containing integrins and are contractile cells capable 
of exerting force on tethered ligands.  The recently solved crystal structure of the small 
latent complex of TGFβ demonstrates that mechanical force generated by the 
contractile actomyosin cytoskeleton and transmitted by integrins is a common 
mechanism for activating latent TGFβ345.  In vitro studies of myofibroblasts have shown 
that they can use alternative αv-containing integrins that share the αv subunit, 
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including αvβ1, αvβ3, αvβ5, αvβ6 and αvβ8, can recognize the same RGD peptide motif 
and at least in some circumstances can activate latent TGFβ343 345-348. 
 
Several investigators have shown that TGFβ activation by αvβ6 integrin has an 
important role in models of fibrosis in the lungs, biliary tract and kidney343 389 390.  
Henderson et al., showed that activation of latent TGFβ1 from the extracellular matrix 
by αv integrins is a key event in liver pericyte to myofibroblast differentiation and that 
inhibition or deletion of the αv subunit blocks liberation of active TGFβ1, myofibroblast 
differentiation and development of fibrosis351.  
 
We therefore focused on the integrin αv subunit because of the role of multiple αv 
integrins in activating latent TGFβ and its demonstrated regulation of the transition of 
pericytes to myofibroblasts in multiple solid organs.  The aim of this chapter was to 
establish whether this key role of αv integrins on PDGFRβ+ perivascular cells was 
conserved within skeletal muscle. 
 
Selective αv integrin depletion in PDGFRβ+ perivascular 
cells regulates skeletal muscle fibrosis 
To investigate whether loss of αv integrins on PDGFRβ+ perivascular cells influences 
the development of skeletal muscle fibrosis we used Itgavflox/flox;PDGFRβ-Cre mice, 
(which are null for αv in PDGFRβ expressing cells) in our CTX model of muscle injury. 
Itgavflox/flox;PDGFRβ-Cre mice were significantly protected from CTX induced fibrosis, as 
determined by picrosirius red (PSR) staining for collagen (Figure 70, p205).  This was 
not due to changes in the degree of initial injury caused by CTX, as determined by Evans 
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blue accumulation in damaged muscle fibres 8 days following CTX injection (Figure 71, 
p206).     
 
 
Figure 70  Deletion of αv integrins on PDGFRβ+ perivascular cells protects mice from CTX-
induced skeletal muscle fibrosis 
Itgavflox/flox;PDGFRβ-Cre and control mice received IM CTX injection to tibialis anterior 
muscle and PBS to the contralateral side.  At day 21 muscles were harvested for analysis 
(A).     Digital image analysis quantification of picrosirius red staining (collagen deposition) of 
muscle tissue after PBS or CTX treatment of control and itgav
flox/flox
;PDGFRβ-Cre mice (n=5 
mice in each group). Data are mean ± SEM. **P < 0.01 (Student’s t test) (B).  Representative 
images of picrosirius red stained sections from control and αv Cre mice 21 days following 
CTX injection (images are x40). 
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Figure 71  The overall efficacy of the regenerative response to injury in control and 
Itgav;PDGFRβ-Cre mice.   
We gave mice an intraperitoneal injection of Evans blue dye 7 days following CTX injection.  
On harvesting muscles 24 hrs later (8 d following CTX injection) there was no difference in 
Evans blue accumulation, indicating equivalent levels of ongoing muscle damage, in αv null 
and control mice. 
 
To investigate whether loss of αv integrins affected activation-induced induction of 
extracellular matrix protein gene expression, FACS sorted control and αv-null 
(Itgavflox/flox;PDGFRβ-Cre) PDGFRβ+ perivascular cells were activated in culture for 5 d.  
Col1A1 expression was significantly reduced in itgavflox/flox;PDGFRβ-Cre PDGFRβ+ 
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Figure 72 αv integrin depletion on PDGFRβ+ perivascular cells inhibits profibrotic gene 
expression   
(A) qPCR of Col1A1 in control and itgav
flox/flox
;PDGFRβ-Cre  (αv Cre) PDGFRβ+ perivascular 
cells culture activated for 5 days.  (B) qPCR of Col3A1 in control and itgav
flox/flox
;PDGFRβ-
Cre  (αv Cre) PDGFRβ+ perivascular cells culture activated for 5 days. 
 
Furthermore, treatment with an αv-blocking small molecule (CWHM12) (Figure 73, 
p208) inhibited expression of profibrotic genes (Figure 74, p208). CWHM12 is a 
synthetic small molecule RGD peptidomimetic antagonist that consists of a cyclic 
guanidino-substituted phenyl group as the arginine mimetic, and a phenyl substituted 
beta amino acid as the aspartic acid mimetic, both linked via glycine.  CWHM96 is a 
control R-enantiomer of CWHM12 that differs only in the orientation of its carboxyl 
(CO2H) group (Figure 73, p208).  CWHM96 and CWHM12 were kindly provided by 
Michael Prinsen, David Griggs and Peter Ruminski from St Louis University, Missouri, 
USA. 
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Figure 73 The chemical structure of CWHM12 and CWHM96  
 
 
Figure 74 Myofibroblast activation in vitro is attenuated by inhibition of av integrins.  
(A)  qPCR of Col1A1 in eGFP+ cells sorted from mTmG;PDGFRβ mice cultured in the presence of 
CWHM 12 and CWHM 96 for 5 d. (B) qPCR of Col3A1 in eGFP+ cells sorted from mTmG;PDGFRβ 
mice cultured in the presence of CWHM12 and CWHM96 for 5 d.   
 
Assessment of αv integrin heterodimer αvβ8 in skeletal muscle fibrosis 
The αv integrin has five possible β subunit binding partners (β1, β3, β5, β6 and β8), each 
of which has been reported to bind and/or activate latent TGFβ.  We established that 
the expression of a number of the β subunits was significantly raised in response to 
CTX induced muscle injury (Figure 75, p209).  
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Figure 75 β subunit expression in freshly sorted eGFP+ cells from skeletal muscle at day 
10following control (PBS) or CTX intramuscular injection.   
(Data are expressed as mean ± SEM. *p<0.05, ****p<0.0001 (Student’s t-test)). 
 
To further assess a potential contribution of αv integrin heterodimers during skeletal 
muscle fibrosis, we evaluated the response to CTX injection in mice lacking β8 integrins 
on PDGFRβ+ perivascular cells. Depletion of β8 failed to protect mice from CTX induced 
fibrosis (Figure 76, p209), nor did it affect the degree of initial injury caused by CTX. 
 
 
Figure 76  Deletion of β8 subunit on PDGFRβ+ perivascular cells does not influence the 
degree of CTX induced muscle fibrosis.   
Itgβ8;PDGFRβ-Cre mouse muscle was harvested 21 days following CTX injection (A).  There 
was no statistical difference in picrosirius red staining between muscles from β8 null and 
control mice (Error bars are ± SEM, n = 8) 
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Figure 77 The degree of initial injury and efficacy of the initial regenerative response was not 
influenced by depletion of β8 integrin subunit on PDGFRβ+ perivascular cells  
(n = 8, 3 representative muscles shown). 
 
Blockade of αv integrins attenuates skeletal muscle fibrosis 
Our data indicate that inhibition of αv integrins on PDGFRβ+ perivascular cells might 
represent a valuable therapeutic target. We therefore examined the potential of 
CWHM12 to prevent skeletal muscle fibrosis by inserting Alzet osmotic minipumps 
containing either CWHM12 or control R-enantiomer (CWHM96) into C57BL/6 mice, 
followed by IM CTX injection to the tibialis anterior muscle.  These minipumps provide 
researchers with a method for controlled and continuous agent delivery in vivo, and can 
be used for systemic administration when implanted subcutaneously or 
intraperitoneally.  Correct placement of the minipumps is critical to ensure 
uninterrupted delivery of inhibitor (Figure 78, p211).  Treatment with CWHM12 
(2.5mg/day/25mg mouse) significantly reduced skeletal muscle fibrosis, as determined 
by staining for collagen (picrosirius red staining) (Figure 79, p211).   
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Figure 78 Correct positioning of the Alzet minipump 
The usual site for subcutaneous implantation of osmotic pumps in mice is on the back, 
posterior to the shoulder blades and lateral to the midline.  The subcutaneous pocket should 
be large enough to allow some free movement of the pump without allowing the pump to turn 
around or slip down the flank.  The pump should not rest immediately beneath the incision, 




Figure 79 Blockade of αv integrins by the small molecule CWHM12 attenuates skeletal 
muscle fibrosis in a prophylactic model 
(A) Dosing regime in the prophylactic skeletal muscle fibrosis model.  Alzet osmotic 
minipumps containing CWHM12 or CWHM96 (control) were inserted, followed by 
intramuscular CTX injection.  Tissues were harvested at day 21 following CTX injection. (B) 
Digital image analysis quantification of collagen (picrosirius red staining) in prophylactic 
model (n=11). (C) Picrosirius red staining of skeletal muscle tissue from control and CWHM 
12 treated mice (prophylactic model) on day 21 following CTX injection. (images are x40).   
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We next asked whether CWHM12 could prevent further progression of established 
fibrosis.   Alzet osmotic minipumps containing CWHM12 or CWHM96 were inserted 
subcutaneously 10 days following CTX injection.  Mice then received 11 days of 
constant dosing prior to muscle harvest at d 21 following CTX injection. CWHM 12 
significantly reduced skeletal muscle fibrosis even after the fibrotic disease had become 
established (Figure 80, p212) 
 
 
Figure 80 Blockade of αv integrins by the small molecule CWHM 12 attenuates skeletal 
muscle fibrosis in a therapeutic model   
(A) Dosing regime in the therapeutic skeletal muscle fibrosis model.  10 days following 
intramuscular CTX injection, Alzet osmotic minipumps containing CWHM 12 or CWHM 96 
(control) were inserted.  Tissues were harvested at day 21 following CTX injection.  (B) 
Digital image analysis quantification of collagen (picrosirius red staining) in the therapeutic 
model (n=10). (C) Picrosirius red staining of skeletal muscle tissue from control and CWHM 
12 treated mice (therapeutic model) mTmG;PDGFRβ-Cre reporter mice. (images are x40).  
Data are mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 (Student’s t-test) n = 12 mice per 
group.
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In this section we sought to establish the role of PDGFRβ+ perivascular cells in the 
development of skeletal muscle fibrosis.  In order to achieve this we used transgenic 
mouse technology including Cre/Lox recombination, fluorescent reporters and gene 
knockdown.  We were able to confirm that PDGFRβ-Cre targets PDGFRβ+ perivascular 
cells in skeletal muscle with high efficiency. We show that PDGFRβ-Cre targets a 
population of perivascular pre-MSC that proliferate and transition to a myofibroblast 
like phenotype in response to skeletal muscle injury. We have confirmed that the 
critical role for αv integrins in mediating myofibroblast activation and fibrogenesis 
within visceral organs also applies to skeletal muscle. 
 
PDGFRβ-Cre labels perivascular cells with high efficiency 
PDGFRβ-Cre has previously been used by our group to target pericytes that contribute 
to fibrosis in liver, lung and kidney351.  We therefore used this system to target pro-
fibrotic cells within skeletal muscle.  We firstly sought to establish the phenotype of 
cells targeted using this constitutive system.  Using the double reporter mouse mTmG 
we found that the PDGFRβ-Cre resulted in extremely efficient recombination in 
PDGFRβ+ cells with over 97% of PDGFRβ+ cells reporting for eGFP.    We were also able 
to show that over 95% of GFP expressing cells stained positively for the antibody – 
confirming that eGFP was expressed in a minor number of cells that no longer 
expressed PDGFRβ.   
 
PDGFRβ was only found in perivascular locations and was not expressed on endothelial 
cells.  However, we found that PDGFRβ labeled a heterogeneous population of stromal 
cells residing in perivascular locations that could be subdivided based on their 
expression of PDGFRα and CD146 among others. The phenotype observed suggested 
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that PDGFRβ labels two populations of perivascular stem cells: namely 
PDGFRβ+PDGFRα+CD34+ adventitial cells and PDGFRβ+PDGFRα-CD34- pericytes.  
Both these populations fulfill the definition of MSC predecessors33 and have been well 
characterized by our group and others14 83. 
 
eGFP+ myofibres in uninjured skeletal muscle of 
mTmG;PDGFRβ-Cre mice 
Skeletal muscle fibres form by fusion of mesoderm progenitors called myoblasts.  After 
birth, muscle fibres do not increase in number but continue to grow in size because of 
fusion of satellite cells, the postnatal myogenic cells responsible for muscle growth and 
regeneration.  Numerous studies suggest that, on transplantation, cells from tissues 
other than muscle (for example bone marrow, brain, adipose tissue) can fuse with 
regenerating muscle fibres and also contribute to the satellite cell pool211 391-393.  It was 
important to establish whether this contribution to skeletal muscle was restricted to 
the artificial conditions created by transplantation or whether it occurs in development 
and injury in vivo.  Dellavalle et al.121, demonstrated that pericytes, transgenically 
labelled with an inducible alkaline phosphatase CreERt2, but not endothelial cells, fuse 
with developing myofibres and enter the satellite cell compartment during 
unperturbed postnatal development. They reported that the percentage of myofibres 
originating from AP+ cells varied markedly between tissues with highest percentage 
seen in uninjured diaphragm (7.3 ± 1.2%) while only 0.6% ± 0.2% myofibres in TA 
originate from AP+ cells.  They noted that the contribution of myofibres from pericytes 
was randomly distributed between fast and slow myofibres.  
 
Dellavalle et al., reported that the pericyte contribution to myogenesis increases 
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following acute injury or in chronically regenerating dystrophic muscle121.  Following 
injury the percentage of myofibres originating from pericytes in tibialis anterior 
muscles had risen to 5%.  In these experiments the tamoxifen was given at post-natal 
day (p) 1-3 and the authors note that if tamoxifen was given later (beyond p8) then the 
contribution of pericytes to myofibres drops dramatically.  They were also able to show 
that the contribution of AP+ pericytes to myogenesis was minimal in adult muscle.  
When tamoxifen is given in mice aged 2-3 months minimal reporting was seen in 
myofibres.  Furthermore, this minimal contribution in adulthood did not significantly 
increase after cardiotoxin-induced regeneration. (0.15 ± 0.1 in control TA and 0.93 ± 
0.4 in CTX TA).  In summary, this study demonstrated that AP+ cells could contribute to 
muscle fibres and the satellite cell pool but that this contribution occurs during the first 
month of postnatal growth becoming negligible in adult mice. 
 
These findings are in keeping with the present study where we observed that around 
2% of myofibres from mTmG;PDGFRβ-Cre mice in uninjured muscle expressed eGFP, 
indicating that they expressed PDGFRβ at some stage in their ontogeny.  The 
contribution is marginally larger than those by Dellavalle et al.121, (2.1% compared to 
0.7%) which likely reflects contributions occurring prior to p1 in this constitutive Cre 
and differences in the PDGFRβ+ population compared to the NG2+ population. 
 
It is also possible that the PDGFRβ+ cells do not contribute to myogenesis in vivo with 
transgenic artifact resulting in aberrant reporting of myofibres in our study.  This can 
result from the random integration of Cre expression vectors and leak activity of cell 
type-specific Cre expression systems394.  This may account for 'non-true reporting' of 
myofibres in our study.  It is also possible that the PDGFRβ+ cell contribution to 
myogenesis is underestimated in the transgenic mouse model.  We have seen that a 
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very small percentage of PDGFRβ+ cells do not express the eGFP reporter in 
mTmG;PDGFRβ+ mice.  If these were precisely those involved in myogenesis then the 
true contribution of these cells to myogenesis would be underestimated. 
 
Limitations of transgenic mouse systems 
The rapid increase in powerful, sophisticated mouse genetic tools has greatly facilitated 
cellular fate-mapping and the understanding of gene function in multiple biological 
processes including fibrosis.  The Cre/loxP system is widely used for this purpose395. A 
major problem in pericyte biology is the lack of specific markers246, with pericytes 
recognized by their position in the vasculature more than by a precise phenotype42 396.  
As such investigations using transgenic technology must be carefully designed and 
interpreted accordingly. 
 
Targeting populations that do not have a specific marker 
The myofibroblast is widely considered to be the key cell type responsible for 
regulating fibrosis through the deposition of extracellular matrix397.  Recent research 
has focused on defining the origin of myofibroblasts in different organs in order to 
accelerate the design of targeted anti-fibrotic therapies398.  Preventing the transition 
from progenitor to myofibroblasts, or even reversing this process may facilitate the 
treatment of fibrosis in a broad spectrum of clinical settings399.  Many cell types have 
been proposed as being a source for myofibroblasts including bone-marrow derived 
cells400, fibrocytes177 401 402, epithelial cells (via epithelial-mesenchymal transition 
(EMT))175 176 and tissue resident cells179.   The lack of a specific marker to target cells 
using recombination based technology is a major challenge to the field.  
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Perivascular cells, particularly pericytes, are emerging as the key protagonists in 
fibrosis across all organs398.  To target these cells we elected to use PDGFRβ-Cre 
because it is known to label perivascular cells of mesenchymal origin important to 
fibrosis in liver, lung and kidney.  However, alkaline phosphatase(AP)121, NG2382 and 
ADAM12185 have also been used to target perivascular cells. Using an AP-Cre to target 
pericytes Dellavalle et al., demonstrated that pericytes are a minor contributor to 
skeletal myofibres in normal development and following injury121.  However, AP-Cre 
labels a proportion of endothelial cells.  To overcome this, the authors performed 
parallel lineage tracing experiments with a well defined marker of endothelial cells - 
CD31 - to confirm that any contribution to the myofibre population did not emerge 
from endothelial cells. NG2-Cre has also been used to target pericyte populations in 
skeletal muscle382 and other organs42.  However, NG2 is thought to label only a subset of 
pericytes, limiting its value as a tool for “knockdown” experiments where high 
population coverage is generally required to ensure that experimental phenotypes are 
not masked.  Furthermore, NG2 is found outside the vasculature on cell types other 
than pericytes such as glial progenitors403. 
 
ADAM12 is a membrane anchored metalloproteinase, expressed in several human 
diseases with a fibrotic component and in a restricted fashion during development398.  
Dulauroy et al., demonstrated that ADAM12 labels a distinct subset of PDGFRα 
perivascular progenitors with a specific pro-fibrotic fate185.  The authors fate mapped 
these cells with an inducible, tetracycline transactivator based system, involving the 
generation of triple transgenic mice that expressed tetracycline transactivator under 
the control of the ADAM12 locus, Cre under control of tetracycline transactivator and 
the conditional reporter ROSA26floxSTOP-YFP.  In these mice, yellow fluorescent protein 
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(YFP) labeling of ADAM12+ progeny was temporally controlled by doxycycline 
administration to prevent Cre expression, allowing separate fate-mapping of fetal and 
adult ADAM12+ cells following CTX induced skeletal muscle injury. Using these genetic 
strategies and parabiosis experiments in which transgenic mice were sutured to 
wildtype mice, the authors demonstrated that αSMA+, collagen producing 
myofibroblasts developing following muscle injury descended from ADAM12+ cells.  
Furthermore, ablation of ADAM12+ cells in skeletal muscle (using mice that also 
expressed the human diphtheria toxin receptor under control of the ADAM12 locus) 
markedly reduced the generation of pro-fibrotic cells and interstitial accumulation.  To 
overcome dual labeling of ADAM12+ nerve cells the authors used a mouse that 
expressed Cre under the control of Wnt1 promoter, crossed to YFP, to confirm that 
Wnt1+ nerve and Schwann cells do not contribute to the pro-fibrotic stromal 
population following injury. By adopting several approaches (fluorescent reports, 
genetic ablation, parallel labeling) the authors were able to address many of the 
limitations of single promoter genetic systems and provide strong support to our 
observations that pericytes are a major contributor to the myofibroblast population 
that develops in muscle scarring. 
 
In an attempt to identify specific markers for pericytes, ongoing studies in our 
laboratory are using RNAseq and Lyoplate (BD Biosciences) technology.  This would 
allow us to target pericytes for fate tracing and knockdown technology while also 
enabling genetic ablation using subtype specific marker CreER/DTA mice, such as done 
by others207 208, to clarify the response of subtypes in response to tissue injury. 
 
Recombination efficiency / coverage 
In addition to population specificity, a number of other factors influence the choice and 
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applicability of Cre-drivers.  PDGFRβ-Cre has been shown to have high efficiency of 
recombination in multiple organs351.  While broad coverage of recombination is not 
essential for lineage tracing studies it is critical in knockdown experiments where 
residual “non-recombined” cells may compensate for those lost to recombination and 
mask a true phenotype.  In general, conditional Cres provide less efficient 
recombination and a lower coverage than constitutive Cre drivers.  
 
PDGFRβ+ perivascular cells are a principal source of 
myofibroblasts in skeletal muscle  
While our laboratory and others have shown that PDGFRβ+ perivascular cells 
contribute to fibrosis in visceral organs, we are the first to confirm this in skeletal 
muscle.  In skeletal muscle, overgrowth of fibrous tissue originates from resident 
progenitors exposed to environmental modification associated with injury221 364. To 
date, the literature investigating pathogenesis of skeletal muscle fibrosis has identified 
PDGFRα, NG2 and ADAM12 as putative markers of myofibroblast precursors. PDGFRα 
has been widely reported to label mesenchymal cells that proliferate early upon muscle 
damage to promote tissue regeneration and show fibro-adipogenic bipotential in 
vitro217 218.  Furthermore, chronic activation of PDGFRα leads to widespread organ 
fibrosis in mice404.  Using transgenic reporters of NG2 and nestin, Birbrair et al., 
demonstrated that a population of NG2+nestin–PDGFRβ+ perivascular cells contribute 
to skeletal muscle fibrosis following injury and these cells have been shown to be 
fibrogenic in vitro382.  This contribution is likely to be underestimated due to the flaws 
in the lineage tracing system used (knock-in rather than inducible Cre). 
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Dulauroy et al., demonstrated that ADAM12+ cells represent a distinct subset of 
PDGFRα+ perivascular progenitors with a specific profibrotic fate and function in 
mouse models of acute muscle injury185.  Using fluorescent lineage tracing and genetic 
cell ablation they elegantly demonstrated that profibrotic progenitors originate from 
ADAM12+ perivascular cells. The progeny of fetal ADAM12+ cells includes a 
subpopulation of PDGFRβ+NG2+ perivascular cells.   
 
While PDGFRα is the most widely recognised marker of pro-fibrotic perivascular 
progenitors in skeletal muscle, PDGFRβ is emerging as the key marker to identify pro-
fibrotic cells within other organs including liver, lungs and kidney181 351.  While there 
are likely to be subtle differences in the roles of cells within different organs, it is 
intuitive that the mechanisms responsible for a number of common processes are 
conserved.  As such, we sought to explore the relationship between PDGFRα and 
PDGFRβ within our population.  We found that there was significant overlap in these 
populations with over 65% of PDGFRα cells expressing eGFP (PDGFRβ-Cre) (Figure 62, 
p193).  When considering our results, the results of previous studies into skeletal 
muscle, and published reports in other organs four possible explanations could marry 
the findings. Firstly the PDGFRβ+ subset represent the pro-fibrotic component of 
PDGFRα+ populations. Secondly, the PDGFRα+ subset are the pro-fibrotic component of 
PDGFRβ+ populations.  Thirdly it is feasible that only cells expressing both PDGFRα and 
PDGFRβ are profibrotic.  Finally it may be that all cells expressing PDGFRα or PDGFRβ 
contribute to the myofibroblast pool following injury. We are now investigating 
PDGFRα+PDGFRβ-, PDGFRα+PDGFRβ+, PDGFRα-PDGFRβ+ subpopulations to 
characterize their contribution to fibrosis.  By exploring in greater depth the 
relationship of the PDGFRα+ and PDGFRβ+ cells it may be possible to identify a 
Discussion 
Section 2:  αv integrin deletion in PDGFRβ+ cells reduces muscle fibrosis 
 
222 
targetable subset of  pro-fibrotic perivascular cells on which to base novel anti-fibrotic 
therapies. 
 
αv integrins regulate skeletal muscle fibrosis 
A number of key physiological and pathological processes (e.g inflammation) are 
common in organs throughout the body and it is intuitive that the processes and 
mechanism of fibrosis would also be shared.  Our laboratory was the first to show that 
the specific targeting of the αv subunit in fibrogenic myofibroblasts effectively reduces 
developing and established fibrosis in liver, kidney and lungs351.  We used this system 
to delete the integrin αv subunit because of the suggested role of multiple αv integrins 
as central mediators of fibrosis in multiple organs339:  TGFβ1 is secreted in a latent form 
and stored in the ECM and that release of the active cytokine depends on the binding of 
the transmembrane integrins αvβ1, αvβ3, αvβ5, αvβ6 and αvβ8 to an arginine-glycine– 
aspartic acid (RGD) consensus sequence in the latent TGFβ1 complex405. In this thesis 
we found that the depletion of myofibroblast αv integrins significantly inhibited 
fibrosis in skeletal muscle, identifying myofibroblast αv integrins as components of a 
core pathway of pathological fibrosis in this tissue.   
 
TGFβ activation in skeletal muscle – αv integrins 
represent a major mechanism 
TGFβ1 is a member of the TGFβ superfamily, a highly conserved group of cytokines, of 
which there are three mammalian isoforms (TGFβ1, -β2, and -β3). TGFβ1 is a 
pleiotropic cytokine that is ubiquitously expressed by all cells and tissues within the 
body. TGFβ1 is synthesized as a small latent complex consisting of active TGF-β1 
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noncovalently associated with the latency associated peptide (LAP), and this is in turn 
is secreted in association with the latent TGFβ–binding proteins as the large latent 
complex. Synthesis of latent TGFβ can be increased by inflammatory mediators such as 
TNF-α; however, it is sequestered as an inactive molecule, which is stored in the 
extracellular matrix and needs to be activated before it exerts a biological effect. 
Activation can occur in vitro through physical processes such as acidification, extreme 
temperature changes, and oxidation.  In addition TGFβ can also be activated by a 
number of proteases, including plasmin, tryptase, thrombin, elastase, matrix 
metalloproteinase (MMP)-2, and MMP-9, and by interactions with thrombospondin or 
integrins. However, integrins remain the only class of TGFβ activators demonstrated to 
exert this effect in vivo. 
 
Attempts to identify αv subunit binding partners critical 
to skeletal muscle fibrosis 
As αv integrin is served by a number of β subunits, we sought to identify a β subunit 
partner responsible for TGFβ1 activation in skeletal muscle.  Contrasting results have 
been reported in different organs.  In mouse lungs, deletion or blocking of the epithelial 
integrin αvβ6 alone is sufficient to prevent latent TGFβ1 activation and development of 
bleomycin induced fibrosis without inducing the side effects of global TGFβ1 
inhibition343 406. Yet αvβ6 depletion does not protect mice from liver fibrosis351. In non-
epithelial tissues such as heart and muscle, mesenchymal cells are thought to come into 
play, expressing and upregulating all of the remaining αv integrins during 
myofibroblast differentiation in conditions of fibrosis.  
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Because we found β8 subunit to be highly expressed in injured skeletal muscle (and as a 
suitable transgenic mouse was available in our laboratory), we asked whether β8 was 
critical to skeletal muscle fibrosis.  However, we were unable to effectively inhibit 
skeletal muscle fibrosis by individual depletion of the β8 subunit partner of αv.  
Depletion of β8 integrins also did not protect against liver fibrosis351.  In fact, Henderson 
et al., found that global deletion of some individual β integrin subunits that only pair 
with αv integrin (such as β3 and β5) did not protect against fibrosis in the liver351.  This 
suggests that inhibition of multiple αv containing integrins may be required to 
effectively treat fibrosis or that the protection seen with αv depletion was due to loss of 
αvβ1 (which cannot be studied with the genetic tools currently available). 
 
Mesenchymal cells may simply use the αv integrins which they express to activate 
latent TGFβ1. Rapid tissue repair by TGFβ1–differentiated myofibroblasts is 
fundamental for organism survival, and it is conceivable that different αv integrins are 
redundant in their function of latent TGFβ1 activation. Mesenchymal cells can pair αv 
with alternative β integrin subunits thus compensating for loss of any β integrin. 
Indeed, different αv integrins have been shown to activate latent TGFβ1 in vitro either 
by inducing a conformational change in latent TGFβ1 through cytoskeletal force 
transmission345 407 or by supporting proteolytic activation347. It is conceivable that 
different αv integrins contribute to latent TGFβ1 activation in a setting dependent 
manner. For instance, αvβ6 integrin may be more important for the onset of lung 
fibrosis upon lung epithelial injury, whereas ‘mesenchymal’ αv integrins drive the 
progression and persistence of the disease, distant from the original insult339. 
 
So far the evidence suggests that only TGFβ1 and TGFβ3 are activated by αv integrins, 
not the TGFβ2 isoform.   In vitro all five of the αv beta subunits i.e. αvβ1, αvβ3, αvβ5, αvβ6 
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and αvβ8 have been shown capable of activating TGFβ1 in in vitro cellular assays. 
However, in vivo data points toward a prominent role for β1, β6 and β8, although it may 
be the case that all play a role to greater or lesser extents in vivo.  
 
Culture conditions influence myofibroblast activation 
We have shown that the PDGFRβ+ perivascular cells spontaneously transition to a 
myofibroblast phenotype in vitro.  This transition occurred in both standard basal 
medium (DMEM10%FCS1%PS) and EGM2, although the expression of myofibroblast 
markers was significantly higher in DMEM10%FCS1%PS with αSMA expression rising 
by a mean 431.40 (SEM 19.01) compared with the mean fold change of 33.09 (SEM 
0.95) in cells cultured in EGM2 (Figure 68, p200 and Figure 69, p201).   
 
Macroscopic tissue stiffening is a feature of fibrotic disease, and it has been shown that 
the mechanical properties of underlying matrix are a principal determinant of pericyte 
activation to a myofibroblast phenotype.408  In studies exploring liver pericyte (hepatic 
stellate cell) activation, the degree rather than speed of HSC activation correlated with 
substrate (polyacrylamide) stiffness, with cells cultured on supports of intermediate 
stiffness adopting intermediate phenotypes409.  Changes in gene expression on 
increasingly stiff substrate parallel those observed with myofibroblastic differentiation 
on plastic.  The rapid myofibroblastic activation of PDGFRβ+ perivascular cells on cell 
culture plastic is therefore not unexpected. 
 
During normal wound healing, coagulation of extravasated blood initiates a complex 
cascade of signals that recruit inflammatory cells, stimulate fibroblasts and epithelial 
cell proliferation, direct cell migration, and induce angiogenesis to restore tissue 
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integrity410.  Increasing serum concentrations have been shown to enhance the 
activation toward a myofibroblast phenotype411, although there are contradicting 
reports412.  Orlova et al., showed that upon culture in DMEM10% FBS, stimulation with 
TGFβ and stimulation with PDGF-BB for 3 days pericytes upregulated the expression of 
myofibroblast markers αSMA, smooth muscle specific protein 22 (SM22) and 
caldesmon higher than those cells cultured in EGM2413.  It is likely that the increase in 
serum concentration in DMEM10%FCS1%PS (10% FCS) over EGM2 (2% FCS) is 




A critical point raised in this thesis is the fibrosis/regeneration balance in the function 
of muscle pericytes.  Although neglected for many years, pericytes have recently 
become an intensively studied cell population in skeletal muscle biology and 
pathophysiology.  Pericytes are being shown to fulfil increasingly diverse roles49.  
Pericytes are stromal cells that support vasculature and can become MSC.  They have 
been shown to play a critical role in angiogenesis246, regulation of blood flow246, as 
myogenic precursors121 and progenitors of interstitial myofibroblasts181 351.   
 
We and others have shown that the pericyte population in skeletal muscle is 
heterogeneous in terms of marker expression414 415.  Although their functional diversity 
is still unexplored, different pericyte subtypes may regulate each of the many 
demonstrated functions416.  We have demonstrated that PDGFRβ + perivascular cells 
contribute to skeletal muscle regeneration by becoming myofibres, while also 
demonstrating their capacity to differentiate into myofibroblasts contributing to 
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fibrosis.  While it is feasible that all pericytes are capable of fulfilling each and every 
one of these functions it appears more likely that pericyte subsets exist that are 
committed to fibrosis or the regenerative response. 
 
Pericytes have been classically subdivided in two groups based on their ontogeny: 
during development, most of them derive from the mesoderm417-420, while brain and 
thymus pericytes derive from the ectoderm421-425.  However, with increasing evidence 
suggesting their phenotypic heterogeneity, attempts are being made to identify 
functionally distinct subsets.  Using NG2DsRed nestinYFP knock-in reporters, Birbrair 
et al., identified two subtypes of pericytes based on the expression of Nestin and NG2.  
In their classification Type 1 pericytes (NG2+nestin+) contributed to fibrosis in skeletal 
muscle while type 2 pericytes (NG2+nestin-) did not.  However, this study provides 
limited insight as type 2 pericytes may have contributed to fibrosis by becoming NG2- 
myofibroblasts that would therefore no longer report DsRed382.  In a further study 
utilising similar genetic systems, Birbrair et al., showed that in skeletal muscle, only the 
subset of type 1 pericytes that is not involved in myogenesis produces collagen, thus 
contributing to fibrous tissue deposition in older mice382. 
 
In contrast to the dominant role of pericytes in skin, liver, and skeletal muscle 
fibrosis185 426 their contribution to fibrous tissue formation in other organs remains 
controversial.  Some kidney and lung studies show important participation181 427; others 
do not180 428. Variations in the results of reported studies may reflect the use of different 
mouse models, the small percentage of cells undergoing recombination in some studies, 
and pericyte markers expressed by other cells such as fibroblasts.   Differing 
contributions of pericytes to fibrosis and regeneration between organs may also reflect 
differences in the proportions of functionally distinct pericyte subtypes.  In future work 
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I aim to further clarify the differences in the roles of pericyte subtypes, so they can be 
used as increasingly specific cellular targets susceptible to pharmacological 
manipulation. 
 
Strengths and limitations of the CTX model 
To investigate the response to muscle injury and the basis of fibrosis we used 
cardiotoxin (CTX) to acutely injure the tibialis anterior (TA) muscles of mice.  CTX 
administration induces local muscle necrosis, which is rapidly followed by recruitment 
of inflammatory cells, clearance of cellular debris and regeneration of injured 
muscle218.  Information regarding the mechanistic basis for muscle injury and fibrosis 
has generally been obtained from studies using CTX, barium chloride (BaCl2) or 
notoxin.  The CTX model is extremely simple and highly reproducible216 380 and is 
emerging as the method of choice for producing injury in high impact publications 
investigating regeneration and fibrosis in skeletal muscle14 215 216 360.  In particular the 
reproducibility of this model allows the detection of subtle phenotypes.  However, 
whether the events that ensue following this extreme injury reflect the precise 
adaptions that occur in clinical injury has not been established429. 
 
Adult skeletal muscle possesses a remarkable regenerative ability and it has been 
argued by some that skeletal muscle regenerates almost completely without 
development of fibrotic scar tissue after CTX injury430 431, and that this model reflects a 
reversible repair process rather than irreversible fibrosis432.  However, we found that 
elevated ECM and disordered structure persist even at 60 days post CTX injection.  In 
addition, fibrosis and disordered architecture is recognised following single acute 
muscle injury in human populations, such as sports injuries or surgical incisions433 434. 
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In conditions of chronic injury, as occurs in muscular dystrophies, chronic 
inflammatory events result in the excessive accumulation of ECM components, which 
inhibit myogenic repair and lead to muscle being replaced by fibrotic/scar tissue192.  In 
order to achieve a more dramatic phenotype I would like to repeat the experiments in 
dystrophic mice in future studies.  The dramatic phenotype may then be amenable to 
functional testing and would confirm our findings in another setting of fibrosis. 
 
Limitations of fibrosis quantification methods 
The precise quantification of skeletal muscle fibrosis can be difficult.  Typically, 
skeletal muscle assays quantify the cross-sectional area fraction of ECM by excluding 
muscle fibres using image-processing tools reporting the amount of ECM as ‘area 
fraction’.  Frequently, a number of arbitrary fields are selected from within a muscle 
section of each biological replicate.  In order to minimise bias, we used a stereology 
microscope to select random fields within the injured area.  Although the area of injury 
was carefully selected on the basis of centralisation of nuclei and myofibre size, this 
semi-quantitive method could theoretically introduce bias.  
 
A further limitation of this approach is that if muscle fibres atrophy and ECM remain 
the same, ECM will occupy a greater fraction of the muscle cross section.  This 
approach also gives no information about isoforms and cross-linking, which can also 
affect function.  For normal muscle the ECM area fraction is typically below 5%, but 
this value can increase dramatically in diseased or injured states. In addition to the 
increased fractional area of ECM in fibrotic muscles, because the pathological response 
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often includes fibre degeneration and regeneration, muscle fibrosis is also 
accompanied by a large increase in muscle fibre size variation.  
 
Skeletal muscle fibrosis can also be expressed in terms of the total amount of collagen 
present in the tissue, as measured by the content of hydroxyproline, a major 
component of collagen derived from hydroxylation of the amino acid proline by 
prolyloxidase. While this assay has been used for many years, expression of collagen 
mass relative to a known muscle protein is only rarely reported.  
 
Functional assessment of muscle function 
The primary function of skeletal muscle is to generate force.  Muscle force is 
compromised in various forms of acquired and or inherited muscle diseases.  An 
important goal of muscle therapies is to recover muscle strength.  Methods for 
measuring murine muscle function include ex-vivo and in-situ analysis of the 
contractile profile of a single intact limb muscle, grip force and downhill treadmill 
exercise.  Ex-vivo force measurement in a single muscle is extremely useful for analysis 
following discrete injury while grip force and treadmill assessment offer body wide 
evaluation of global muscle health. 
 
In future studies I would like to incorporate functional assessment of muscle fibrosis, 
although this would be challenging using the CTX model used in this thesis.  The 
degree of fibrosis seen following a single CTX injection is considerably lower than 
those seen with dystrophic muscle or chronic inflammation and the notoriously 
insensitive in vivo functional assessments may not pick up small yet significant 
differences seen on histological examination.  Furthermore the tibialis anterior muscle 
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is difficult to functionally isolate with surrounding muscle groups compensating for 
reduced function even in severe fibrosis.  This was illustrated by the mices’ ability to 




The capacity for pericytes to play so many diverse roles in normal development and the 
response to injury highlights the complexity that underlies their regulation.  Their roles 
in disease processes are increasingly appreciated, with pathological activation of the 
mesenchymal and fibroblastic phenotypes emerging as key themes in disease of 
skeletal muscle and other organs.  Understanding how the expression of pericyte 
potentials is regulated within the perivascular niche will facilitate the development of 
therapeutic strategies to treat a wide range of skeletal muscle diseases including 
heterotopic ossification and fibrosis. 
 
In addition to targeting the pathological behaviour of pericytes in disease, the 
regenerative capacities of pericytes holds great promise for regenerative medicine and 
tissue engineering.  The work in this thesis has highlighted the diverse pathways 
involved in pericyte regulation, and the broad range of functions skeletal muscle 
pericytes display in both health and disease.   The heterogeneity of pericyte populations 
is increasingly appreciated and the discovery of distinct “specialist” subsets of pericytes 
primarily responsible for each of the many biological roles described will facilitate the 
discovery of highly targeted therapies in the future. 
 Conclusions – perivascular cells at the 
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